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1. Abstract  
The structure of cobalamin has an upper β- axial ligand group and a lower α-axial 
ligand base. Different groups can attach to the upper ligand to form different forms of 
cobalamin.  When the lower ligand base is changed, the molecule becomes unusable 
for humans. These are called the lower ligand analogues and are found most 
prominently in faecal samples. This study sets out to use a cobamide extraction 
procedure to identify the types of analogues present in faecal samples. It aims to 
investigate the effect of supplementation with B12 on the cobamides detected in 
racehorses’ microbiome. Additionally, it aims to identify possible relations between 
treatment responses and cobamides detected in faecal samples of pernicious 
anaemia patients. Purification of cobamides is done with a His-tagged cobalamin 
binding protein and identification of them are done by HPLC-MS. The results show 
that supplementation does not have an effect on racehorses’ cobamides detected and 
patients who take B12 sublingual spray or tablets have higher amounts of 
cyanocobalamin in their microbiome. Lastly, this procedure can successfully be 
adapted to study cobamides in tissue samples.   
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The basis of this project revolves around identifying the different types of cobamides 
found in tissue and faecal samples. 
5.1 Cobamides 
“Cobamide”, is an umbrella term used to describe molecules belonging to the corrinoid 
family with a cobalt containing centre along with an upper and lower ligand group 
attached (1). It is synthesised exclusively by microbial synthesis (2). The structure of 
the most studied cobamide, “cobalamin” was solved by Dorothy Hodgkin in 1955 by 
X-ray crystallography (3). This water soluble molecule consists of a tetrapyrrole corrin 
ring comprising of a cobalt ion bound to 4 nitrogen atoms. This molecule is able to 
have varying upper β-axial ligand groups and varying lower α-axial ligand bases 
(Figure 1 – lower ligand shown as 5, 6-Dimethylbenzimidazole) (4). Normally referred 
to as vitamin B12, cobalamins varying in their upper ligand groups can be specifically 
termed cyanocobalamin (Figure 1), methylcobalamin, adenosylcobalamin, or 
hydroxocobalamin. 
Biologically, vitamin B12 is usually found in its adenosylcobalamin or methylcobalamin 
form (5). Commercially, vitamin B12 is sold as cyanocobalamin or methylcobalamin (5). 
This is because cyanocobalamin and methylcobalamin is more stable than the rest. 
Cyanocobalamin (Figure 1) is the most stable of the four and is usually found in oral 




Figure 1: Structure of cyanocobalamin. This structure shows the corrin ring coordinating 5, 6-
Dimethylbenzimidazole as its lower axial ligand base and CN in its upper axial ligand. The 
upper ligand group can have different groups as shown. 
 
5.2 Importance of vitamin B12 
Ever since the discovery of vitamin B12 as the anti-pernicious factor by Minot and 
Murphy, much effort have been put into understanding its importance and function (8).  
Although cobalamin deficiency is not as common in animals as it is in humans, a low 
level of cobalamin can still affect cell division, neuropathy, nervous system 
development, and mood (9–11). Thus, serving an important purpose towards their 
overall wellbeing. Deficiency in humans can be due to uptake disorders such as 
5,6-dimethylbenzimidazole 
5-deoxyadenosyl: forms adenosyl cobalamin 
 
Methyl – CH3 : forms methylcobalamin 
 
Hydroxy – OH : forms hydroxocobalamin 
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pernicious anaemia (autoimmune disorder that attacks the intrinsic factor) or dietary 
reasons (12). These vitamin B12 deficient patients usually go through treatment 
regimens such as change in dietary habits, or consumption of supplements. Where 
pernicious anaemic patients are concern, intramuscular B12 injections are 
administered along with supplements if needed. In humans, vitamin B12 is a cofactor 
for two enzymes: methionine synthase and methyl malonyl coenzyme A mutase (13). 
Methionine synthase catalyses the methylation of homocysteine to methionine and 
mutations in this gene are associated with methylcobalamin deficiency. When vitamin 
B12 deficiency happens, the activity of this enzyme is decreased which decreases other 
connected folate enzymes resulting in defective DNA synthesis in cells and anaemia 
(14). Methyl malonyl coenzyme A mutase on the other hand catalyses the conversion 
of methylmalonyl-CoA to succinyl-CoA using adenosylcobalamin as a cofactor (15). 
This enzyme is found in high levels in crucial organs such as the kidney, heart, brain, 
and liver. Mutations in the gene encoding for this enzyme (mut gene) causes 
methylmalonic acidemia and is observed to also appear in children with inability to 
metabolise vitamin B12 .The deficiency or defect in this enzyme will lead to a build-up 
of the substrate L-methylmalonyl-CoA. This substrate will form methylmalonic acid 
which is toxic to the brain (16).   
5.3 Cobalamin and the gut 
Absorption of vitamin B12 
Since there are only two B12 dependent enzymes in humans, this means that vitamin 
B12 is only required in small quantifies per day. This is consumed through our diet as 
only microorganisms possess the ability to synthesize cobalamins (2). Therefore, the 
consumption and metabolism of cobalamins through our digestive system is crucial. 
Firstly, cobalamin from food sources will bind to haptocorrin. This forms the cobalamin-
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haptocorrin complex (Figure 2). This complex prevents the breakdown of cobalamin 
due to the acidic environment in the stomach (17). As it travels towards the intestines, 
pancreatic proteases release the cobalamin from that complex by digesting 
haptocorrin. The released cobalamin then binds to intrinsic factor (IF) in the small 
intestine. This intrinsic factor-cobalamin complex is recognised by the receptors on the 
enterocytes at the terminal ileum. Once absorbed by the enterocytes, intrinsic factor 
is degraded and cobalamin is free to enter the blood stream. In the bloodstream, 
cobalamin binds to transcobalamin II. When needed, lysosomes from cells will 
degrade transcobalamin II and releases the cobalamin to be used (18). Vitamin B12 is 
mainly stored in hepatocytes where it usually take years to deplete this reservoir in a 
healthy human being (11). 
  
Figure 2: Absorption of cobalamin in the human digestive system. Cobalamin from food 
sources is first bounded to Haptocorrin which protects cobalamin from breaking down. 
Cobalamin then binds to IF at the small intestine for recognition by receptors at the enterocytes. 
Degradation of IF release cobalamin to the systemic circulation where it binds to 






Cobalamins and the gut microbiome 
The gut is home to trillions of microbes dominated by Bacteroidetes and Firmicutes 
(19). The microbiome of the gut plays an important role in producing various 
metabolites used by the host which influences the host’s health (20). The microbiota 
is not only important for vitamin production but they impact nutrient digestion and 
absorption, the immune system, normal development, and behaviour of the host (9, 
20–23). In terms of vitamin B12 for humans, it is important to consume enough vitamin 
B12 in through their diet because the microbiome competes with the human host for 
cobalamins (24). This is unlike animals such as horses where their gut microbiome in 
the hindgut is important in producing and supplying enough vitamin B12 (25, 26).  
Interestingly, even when enough vitamin B12 is consumed or supplemented, some 
vitamin B12 deficient people still lack cobalamin in their system. This could be due to a 
lack of intrinsic factor in combination with the competition of cobalamins from the gut 
bacteria (23, 27). With regards to this, establishing the relationship cobalamins and 
the gut microbiome. It has been shown that the composition of gut bacteria is affected 
by competition and exchange of cobalamins within the environment (23, 28). The 
bacteria requiring cobamides outweighs the biosynthesis in the human gut which 
indicates the need for many bacteria to take up cobamides from their environment and 
modify it for usage. This produces cobalamin analogues where the lower ligand base 
of the cobalamin structure is switched to other groups (Figure 1) (23, 29, 30).  
Although there is a difference between the gut microbiome of humans and animals, 




5.4 Lower ligand analogues 
Lower ligand analogues are cobalamin molecules only differing in their lower ligand 
base (Figure 1). The lower base shown in Figure 1 (5,6-dimethylbenzimidazole) is the 
useful base that allows absorption into the human body to be used by cells. Once the 
base changes from 5,6-dimethylbenzimidazole, it is no longer useful to humans. The 
affinity of haptocorrin, intrinsic factor, and transcobalamin towards specific cobalamins 
help humans filter out unwanted cobalamins with other lower bases which would not 
be useful to humans (18). Although these are in place to filter non-useful analogues, 
some are still able to bypass this due to their similarity in structure (33–35). This would 
inhibit efficient uptake of useful cobalamin. There are a variety of cobalamin lower 
ligand analogues discovered to date which can be groups into three classes and 
cobinamide (23, 30, 36–38). Cobinamide is the incomplete corrinoid that is missing 
the lower ligand base. The three classes are the phenols (Figure 3), purines (Figure 
4), and benzimidazoles (Figure 5).  
 
Figure 3: Structure of the lower ligand bases belonging to the phenols group  
             
Figure 4: Structures of the lower ligand bases belonging to the purines group  
Phenol p-cresole 3,4-dimethylphenol 2-amino-p-cresol 




Figure 5: Structure of the lower ligand bases belonging to the benzimidazoles group  
 
Haptocorrin is shown to bind to all cobalamin analogues with high affinity. Binding with 
haptocorrin delivers these analogues to hepatocytes where the retention of these 
useless cobamides by the liver could act as a shield to prevent the body from using 
them (34, 39). These analogues are then excreted in the urine and faeces over time 
(34, 39). Intrinsic factor binds to cobinamide, purine, and phenol analogues with low 
affinity while transcobalamin binds to cobinamide and phenol analogues with low 
affinity (33–35, 39). After entering into the bloodstream, these analogues can either 
go to the hepatocytes where it is stored, excreted, or transported around the circulatory 
system where cells can utilize them.  
Not much is known about these lower ligand analogues except they are a product of 
microbial modification. The role of these analogues are not well established but it can 
be noted that the analogues could have implications in influencing the composition of 
the microbiome and subsequently the health of the host. This is further illustrated when 













40). Faeces contain a large amount of microbes and it has been shown that different 
cobalamin analogues can alter the population of microbes differently (23, 41, 42).  
Humans and microbes both compete for cobalamins (23, 24, 27). Humans only need 
the 5,6-dimethylbenzimidazole analogue (cobalamin) while different bacteria are able 
to utilise different analogues for metabolism. This means that bacteria can take up the 
‘useful’ cobamide and the product of their metabolism is molecule with a modified the 
lower ligand base. This competition with the host is amplified if the person has a 
bacterial overgrowth in the gut (27, 43). This results in even lower levels of useful 
cobalamin within the blood stream available for the host. Moreover, cobalamins 
produced by the gut bacteria located in the large intestine are unable to be absorbed 
as the site of absorption for humans is further upstream. This can be linked towards 
vitamin B12 deficiency where a lack of cobalamin uptake means increased competition 
for useful cobalamin since majority of the human gut microbiome is shown to require 
exogenous corrinoids (24).  
The competition for cobalamin analogues can also be seen in certain animals. Mainly 
non-ruminants and animals who are not observed to practice coprophagy (44). The 
animals that practice coprophagy are capable of obtaining cobalamin produced by 
their gut microbes by consuming their faecal matter which contains the needed 
cobalamins. This allows them to move the cobalamins to the upper digestive tract 
where absorption takes place (32, 44). Ruminants are able to absorb cobalamins 
produced by the bacteria in the rumen where it is located before the absorption site of 
cobalamin (31). These can compensate for the competition for cobalamins at the site 
of absorption between the host and the gut microbes. Thus, deficiency is not as 
prevalent in animals as in the human population.  
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Moreover, the distribution of cobalamin analogues in animal tissues are different from 
one another which reinforces the relevance of these analogues in the wellbeing of an 
animal (38)(45). In this report, where analogues are mentioned, it refers to the lower 
ligand analogues. 
5.5 Aim 
The main aim of this project is to utilise a cobamide extraction procedure developed 
to identify cobamides in faecal samples. Secondly, the protocol is changed with an 
aim to adapt it for use on tissue and serum samples. It involves the use of the E. coli 
BtuF protein involved in cobalamin uptake to capture these cobamides (46).   
5.5.1 Faecal sample trial extraction analysis 
The protocol was first familiarised and tested using rabbit and hedgehog faecal 
samples as they were readily available. These two animals are different in their habits 
and thus, the cobamides in their gut should be different and should be shown if the 
protocol works well (17, 44). 
5.5.2 Optimisation of extraction protocol with horse faecal samples  
The protocol was then optimised using horse faecal samples as they were available 
in abundance. The aim here is to improve or maximise the types of cobamides being 
able to be detected by High performance liquid chromatography- mass spectrometry 
(HPLC-MS). It will investigate how different mass of faecal samples and changing the 





5.5.3 The effect of supplementation on cobamide extraction profile of racehorse 
faecal samples 
Once optimised, the protocol is used to investigate the effect of vitamin B12 
supplementation on the composition and types of lower ligand analogues (cobamides) 
in racehorses’ faecal samples. Because of cobalamin’s association with metabolism, 
it can be investigated for its effect on stamina or performance of racehorses in this 
case (25, 26). It has been observed that supplementing horses with vitamin B12 is 
crucial in preventing anaemia and increasing appetite which could have ripple effects 
on its performance (26). This experiment will be analysed in parallel with a related 
study (supplementary S13) to see if there are any implications towards their 
performance.  Racehorses live a high stress and strict diet life which can have a 
negative effect on its gut microbiome. This is important because the gut microbiome 
for horses is crucial in supplying them with enough vitamins including B12 which are 
needed for their wellbeing or performance (25, 26). Thus, if a shift in composition of 
cobamides is observed after supplementation, it indicates a shift in the microbiome of 
the horse which could identify potential markers of a racehorses’ wellbeing and 
predicted performance.  
5.5.4 Relationship between the cobamide composition in faecal samples and the 
treatment responses of pernicious anaemia patients 
Lastly, this project aims to find if there is a relationship between the cobamide 
composition of pernicious anaemia patients and their treatment responses from three 
monthly Vitamin B12 intramuscular injections. Two groups of patients who are either 
happy or unhappy (needs more frequent treatments) with their injections are studied. 
This is studied because pernicious anaemia patients have varied responses towards 
their injections and the reason for this is not fully understood. One of it could be due 
to the difference in gut microbiome which can be reflected through the types of 
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cobamides present as different bacteria are able to make changes to the lower ligand 
base of the cobalamin molecule (23, 27, 30). Therefore, it will be of interest to look at 
their cobamide composition in disease states particularly when different treatment 
outcomes are concerned. 
The data will be analysed along with a corresponding study (supplementary S15) 
whereby the types of bacteria present in the patients’ faecal samples were identified 
by sequencing. This will reveal any correlation between the types of microbiome found, 
the cobamides that are present, and their treatment responses. By combining these, 
we hope to elucidate more clues into why there are different reactions to treatments. 
5.5.5 Tissue and serum sample adaptation 
The cobamide extraction protocol was altered for use on animal tissue and serum 
samples. This is done to see if the methodology is capable for tissue or serum 
cobamide analysis studies. 
6. Materials and Methods 
Overview:  
1) Preparation of His-BtuF (His-tagged cobamide binding protein) nickel resin  
2) Production and purification of HBAH molecule (spiked into samples for 
normalisation of data) 
3) Extraction and purification of cobamides from faecal, tissue, or serum 
samples 
4) HPLC-MS detection of cobamides found in samples 
5) How HPLC-MS data was analysed 
6.1 Preparation of His-BtuF IMAC nickel resin for the capture of cobamides 
Expression and purification of E.coli His-BtuF in E.coli BL21 star (DE3) pLysS 
Plasmid: pET14b-btuFhis gift from Dr. Evelyne Deery 
Competent cell: E.coli BL21 star (DE3)pLysS from Promega (Catalog No: L1191 )  
Transformation Protocol:  
The plasmid pET4b-btuFhis  was transformed into BL21 star (DE3)pLysS for the 
production of His-BtuF.  
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50 µL of E.coli BL21 star (DE3)pLysS was mixed with 0.5 µL of pET14b-btuF. The 
mixture was left on ice for 15 minutes before a 42 oC heat shock for 1 minute. The 
mixture was then placed back on ice for 2 minutes before adding 200 µL of SOC 
medium (Table 1). The mixture was left in 37 oC water bath for an hour before being 
plated on LB-agar with 100 µg/mL of ampicillin (Melford, Catalog no: 40801-43025) 
and 34 µg/mL of chloramphenicol (Melford, Catalog no: 100M0061V). The plate is left 
to incubate at 37 oC overnight.  
Table 1: Composition of SOC growth medium for per 100 mL:  
Component Amount 
Tryptone 2 g 
Yeast extract 0.5 g 
NaCl 0.01 M 
KCl 00025 M 
Mg2+ * 0.02 M 
Glucose 0.02 M 
Tryptone, yeast extract, NaCl, and KCl were dissolved in distilled water then 
autoclaved. The other components were then added to make up to 100 mL. 
*Composition of Mg2+ = 2 g of MgCl2.6H2O and 2.5 g of MgSO4,7H2O to 10 mL of 
distilled water then filter sterilised 
Inoculation protocol for starter culture: 
In a sterile environment, a single colony of E.coli picked up from the LB-agar plate, it 
was inoculated into 10 mL of LB-medium containing 100 µg/mL of ampicillin and 34 
µg/mL of chloramphenicol. This is incubated at 37 oC with shaking overnight. 
Inoculation of starter culture into 1 L flask for large scale growth: 
In a sterile environment, 10 mL of starter culture was added to 1 L of LB-medium 
containing 100 µg/mL of ampicillin and 34 µg/mL of chloramphenicol. This was left to 
shake at 37 oC until OD600 reaches 0.6 – 1. Then, 400 µM of IPTG (Melford, Catalog 





1 L of growth culture was spun down at 2392 RCF for 20 minutes. The pellet was 
resuspended in 30 mL of binding buffer containing 20 mM of imidazole, 20 mM of pH 
7.5 Hepes, and 500 mM of NaCl. The resuspended pellet was sonicated for 5 minutes 
with 30 seconds/30 seconds of pulse and 55% amplitude. The lysed cells were then 
centrifuged for 20 minutes at 26 000 RCF. The supernatant was kept on ice. 
Purification of His-BtuF (recombinant protein) using IMAC and making His-BtuF 
resin. 
In an empty column, 10 mL of Chelating SepharoseTM resin (from GE healthcare, 
Catalog No: 10280810) was added and charged with 20 mL of 0.1 m NiSO4. It was 
then washed with 60 mL of binding buffer containing 20 mM of imidazole, 20 mM of 
pH 7.5 hepes, and 500 mM of NaCl. The supernatant containing His-BtuF was loaded. 
The column was then washed with 50 mL of the same binding buffer. Then it was 
washed with 30 mL of wash buffer containing 60 mM of imidazole, 20 mM of pH 7.5 
hepes, and 500 mM of NaCl. Next, the column was washed with 20 mL of final buffer 
containing 20 mM of pH 7.5 hepes and 100 mM of NaCl. The resin in the column was 
mixed evenly before being transferred into a beaker for storage at 4 oC. The his-tagged 
protein was not chelated from the nickel column and thus the His-BtuF resin can be 
used to capture cobamides. 
Check the binding of His-BtuF to cyanocobalamin: 
The His-BtuF resin was checked for its ability to bind to cobamides by loading 1 mL of 
100 µM cyanocobalamin onto 800 µL of the His-BtuF resin on a mini-chromatography 
column (from Bio-Rad, Catalog no: 732-6207). The mini column was washed with final 
buffer until drops become clear. The resin should stay pink which indicate binding of 
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cyanocobalamin to the resin. Then, cyanocobalamin was eluted from the resin by 
denaturing the His-BtuF protein on the column. It was eluted with 8 M urea buffer 
solution containing 20 mM of pH 7.5 hepes and 100 mM of NaCl. The denaturation of 
His-BtuF releases cyanocobalamin (pink elution fractions) while still remaining bound 
to the column.  
6.2 Production of Hydrogenobyrinic acid hexamide (HBAH) for the normalisation of 
HPLC-MS data 
The molecule HBAH is used for normalisation of integrated peak areas of peaks 
detected in the HPLC-MS (High performance liquid chromatography-Mass 
spectrometry). The same concentration (7.5 µg/mL) of HBAH is spiked into each 
sample and the recovery of this molecule represented by its signal peak in the HPLC-
MS is used to standardize the data values of cobamides. This serves as an internal 
standard and enables fairer comparison of integrated peak areas across different 
batches of samples going through the HPLC-MS. 
Strain ED663: E.coli BGEC043 with (T7P)-AIG*JFMKLH-AlvBQ-E*- integrated in the 
fim operon and ∆lacZYAΩ(T7RNAP) ∆btuF gift from Dr. Evelyne Deery 
Inoculation into starter culture: 
A single colony of E.coli strain ED663 was inoculated into 10 mL of LB-medium 
containing 0.2% glucose. This culture is incubated at 28 oC overnight with shaking.  
Inoculation of starter culture into 1 L of ‘2YTNN’ medium: 
10 mL of starter culture was inoculated into 1 L of 2YTNN medium (Table 2). This was 
incubated at 28 oC shaking until OD600 is 1 – 1.5. Then, 400 µM of IPTG was added 




Table 2: Composition of 2YTNN medium per litre of distilled water 
Component Amount 
Yeast extract 10 g 
Tryptone 16 g 
NaCl 5 g 
Na2HPO4 10.99 g 
NaH2PO4 2.71 g 
NH4Cl 1 g 
 
Purification of HBAH using His-BtuF resin: 
The 1 L culture was centrifuged at 2392 RCF for 20 minutes. The supernatant 
containing HBAH was kept on ice. His-BtuF resin from 3 L of culture was loaded onto 
an empty column. The supernatant was loaded onto the column containing His-BtuF 
resin. The column was then washed with 50 mL of binding buffer containing 20 mM of 
imidazole, 20 mM of pH 7.5 hepes, and 500 mM of NaCl. Then it was washed with 30 
mL of wash buffer containing 60 mM of imidazole, 20 mM of pH 7.5 hepes, and 500 
mM of NaCl. Next, the column was washed with 30 mL of final buffer containing 20 
mM of pH 7.5 hepes and 100 mM of NaCl. HBAH was eluted with 8 M urea buffer 
solution containing 20 mM of pH 7.5 hepes and 100 mM of NaCl. The coloured 
fractions were collected and kept away from light (light sensitive) at 4 oC or –20 oC. 
Concentrating the elution fractions using RP18 columns from Merck: 
Purified HBAH fractions from IMAC was loaded into a RP18 column equilibrated with 
5 column volumes of 0.1% of trifluoroacetic acid (TFA). The column was then washed 
with 3 column volumes of 0.1% TFA. Then, the column was washed with 5, 10, 20, 30, 
and 50% methanol to elute the concentrated HBAH. The coloured fractions (pink) was 
collected and kept in the dark at 4oC or -20 oC. This sample was then sent for HPLC-




Re-suspending HBAH in binding buffer to obtain a concentration of 7.5 µg/mL: 
The eluted fractions from RP18 column were vacuum dried using a rota-evaporator. 
The methanol was first removed before switching the settings to remove water. Once 
the HBAH is dried, it was resuspended in 5 mL of 0.1 M pH 7.6 potassium phosphate 
buffer (KPi buffer). 0.1 M of pH 7.6 KPi buffer was made by adding 86.6 mL of 1 M 
K2HPO4  and 13.4 mL of 1 M KH2PO4 . The volume was then adjusted to 1 L using 
distilled water. 
The resuspended HBAH solution was checked for its concentration by finding the peak 
on the UV-Vis scan (peak at around 330 nm) and calculating the concentration 
(Extinction coefficient = 50 000 M-1 cm-1). The concentration of HBAH was then diluted 
down using KPi buffer to obtain a concentration of 7.5 µg/mL. This was stored at -20 
oC and defrosted before use.  
6.3 Extraction from faecal samples and conversion of cobamides into its cyano-form 
Release of cobamides and conversion into the cyano-form of those cobamides 
(cyanocobalamin analogues): 
Faecal samples were thawed overnight at 4 oC and weighed out into 50 mL falcon 
tubes. Each sample was then vortexed with 30 mL of 0.1 mg/mL KPi/KCN buffer (Table 
3). Adding this buffer allows the conversion of all cobalamins into the cyano-form which 
is more stable.  
Table 3: Composition of 0.1 mg/mL KPi/KCN buffer per 300 mL 
Component Amount 
0.1 M pH 7.6 KPi buffer 300 mL 
KCN (potassium cyanide) 0.03 g (30 mg) 
 
The samples were then kept in boiling water bath with the lids off for 20 minutes with 
stirring every 5 minutes. This denatures cells and proteins which releases the 
cobamides into the solution. The cyanide in the buffer should make all the cobamides 
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in the solution to have the cyano-group attached to the upper ligand. Thus, all 
cobamides will only differ in their lower ligand base (lower ligand analogues).The lids 
were placed back on and samples were then allowed to cool to room temperature. 
These were then incubated in 4 oC overnight.  
The samples containing KPi/KCN were then centrifuged at 4000 RPM for 45 minutes. 
The supernatant was transferred into new 50 mL falcon tubes. 100 µL of 7.5 µg/mL 
HBAH was added into the supernatant of each falcon tube. Then, 800 µL of His-BtuF 
resin was added into each falcon tube. The entire mixture is left at 4 oC for 18 hours 
with gentle shaking.  
Checking the elution volume of His-BtuF resin on the mini chromatography 
columns: 
800 µL of His-BtuF resin was pipetted into a mini chromatography column. The column 
was washed with 3 mL KPi buffer then 1 mL of 100 µM cyanocobalamin was loaded 
onto the column. The column was washed with KPi buffer until the drops turn clear. 
The resin should be observed to be pink. Wash the column in 200 µL of 8 M urea 
elution buffer solution containing 20 mM of pH 7.5 hepes and 100 mM of NaCl one at 
a time. The void volume (volume before pink is eluted out) and the elution volume 
(volume from first drop of pink to the last drop) were recorded.  
Purifying cobamides: 
The falcon tubes containing the His-BtuF resin, supernatant of stool sample, and 
HBAH is taken out of 4 oC and centrifuged for 60 seconds at 500 RPM. This is to 
collect the His-BtuF resin at the bottom. The supernatant in each falcon tube was 
carefully decanted (beware not to pour out the resin) into a KCN waste bottle. The 
pellet was then re-suspended with KPi buffer. A fresh mini chromatography column 
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was prepared for each sample and 800 µL of His-BtuF resin was pipetted into each 
column. A plastic pipette was used to transfer all the resuspended pellets 
(resuspended resin) from the falcon tubes to run through the mini columns containing 
His-BtuF resin. Then, two washes of KPi buffer were done on each mini column. The 
void volume of 8 M urea elution buffer solution containing 20 mM of pH 7.5 hepes and 
100 mM of NaCl was loaded onto the column and flow through not collected. Then, 
the elution volume of the same urea elution buffer was loaded and flow through was 
collected in 2 mL eppendorf tubes. For each sample, 400 – 500 µL of the elution 
fraction was pipetted into HPLC-MS vials. The samples are now ready for HPLC-MS 
analysis.  
Method testing with pet hedgehog and pet and wild Rabbit 
The above procedure (Section 6.3) was repeated for hedgehog and rabbit faecal 
samples. 4 g of samples were used for pet hedgehog, pet rabbit, and wild rabbit 
samples.  
Optimisation of protocol with horse samples to maximise the types of 
cobamides detected 
i) Varying the mass of samples 
The extraction procedure was the same as above (Section 6.3) except the masses of 
the samples were changed. The incubation time with the His-BtuF resin was kept 
constant at 18 hours. The masses investigated were: 2, 4, 6, 8, 10, and 12 grams. 
ii) Incubating samples with His-BtuF resin for different time periods 
The extraction procedure was the same as above (Section 6.3) except the incubation 
time with the His-BtuF resin was changed. The mass used for these samples were 6 
g. The time periods investigated were: 1, 3, 6, 18, and 24 hours.  
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Racehorse faecal samples 
The protocol was conducted same as above (Section 6.3). Racehorse faecal samples 
from three different months (June, August, and September) were sent to find if there 
are differences in the cobamides present between the control racehorses and 
supplemented racehorses that were injected with hydroxocobalamin in the month of 
June 2018. 
i) JUNE (Month of supplementation) 
The mass of all control and treatment group samples used for this month was 6 g. 
ii) AUGUST (2 months after supplementation) 
Table 4 and 5 shows the mass of samples used for the control and treatment group in 
the month of August. Abbreviations of the names are in brackets and will be used in 
place of the full name for this report. Treatment group horses will be differentiated with 
a (+) beside their abbreviated name. Example: COR (+). 
Table 4: Mass of faecal samples used for control group 
Control group Mass (g) 
Ashington (ASH) 5.01 
Buxted Dream (BD) 5.00 
Coolongolook (COOL) 5.09 
Drill (DR) 5.58 
Edelline (EDE) 4.00 
Farewell to you (F2U)  5.08 
God Given (GG) 5.35 
La Rav (LR) 5.05 
Loveheart (LH) 5.04 










Table 5: Mass of faecal samples used for treatment group 
Treatment group (+) Mass (g) 
Alwaysandforever (A&4E) 5.20 
Cortado (COR)  NO SAMPLE RECEIVED 
Drap d’or (DDR) 5.34 
Fairlight (FL) 5.10 
Floria Tosca (FT) 4.00 
Four white socks (4WS) 5.00 
Plentiful (PL)  NO SAMPLE RECEIVED 
Swansdown (SD) 5.11 
Valyrian (VAL)  NO SAMPLE RECEIVED 
Warsaw road (WR) 4.92 
 
iii) SEPTEMBER (3 months after supplementation) 
Table 6 and 7 shows the mass of samples used for the control and treatment group in 
the month of September. 
Table 6: Mass of faecal samples used for control group 
Control group Mass (g) 
Ashington (ASH) 5.04 
Buxted Dream (BD) 5.26 
Coolongolook (COOL) 5.01 
Drill (DR) 4.83 
Edelline (EDE) 5.25 
Farewell to you (F2U)  NO SAMPLE RECEIVED 
God Given (GG) 5.03 
La Rav (LR) 5.56 
Loveheart (LH) 5.33 
Recollect (REC) 5.50 
 
Table 7: Mass of faecal samples used for treatment group 
Treatment group (+) Mass (g) 
Alwaysandforever (A&4E) 5.05 
Cortado (COR)  NO SAMPLE RECEIVED 
Drap d’or (DDR) 5.04 
Fairlight (FL) 5.29 
Floria Tosca (FT) 5.03 
Four white socks (4WS) 5.02 
Plentiful (PL)  NO SAMPLE RECEIVED 
Swansdown (SD) 4.85 
Valyrian (VAL)  NO SAMPLE RECEIVED 





Human faecal samples (Vitamin B12 deficient patients) 
Table 8 shows the mass of the human faecal samples sent by the pernicious 
anaemia society (PAS) that were used for cobamide extraction. 
Table 8: Mass of samples used for the human faecal samples  
Patient sample code Mass of sample 
H2 6.21 
H5 5.48 












U6 * 0.11 
U7 5.34 
U9 7.87 
U12 * 0.19 
*Masses used for these samples are lower than 2 g and would need to be taken into 
account when analysing the results,  
 
6.4 Extraction of cobamides from tissue samples 
Method testing with lamb liver 
i) Without methanol 
Tissue samples were thawed overnight at 4 oC and transferred onto a clean pestle and 
mortar. Liquid nitrogen is poured onto the sample and the sample is ground. The 
freeze, thaw, and grind process is repeated 3 times to get a fine powder. 0.1 mg/mL 
of KPi/KCN buffer is poured into the pestle and mortar to mix with the fine powder. The 
mixture was poured into a 50 mL falcon tube. The sample was vortexed to mix it evenly. 
Caps off, the falcon tube was placed in boiling water bath for 10 minutes. The sample 
is left to cool and kept at 4 oC overnight.  
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Then, the sample was centrifuged at 4000 RPM for 10 minutes. The supernatant was 
collected into a new 50 mL falcon tube. 800 µL of His-BtuF resin and 100 µL of 7.5 
µg/mL HBAH was added to the falcon tube. The mixture was left in 4 oC for 18 hours 
with gentle shaking. The cobamides was then purified and treated the same way as 
described previously. 
ii) With methanol 
The same method for without methanol was performed for the trial with methanol. The 
only difference was the addition of 10 mL of 50% v/v Methanol was added to the fine 
powder after grinding along with 0.1 mg/mL of KPi/KCN. 
Mice Kidney and Liver 
The same method described for method testing with lamb liver without methanol was 
used (Section 6.4 part (i) ). 
6.5 Extraction of cobamides from serum samples 
The procedure was adapted from the faecal sample procedure and two other studies 
(47, 48).Table 9 shows the volume of serum used for the cobamide extraction 
procedure. The serum and twice the serum volume of 0.6 M pH 4 acetate buffer with 
0.1 mg/mL of KCN was added into a 50 mL falcon tube. The samples were placed in 
boiling water bath for 10 minutes with stirring every 2 minutes. The samples were 
allowed to cool and left in 4 oC overnight. The samples were then centrifuged for 10 
minutes at 4000 RPM. The supernatants were collected onto a new falcon tube and 
1.5 times the serum volume of 0.3 N NaOH neutralizing buffer was added. Then, 1 
serum volume worth of 0.1 M pH 7.6 KPi buffer was added. The mixture was vortexed 
then 800 µL of His-BtuF resin and 100 µL of 7.5 µg/mL HBAH was then added. The 
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mixture was left in 4oC for 18 hours with gentle shaking. The cobamides was then 
purified and treated the same way as described previously. 
Table 9: Volume of serum samples analysed  
Sample Volume (mL) 
Racehorse DDR (+) JUN 2.5 
Racehorse DDR (+) AUG 3.0 
Racehorse DR JUN 3.5 
Racehorse DR AUG 3.0 
Mice 1 0.5 
 
6.6 HPLC-MS detection of cyanocobalamin analogues found after IMAC 
400-500 µL of sample were pipetted into HPLC-MS vials ready for the HPLC-MS 
(Agilent 1100 series HPLC coupled to a micrOTOF-Q (Bruker) mass spectrometer). 
The solvents used were 0.1% v/v of TFA as solvent A and 100% acetonitrile as solvent 
B. 50 µL of each sample was injected. Table 10 shows the 16 different lower ligand 
bases looked for and their corresponding masses. 
 
Table 10: Lower ligand analogues and their masses in ascending order searched 
in the HPLC-MS  





















6.7 Analysing HPLC-MS data 
An example of the method for collecting and analysing HPLC-MS data is shown in 
Figures 6 and 7. For example: Collecting the results for racehorse BD’s August sample. 
Peaks will appear where a signal is found in the corresponding mass. In Figure 6, the 
mass looked for is 672.78 (adenine). A clear peak is seen and the isotopic pattern for 
that detection further confirms the presence of this analogue. Thus the peak area of 
this analogue is integrated. An example where no peak is detected (just noise signals) 
can be seen in Figure 7. This means that this analogue is not present in the sample. 
 
 
























Figure 7: Example of an analogue not detected. No clear peak is seen. 
 
This method of analysis is applied to every analogue in every sample to create a profile 
of integrated peak areas according to the analogues detected. This can then be 
normalised by dividing it against the integrated peak area of HBAH to make the 
‘normalised peak area’. The prevalence of each analogue as a percentage of the total 
cobamides detected within each sample are calculated from the normalised peak 
areas. The integrated peak areas of each detected analogue for each sample can be 





Extraction of cobamides was performed on faecal samples from hedgehog, rabbit, 
horse, and humans. Firstly, the procedure was tested on hedgehog and rabbit faecal 
samples while the horse samples was used to optimise the procedure before using it 
for the racehorse faecal samples. Then, extraction was performed on the human 
faecal samples (pernicious anaemia patients) sent by PAS. Finally, this extraction 
procedure was adapted to try and find the types of cobamides present in mice tissue 
and horse or mice serum samples.  
The analysis of results involved a comparison of the integrated peak area/HBAH/g of 
each lower ligand analogue within each sample (normalised peak area). This 
comparison allows an indication of the relative amounts found between samples since 
quantification of the amount of each analogue was not possible without standards. 
Additionally, it is possible to calculate the relative amount of each analogue with 
respect to the total level of cobamides within the sample (prevalence of a certain 
analogue as a percentage of the total cobamides detected within each sample).  
Since vitamin B12 (cyanocobalamin) is commercially available, it is possible to more 
accurately determine the level of the analogue with the lower base 5,6-
dimethylbenzimidazole through the use of standards. This allows further analysis of 
this analogue in terms of quantifying it in ng of cyanocobalamin per gram of sample. 
Finally, the data were analysed using the three methods and results will be shown 
where significant observations are noted from either of the three comparisons 




7.1 Cyanocobalamin standard curve 
Table 11 below shows the amount of cyanocobalamin in ng injected into the HPLC-
MS for detection and the integrated peak area for each amount. It is translated into a 
graph in Figure 8 to generate the line of best fit equation. This graph is used for 
quantifying the analogue with 5,6-dimethylbenzimidazole as lower ligand base when 
needed for further analysis.  0.014 ng or (2 nM) of cyanocobalamin was loaded but the 
HPLC-MS was not sensitive enough to be detect it.  
Table 11: Integrated peak area values of different cyanocobalamin amounts 
injected into the HPLC-MS. 








Figure 8: Cyanocobalamin standard curve. R2 of 1 indicates a reliable trend line and thus, 
the equation of it can be used to quantify the amount of cyanocobalamin detected in samples.   























7.2 HPLC-MS detection of purified HBAH 
HPLC-MS run was performed for purified HBAH to check the purity of the molecule 
before using it for subsequent experiments (Figure 9). The HPLC-MS data indicated 
that this batch of HBAH is pure enough for use in subsequent experiments for 
normalising integrated peak areas of analogues detected. This enables HBAH to act 
as an internal standard allowing the peak areas to be compared fairly.   
 
 
Figure 9: HPLC-MS of HBAH. 
HPLC-MS profile of purified HBAH. There is just one large clear peak indicating a 
successful purification. Further analysis confirmed the peak is due to the presence of 
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7.3 Trial extraction and optimisation using faecal samples from various 
animals 
This methodology was tested with hedgehog and rabbit samples as a test run and to 
become familiar with the protocol before optimisation with the more abundant horse 
samples. 
7.3.1 Pet Hedgehog and Wild and Pet Rabbit – Trial extraction 
A trial extraction was performed to familiarise with the protocol using hedgehog and 
rabbit faecal samples. 
Pet Hedgehog 
Table 12 shows the types of cyanocobalamin analogues detected in the HPLC-MS 
and its corresponding integrated peak area per gram, normalised with HBAH. Table 
13 shows the percentage each detected analogue represents compared to the total 
picked up in each sample. This indicates that in this hedgehog, analogues with 2-
methyladenine and 2-methylthioadenine as its lower ligand base forms represent the 
majority of the cobamides found in its microbiome.  The lowest level of analogue was 
cobinamide, the incomplete cobamide that is missing the lower loop. The amount of 
cyanocobalamin present per g is 3.44 ng (Table 14). 
Table 12: Normalised integrated peak area per gram of detected lower ligand 
bases’ peaks.  
Lower ligand bases Integrated peak area/HBAH/g 
cobinamide 0.033 
3,4-dimethyl phenol 0.047 
2-amino-p-cresol 0.308 









Table 13: Prevalence of each analogue as a percentage of the total cobamides 
detected in the sample 
Lower ligand bases Percentage total in each sample (%) 
cobinamide 0.22 
3,4-dimethyl phenol 0.42 
2-amino-p-cresol 2.71 






Table 14: Quantification of 5,6-dimethylbenzimidazole  
Sample Amount of cyanocobalamin per g (ng) 
Pet hedgehog 3.44 
 
Wild and Pet Rabbit 
The same analysis performed on the hedgehog samples were done on wild and pet 
rabbits to see if any significant differences could be observed perhaps reflecting a 
different living environment. Table 15 gives a profile of which analogues were detected. 
The difference observed between the wild and pet rabbit were the presence of 
cobamides with cobinamide as its lower ligand base in pet rabbit samples and the 
presence of cobamides with 5-methoxy,6-methylbenzimidazole as its lower ligand 
base in wild rabbit samples. The percentage total data in Table 16 shows that the most 
prevalent cobamide detected was with 2-methyladenine as its lower ligand base for 
both wild and pet rabbit samples. The proportions of other analogues were similar to 
each other except for 5,6-dimethylbenzimidazole whereby it is significantly higher at 
19% in wild rabbit than pet rabbit at 8%. Lastly, comparing the amount of 
cyanocobalamin in each sample in Table 17, wild rabbit is observed to have higher 




Table 15: Normalised integrated peak area per gram of detected lower ligand 
bases’ peaks in wild and pet rabbit faecal samples.  
Integrated peak area/HBAH/g 
Lower ligand bases Wild  Rabbit Pet Rabbit 
cobinamide - 0.707 
3,4-dimethyl phenol 0.039 0.085 
2-amino-p-cresol 0.033 0.038 
adenine 0.057 0.370 
5,6-dimethylbenzimidazole 0.906 1.021 
2-methyladenine 2.512 7.115 
5-methoxy,6-methylbenzimidazole 0.077 - 
2-methylthioadenine 1.142 3.344 
Note: “– “ denotes no detection in the HPLC-MS and thus, no peaks integrated. 
Table 16: Prevalence of each analogue as a percentage of the total cobamides 
detected in the sample  
Percentage total in each sample (%) 
Lower ligand bases Wild  Rabbit Pet Rabbit 
cobinamide - 5.58 
3,4-dimethyl phenol 0.83 0.69 
2-amino-p-cresol 0.68 0.29 
adenine 1.20 2.91 
5,6-dimethylbenzimidazole 19.01 8.04 
2-methyladenine 52.70 56.12 
5-methoxy,6-methylbenzimidazole 1.61 - 
2-methylthioadenine 23.97 26.37 
Total 100 
 
Table 17: Quantification of 5,6-dimethylbenzimidazole (cyanocobalamin) 
Sample Amount of cyanocobalamin per g (ng) 
Wild rabbit 1.27 





7.3.2 Horse – Optimisation for more variety of analogues detected  
The method tested on hedgehog and rabbit samples showed that the extraction 
procedure can be utilized to obtain cobamide extraction profiles from animal faeces 
via HPLC-MS. This procedure was further optimised with a horse named ‘Ziggy’ in 
preparation for extraction of cobamides from racehorse samples. The two main factors 
investigated were the optimum time samples should be incubated with His-BtuF nickel 
resin and the optimum mass of the sample per falcon tube. The purpose of this is to 
maximize the types of cobamides detected when running the racehorses’ samples.  
i) Varying the mass of faecal samples 
Table 18 shows the different lower ligand bases detected when different masses of 
sample were used. This allows the determination of the minimum mass that gives a 
reliable result and therefore, results from samples with lower masses needs to be 
omitted or analysed with precaution. From three trials, it is better to use samples of 
more than 2 g for HPLC-MS analysis as the number of analogues detected was lowest 
with low level of material although the quantity of 5,6-dimethylbenzimidazole was not 
the lowest as shown in Table 19. If the provided sample was below 2 g, the 
concentration of cobinamides present was likely not high enough to yield a reliable 
result. This will need to be taken into account for observing patterns and deriving 
conclusions from samples in later experiments. From the trials conducted, it is 
observed that using 8 g of sample for every 50 mL falcon had the highest number of 




Table 18: List of lower ligand bases detected when using different masses of 
faecal samples and their respective integrated peak area/HBAH/g values.  
Integrated peak area/HBAH/g 
Lower ligand base 2 g 4 g 6 g 8 g 10 g 12 g 
cobinamide 1.625 2.401 2.094 0.563 0.710 0.319 
p-cresole - - - 0.038 - 0.023 
3,4-dimethyl phenol - 0.141 - 0.036 - - 
2-amino-p-cresol - 0.309 0.251 0.086 0.176 0.057 
5-
hydroxybenzimidazole 0.995 1.488 1.681 0.236 0.421 0.172 
Adenine  - 1.384 - - - - 
5,6-
dimethylbenzimidazole 2.007 2.030 2.495 0.442 0.757 0.234 
5-
methoxybenzimidazole - 0.630 - - - - 
2-methyladenine 13.437 16.146 19.913 3.002 5.470 1.837 
5-methoxy,6-
methylbenzimidazole - - - - - 0.011 
2-methylthioadenine 0.352 0.253 0.418 0.063 0.084 0.032 
 
Table 19: Quantification of 5,6-dimethylbenzimidazole averaged from three 
trials. 








ii) Incubating samples with His-BtuF nickel resin for different time periods. 
Table 20 shows the different cobamide with different lower ligand bases detected in 
the HPLC-MS. The samples were incubated with His-BtuF nickel resin (cobalamin 
binding protein attached to nickel resin) for different time periods to check if it has an 
effect on the number of analogues detected. Five different time points were used. As 
seen in Table 20, both 1 hour and 3 hour incubations had one less analogue detected 
compared to the other time points. This indicates that 1 hour and 3 hours incubation 
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may be inconsistent. The base 2-methylthioadenine was not detected in the 24 hour 
time point when it was detected in all others. On the other hand, only the 24 hour time 
point had the base 5-methoxy,6-methylbenzimidazole present. Next, the amount of 
5,6-dimethylbenzimidazole detected is compared in Table 21. The amount of 
cyanocobalamin in the 24 hour incubation is higher than the rest. This could indicate 
that 24 hour incubations are better for capturing more cyanocobalamin, however the 
number of cobamides detected may vary. Therefore to standardise and reduce 
inconsistencies, the incubation time with His-BtuF resin for racehorses’ samples was 
set between from 6 to 18 hours as it is observed to have the same detection profiles 
(Table 20). 
Table 20: List of lower ligand bases of cobamides detected when incubated with 
His-BtuF nickel resin for different time periods and their respective integrated 
peak area/HBAH/g values.  
Integrated peak area/HBAH/g at different time points 
Lower ligand base 1 hour 3 hours 6 hours 18 hours 24 hours 
cobinamide 0.227 0.249 0.262 0.352 0.339 
p-cresole 0.034 0.030 0.035 0.053 0.042 
3,4-dimethyl phenol 0.006 - 0.009 0.011 0.011 
2-amino-p-cresol - 0.007 0.013 0.011 0.014 
5-hydroxybenzimidazole 0.081 0.076 0.106 0.165 0.129 
Adenine  0.130 0.129 0.142 0.210 0.169 
5,6-
dimethylbenzimidazole 
0.057 0.066 0.101 0.139 0.265 
2-methyladenine 0.797 0.733 1.101 1.689 1.399 
5-methoxy,6-
methylbenzimidazole 
- - - - 0.006 
2-methylthioadenine 0.006 0.006 0.011 0.017 - 
 
 
Table 21: Quantification of 5,6-dimethylbenzimidazole  
Incubation time (hour(s)) Amount of cyanocobalamin per g (ng) 
1 0.57 







7.3.3 Summary of results from trial extraction and optimisation 
The extraction procedure was tested on hedgehog and rabbit faecal samples and it is 
observed that the 5-methoxy,6-benzimidazole analogue is only present in wild rabbits 
compared to pet rabbit and hedgehogs. On the other hand, wild rabbits do not have 
the cobinamide analogue which is present in pet rabbit and hedgehog samples. The 
most prevalent analogue as a percentage of the total cobamides within each sample 
is 2-methyladenine for both groups. However, the percentages for 2-methyladenine 
and 2-methylthioadenine are within 1 % of each other and could between them 
represent the most prevalent analogues. This was not observed in rabbit samples 
where the second most prevalent analogue (also 2-methylthioadenine) is 30 % lower 
than the highest.  Comparing the amount of the 5,6-dimethylbenzimidazole analogue, 
pet hedgehog  was observed to have the highest amount of this analogue in its faeces 
at 3.44 ng per gram of sample. Next was the wild rabbit samples at 1.27 ng per gram 
and lastly pet rabbit samples were found to contain 0.81 ng per gram. This difference 
could be an indication of difference in gut microbiome or dietary habits. 
Optimisation of the protocol using the horse samples showed that if 2 g samples were 
used for analysis, the number of cobamides detected will be lower than if 4 g of 
samples were used. Furthermore, incubating samples with His-BtuF nickel resin for 
different time periods reveal that 1 and 3 hour incubations showed inconsistencies 
although longer incubations had higher amounts of 5-dimethylbenzimidazole detected. 
Therefore, to standardise the protocol for racehorse samples, between 4 – 8 g of 




7.4 Racehorses’ faecal sample data 
The aim here is to identify any differences between treatment and control group 
racehorses in the level of analogues in their faecal samples. The treatment group 
horses are supplemented with 3mL of hydroxocobalamin by injections weekly for one 
month from June 2018. The control group received no injections. The two groups of 
thoroughbred racehorses studied are shown in Table 22. Their faecal samples were 
collected for 3 months, June (month of injection), August (2 months after injection), 
and September (3 months after injection).  
Table 22: The names of the racehorses used in the study.  
Control group Treatment group (+) 
Ashington (ASH) Alwaysandforever (A&4E) 
Buxted Dream (BD) Cortado (COR) * 
Coolongolook (COOL) Drap d’or (DDR) 
Drill (DR) Fairlight (FL) 
Edelline (EDE) Floria Tosca (FT) 
Farewell to you (F2U) * Four white socks (4WS) 
God Given (GG) Plentiful (PL) * 
La Rav (LR) Swansdown (SD) 
Loveheart (LH) Valyrian (VAL) * 
Recollect (REC) Warsaw road (WR) 
*Normalisation of peak area for VAL was not possible because the HBAH peak was 
undetected. Only June and August data available for F2U. Only June data available 
for COR (+), and PL (+). Thus, these have been omitted in the results. 
 
Table 23 shows the lower ligand bases present in the racehorse samples Of the 16 
different cobamide lower ligand masses looked for, no more than 10 was detected in 
each racehorse sample. The detected analogues will be discussed according to the 
groups these analogues belong in (phenols, benzimidazoles, purines, and 
cobinamide). Where applicable, bar charts are used to display any observable patterns. 
The three bars within each sample represents the values for June, August, and 
September (left to right). Where there are no bars, it indicates that the specific 
analogue was not detected.  
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Table 23: The lower ligand bases detected in the racehorse samples arranged 
according to the groups they belong in (phenols, benzimidazoles, purines, or 
cobinamide). 
Phenols Benzimidazoles Purines Cobinamide 













The three phenolic analogues present are p-creole, 3,4-dimethyl phenol, and 2-amino-
p-cresol. No observable differences between the two groups were noted for the results 
of 3,4-dimethyl phenol and 2-amino-p-cresol. 
Overall, the normalised peak area values of these three analogues in the month of 
June is much higher than in August or September shown in Figures 10-1 to 10-3. This 
observation is true for all samples except for COOL and SD (+) where the normalised 
peak area value of 2-amino-p-cresol in the month of August is higher (Figure 10-3).  
A difference between the treatment and control group’s normalised peak area values 
for p-cresole is observed. Figure 10-1 shows a gradual decrease in the normalised 
peak area levels of p-cresole from June to September in all treatment group samples 
which was not observed in the treatment group samples. However, when looking at 





Figure 10-1: Integrated peak area/HBAH/g of p-cresole in June, August, and September 
in racehorse samples. 
 
 
Figure 10-2: Integrated peak area/HBAH/g of 3,4-Dimethyl phenol in June, August, and 
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Figure 10-3: Integrated peak area/HBAH/g of 2-amino-p-cresol in June, August, and 








Figure 10-4: Prevalence of p-cresole as a percentage of the total cobamides detected 
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No observable differences for the normalised peak area or percentage prevalence was 
noted between the two groups for this class of analogue. Quantification of 5,6-
dimethylbenzimidazole show no observable differences between the control and 
treatment group. 
However, a similarity is that the normalised peak area values for June is much higher 
than August and September for all samples shown in Figures 11-1 to 11-3. Moreover, 
for the 5-hydroxybenzimidazole analogue, both groups showed a gradual decrease in 
5-hydroxybenzimidazole detection levels from June to September in Figure 11-1 
except for DR, EDE, and DDR (+). Lastly, 1H-naphtho [2,3-d] imidazole only present 
in 5 of the 16 samples. This could indicate the low requirement of this analogue 
towards the horses’ wellbeing.   
 
Figure 11-1: Integrated peak area/HBAH/g of 5-hydroxybenzimidazole in June, August, 
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Figure 11-2: Integrated peak area/HBAH/g of 5,6-dimethylbenzimidazole in June, 




Figure 11-3: Integrated peak area/HBAH/g of 1H-naphtho [2,3-d] imidazole in June, 
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No significant differences were observed between the control and treatment groups 
for all the analogues detected within this class. All three analogues showed higher 
levels of normalised peak values in June than August and September as shown in 
Figures 12-1 to 12-3. Moreover, there is a gradual decrease in the normalised peak 
area values from June to September observed in adenine (except for EDE) and 2-
methyladenine (except for EDE and WR (+) where September values are higher than 
August). Lastly, 2-methyladenine is the most prevalent analogue for all samples in 
terms of its percentage relative to the total cobamides detected within each sample as 
shown in Figure 12-4. No patterns were seen in the treatment group from June to 
September and showed no significant difference compared to the control groups. 
 
 
Figure 12-1: Integrated peak area/HBAH/g of adenine in June, August, and September 
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Figure 12-2: Integrated peak area/HBAH/g of 2-methyladenine in June, August, and 






Figure 12-3: Integrated peak area/HBAH/g of 2-methylthioadenine in June, August, 
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Figure 12-4: Prevalence of 2-methyladenine as a percentage of the total cobamides 
detected within each sample. 
 
iv) Cobinamide 
A difference is observed between the treatment and the control group. Shown in Figure 
13-1, treatment group samples showed a gradual decrease in this analogue’s 
normalised peak area values from June to September which was not observed in the 
control group. However, when comparing the percentage prevalence, there were no 
significant patterns observed (Figure 13-2).  
 
Figure 13-1: Integrated peak area/HBAH/g of cobinamide in June, August, and 
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Figure 13-2: Prevalence of cobinamide as a percentage of the total cobamides 
detected within each sample. 
 
 
7.4.1 Summary of racehorse faecal sample results 
The similarities between the two groups (supplemented and control racehorses) of 
samples are; firstly, the cobamide with 2-methyladenine as its lower ligand base is the 
most prevalent analogue due to highest percentage prevalence (Figure 12-4). 
Secondly, most detected cobamides had higher ‘normalised peak area’ values in June 
than August or September except for cobamides with 2-amino-p-cresol, cobinamide, 
and p-Cresole as its lower loop ligand.  
The last similarity noted is the gradual decrease of normalised peak area values of 2-
methyladenine and adenine from June to September (except the sample: EDE and 
ASH, Figures 12-1 and 12-2). 
For differences between the two groups, the normalised peak area value of cobamide 
and p-cresole showed a pattern of gradual decrease from June to August to 
September in the treatment group. This was not observed in the control group where 






























7.5 Vitamin B12 deficient human patient faecal samples 
The aim here is to find a correlation between the treatment responses of pernicious 
anaemia patients and the composition of cobamides or lower ligand analogues found 
in their faecal samples. These patients are treated by three monthly hydroxocobalamin 
intramuscular injections. Faecal samples from 18 patients split into two groups of 9 
were investigated.  
Group H: patients who are happy with their three monthly injection 
Group U: patients who are unhappy with their injection and require more frequent 
treatment to maintain wellbeing. 
Table 24 shows the information about remarks made by the patients regarding their 
treatment responses and if additional supplements were taken. This will be taken into 
account when analysis the HPLC-MS data of their faecal samples. 
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Table 24: Patient’s answers towards their reaction to their treatment and additional supplementations. 
Patient 
code 
Days since last injection from 
day of sample collection 
Happy with 3-monthly injections? 




Additional Vitamin B12 
supplements 
H2 45  Yes - - 
H5 No information provided 
H7 14 Injections every 2 months - - 
H9 ~365 (12 months) Yes - - 
H10 ~120 (4 months) Yes - - 
H11 75 Yes 10–11 weeks  Tablets, Spray 
H12 65  No 2 months - 
H13 31  Yes - - 
H15 No information provided 
U1 0 No, monthly injections - - 
U2 8 No 1.5 weeks - 
U3 1  No 2 weeks Multi-Vitamin with Vitamin 
B12, Spray 
U4 3 No, monthly injections 2 weeks Spray 
U5 24  No, monthly injections 1 month Occasional Tablets but 
not for the last 6 months 
U6 No information provided 
U7 14 (2 weeks) No 1 week Methylcobalamin Tablets, 
Boost sublingual spray 
U9 13 No, monthly injections 3.5 weeks - 
U12 14 No 2 months  
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Table 25 shows the lower ligand analogues detected for the unhappy group (group U). On a whole, the Table indicates that each 
patient has a different profile although certain analogues are detected for every patient (they are cobamides with lower ligand base: 
Cobinamide, 2-amino-p-cresol, Adenine, 5,6-dimethylbenzimidazole, 2-methyladenine, and 2-methylthioadenine). 
 Table 25: The extraction profiles of patient samples belonging to group U.
Integrated peak area/HBAH/g 
Lower ligand bases U1 U2 U3 U4 U5 U6 * U7 U9 U12 * 
Cobinamide 0.117 0.127 1.987 0.044 0.096 - 0.105 0.074 - 
p-cresole 0.028 0.015 0.224 - 0.028 - 0.019 0.018 - 
3,4-Dimethyl phenol 0.021 0.036 0.257 0.020 0.008 0.025 - 0.003 - 
2-amino-p-cresol 0.016 0.038 0.196 0.025 0.004 - 0.145 0.027 - 
5-methylbenzimidazole - - - - - - 0.004 - - 
5-hydroxybenzimidazole 0.117 - - - 0.111 - - - - 
Adenine  0.351 0.259 3.458 0.118 0.121 0.867 0.167 0.077 0.237 
5,6-dimethylbenzimidazole 0.046 0.048 16.947 0.075 0.089 0.281 0.630 0.132 - 
2-methyladenine 0.544 4.341 3.166 1.720 0.651 3.479 1.437 1.031 1.636 
5-methoxy,6-
methylbenzimidazole 
- - 0.099 - - - 0.039 - - 
1H-naphtho[2,3-d] imidazole - - 0.263 - 0.003 - 0.013 0.005 - 
2-methylthioadenine 0.235 0.865 4.396 1.293 0.103 0.675 0.188 0.120 0.212 




The same Table can be made for the happy group (group H) of patients (shown in Table 26). Comparisons between the extraction 
profiles of happy and unhappy patients can be made to identify any obvious or consistent differences and observations. For example, 
detection of the cobamide with 1H-naphtho [2,3-d] imidazole lower base is more prevalent in unhappy patients than happy patients. 
It is only detected once in happy group out of a total of 9 patients while it was detected 4 times out of 9 in the unhappy group. 
Moreover, the cobamide with 5-methoxy,6-methylbenzimidazole as the base was only detected in group U. From both Tables, the 
lower ligand base 2-methyladenine has the highest integrated peak area/HBAH/g value compared to rest of the lower ligand bases. 
This indicates that this base had the strongest signal being detected due to its high amounts. 
Table 26: The extraction profiles of patient samples belonging to group H. 
Integrated peak area/HBAH/g 
Lower ligand bases H2 H5 H7 H9 H10 H11 H12 H13 H15 
Cobinamide - - - 0.053 - 0.062 0.098 0.555 0.128 
p-Cresole - 0.018 - 0.010 - 0.014 0.025 0.135 0.110 
Benzimidazole - - - - - - - 0.006 - 
3,4-Dimethyl phenol - - - 0.008 - 0.021 0.055 0.028 0.023 
2-amino-p-cresol 0.131 0.014 - 0.018 - 0.014 - 0.060 0.039 
5-hydroxybenzimidazole - - - - - - - 0.336 - 
Adenine  0.208 0.047 0.362 0.050 - 0.307 0.312 0.395 0.202 
5,6-dimethylbenzimidazole 0.008 - - - - 0.357 0.082 0.046 0.012 
2-methyladenine 2.345 0.935 1.107 0.839 0.139 2.379 4.537 2.492 1.170 
1H-naphtho[2,3-d] imidazole - - - - - 0.004 - - - 




Again, quantification is not possible without standards but their prevalence of each cobamide can be looked at. This is seen in Table 
27 and 28 where the percentage of each analogue for each patient sample can be compared. Across all samples, 2-methyladenine 
was seen to have the highest peak area in all samples except U3. The percentage for it within each sample is also the highest except 
for U3. For group U, the second most prevalent lower ligand base varies between, adenine, 5-6-dimethylbenzimidazole, and 2-
methylthioadenine. However for group H, it is mainly 2-methylthioadenine except for H15 where it is adenine.  
Table 27: Percentage of each detected analogue relative to the total cobamides detected within the same sample for group 
U samples. 
Percentage (%) 
Lower ligand bases U1 U2 U3 U4 U5 U6* U7 U9 U12* 
Cobinamide 7.94 2.21 6.41 1.32 7.90 - 3.83 4.97 - 
p-Cresole 1.93 0.26 0.72 - 2.29 - 0.68 1.20 - 
3,4-Dimethyl phenol 1.42 0.62 0.83 0.60 0.64 0.46 - 0.18 - 
2-amino-p-cresol 1.05 0.66 0.63 0.76 0.36 - 5.28 1.84 - 
5-methylbenzimidazole - - - - - - 0.14 - - 
5-hydroxybenzimidazole 7.95 - - - 9.13 - - - - 
Adenine  23.80 4.52 11.16 3.58 9.95 16.27 6.08 5.16 11.38 
5,6-dimethylbenzimidazole 3.09 0.84 54.68 2.27 7.31 5.28 22.92 8.91 - 
2-methyladenine 36.89 75.79 10.21 52.23 53.75 65.31 52.32 69.35 78.45 
5-methoxy,6-
methylbenzimidazole - - 0.32 - - - 1.42 - - 
1H-naphtho[2,3-d] imidazole - - 0.85 - 0.21 - 0.49 0.33 - 
2-methylthioadenine 15.93 15.09 14.18 39.25 8.46 12.68 6.84 8.05 10.17 
Total 100 
* Note: The low variety of U6 and U12 detected could be due to low amount of sample (0.11 g and 0.19 g respectively). 
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Table 28: Percentage of each detected analogue relative to the total cobamides detected within the same sample for group 
H samples. 
Percentage (%) 
Lower ligand bases H2 H5 H7 H9 H10 H11 H12 H13 H15 
Cobinamide - - - 3.93 - 1.77 1.72 13.03 4.72 
p-Cresole - 1.16 - 0.79 - 0.41 0.44 3.16 4.07 
Benzimidazole - - - - - - - 0.15 - 
3,4-Dimethyl phenol - - - 0.59 - 0.60 0.97 0.65 0.86 
2-amino-p-cresol 4.38 0.89 - 1.34 - 0.39 - 1.41 1.43 
5-hydroxybenzimidazole - - - - - - - 7.89 - 
Adenine  6.96 3.02 16.62 3.75 - 8.79 5.47 9.28 7.46 
5,6-dimethylbenzimidazole 0.25 - - - - 10.24 1.43 1.09 0.43 
2-methyladenine 78.43 59.90 50.78 62.81 59.17 68.18 79.61 58.54 43.33 
1H-naphtho[2,3-d] imidazole - - - - - - 0.12 - - 
2-methylthioadenine 10.17 9.98 35.03 32.60 26.79 40.83 9.49 10.34 4.80 
Total 100 
 
Translating the data from Tables 25 and 26 into bar charts to compare each cobamide detected across all patient samples like in 
Figures 14-1 and 14-2. They show a clearer picture of any pattern observed. The same can be shown for all detected cobamides 




In this Figure, a more balanced chart is observed in comparison to Figure 14-1. The 
peak area in U3 is the highest in terms of signal strength however the percentage is 
at about 6% which indicates there must be another analogue with stronger signals. 
Overall, the percentage of cobinamide in group U and group H show no real pattern 
with H13 having the most in the sample. 
 
Figure 14-1: Integrated peak area/HBAH/g of cobinamide in each patient sample. No 
real pattern is observed. Sample U3 had the highest value while sample H13 was the 
highest amongst group H. 
 
 
Figure 14-2: Prevalence of cobinamide as a percentage of the total cobamides 






































































The chart for p-cresole in Figure 15-1 shows that again, U3 has the highest peak area 
value while H13 had the highest value in group H. The percentage chart in Figure 15-
2 shows that the percentage of this this cobamide is not as high as cobinamide. p-
cresole had the highest prevalence in H15 at around 4%.  
 




Figure 15-2: Prevalence of p-cresole as a percentage of the total cobamides detected 







































































The cobamide with benzimidazole as its lower ligand base was only detected in H13 
across all patient samples as seen in Figures 16-1 and 16-2. The peak area value is 
a lot lower than the values seen in cobinamide and p-cresole indicating how weak the 
signal for this cobamide was. Thus, as expected, the percentage for this cobamide is 
lower.  
 
Figure 16-1: Integrated peak area/HBAH/g of benzimidazole in each patient sample 
 
 
Figure 16-2: Prevalence of benzimidazole as a percentage of the total cobamides 



































































iv) 3,4-Dimethyl phenol 
In Figures 17-1 and 17-2, U3 again has the highest value of 3,4-dimethyl phenol 
compared to the rest of the samples. In group H, H12 had the highest value. However, 
when looking at percentage of total cobamide, this analogue is most prevalent in U1 
and in H12 for group H. Additionally, group H seems to have similar percentage with 
values from 0.60 to 1 % although more fluctuation is observed in group U. 
 
Figure 17-1: Integrated peak area/HBAH/g of 3,4-dimethyl phenol in each patient 
sample 
 
Figure 17-2: Prevalence of 3,4-dimethyl phenol as a percentage of the total cobamides 

































































From Figure 18-1 and 18-2 no clear pattern can be observed between group U and H. 
A still consistent observation is that U3 also have the highest value for integrated peak 
area/HBAH/g across all samples. Fluctuations in percentage was observed and no 
clear pattern can be deduced.  
 




Figure 18-2: Prevalence of 2-amino-p-cresol as a percentage of the total cobamides 































































This is another analogue where it is only detected in one sample in U7. Like 
benzimidazole mentioned above, the percentage and the peak area value seen in 
Figures 19-1 and 19-2 is very low compared to other analogues which could explain 
why it was only detected in one sample.  
 




Figure 19-2: Prevalence 5-methylbenzimidazole as a percentage of total cobamides 





































































The frequency detected for this analogue as seen in Figures 20-1 and 20-2 is just 3, 
2 of which are detected in group 2. The integrated peak area values are not as low as 
in those that were only detected once. Additionally, their percentage is around 8 to 
9 %. This could indicate that weak signals are unlikely the cause of this low frequency 
of detection. 
 




Figure 20-2: Prevalence of 5-hydroxybenzimidazole as a percentage of the total 





































































In Figures 21-1 and 21-2, U3 again has the highest integrated peak area/HBAH/g 
value but as a percentage, U1 is the highest. This analogue is detected in all patients 
except for H10. The percentage or integrated peak area/HBAH/g values of adenine 
fluctuates and do not display any obvious pattern. 
 




Figure 21-2: Prevalence of adenine as a percentage of the total cobamides detected 



























































Percentage of Adenine 
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ix) 5,6-dimethylbenzimidazole (cyanocobalamin) 
This lower ligand is the usual base that is ‘useful’ for humans. In Figure 22-1, U3 again 
has the highest value. Due to the vast difference, U3 is removed in order to see the 
values of other samples clearer in Figure 22-2. It is observed that this analogue is 
more frequently detected in group U than group H. It is detected in 8 of 9 samples in 
group U and only 5 of 9 samples in group H. Furthermore, when looking at the 
percentage, in Figure 22-3 and 22-4, the group U percentage is higher than the group 
H percentage except for samples H11 and U2.  
 



































Figure 22-2: Integrated peak area/HBAH/g of 5,6-dimethylbenzimidazole in each 
patient sample. This is a chart without U3 to see the bars of other samples clearer due to 




Figure 22-3: Prevalence of 5,6-dimethylbenzimidazole as a percentage of the total 































































Figure 22-4: Prevalence of 5,6-dimethylbenzimidazole as a percentage of the total 
cobamides detected within each sample. This is a chart without U3 to see the bars of 
other samples clearer due to the vast difference in value between U3 and the rest. 
 
 
Quantification of the amount of cyanocobalamin detected per gram in each sample 
Tables 29-1 and 29-2 shows the amount of cyanocobalamin quantified for group U 
and H respectively. This is graphically presented in Figures 22-5 and 22-6. These 
Figures are similar to that of the integrated peak area/HBAH/g figures (Figure 22-1, 
22-2). Nonetheless, the pattern observed remains similar. 
 
Table 29-1: Amount of cyanocobalamin in ng in each gram of group U sample  
Sample U1 U2 U3 U4 U5 U6 U7 U9 U12 
Amount per g (ng) 0.443 0.335 31.679 0.409 1.399 4.160 7.314 3.167 0 
 
Table 29-2: Amount of cyanocobalamin in ng in each gram of group H sample 
Sample H2 H5 H7 H9 H10 H11 H12 H13 H15 






































Figure 22-5: Amount of cyanocobalamin quantified for each patient sample 
 
 
Figure 22-6: Amount of cyanocobalamin quantified for each patient sample. This is a 
chart without U3 to see the amount present in other samples due to the vast difference in 

















































x) 2-methyladenine  
2-methyladenine is detected in all samples and its integrated peak area/HBAH/g value 
is the highest compared to other analogues except for U3 seen in Figure 23-1. Looking 
at both Figures 23-1 and 23-2, there does not seem to be any observable differences 
between group U and group H but the similarity is that this analogue is the most 
prevalent with the highest percentage. 
 
Figure 23-1: Integrated peak area/HBAH/g of 2-methyladenine in each patient sample 
 
 
Figure 23-2: Prevalence of 2-methyladenine as a percentage of the total cobamides 






































































This analogue is only detected in group U patients. The integrated peak area/HBAH/g 
values in Figure 24-1 is not as low as in 5-methylbenzimidazole or benzimidazole 
however it is lower when compared to 5-hydroxybenzimidazole. Thus, the weak signal 
could be a reason why this compound is not more often detected. This is supported 
by looking at the percentage (Figure 24-2). This analogue represents only 1.4 % for 
U7 and 0.3% for U3 which implies there are very low amounts of this analogue in the 
sample to begin with. 
 
Figure 24-1: Integrated peak area/HBAH/g of 5-methoxy, 6-methylbenzimidazole in 
each patient sample 
 
 
Figure 24-2: Prevalence of 5-methoxy,6-methylbenzimidazole as a percentage of the 

































































xii) 1H-naphtho[2,3-d] imidazole 
This analogue is detected more frequently in group U than in group H. As seen in 
Figure 25-1, it is seen in 4 samples in group U while it only appears once in group H. 
U3 again has the highest value for the integrated peak area/HBAH/g for this analogue. 
Additionally, U3 has the highest percentage compared to other samples seen in Figure 
25-2. The percentage value in group U is higher than the group H samples. 
 




Figure 25-2: Prevalence of 1H-naphtho[2,3-d] imidazole as a percentage of the total 

































































This analogue is detected in every sample as seen in Figure 26-1. Again, U3 has the 
highest integrated peak area/HBAH/g value compared to the rest of the samples. 
Considering the percentage values in Figure 26-2, most of group H samples had 
higher percentages than group U samples except for U4. 
 




Figure 26-2: Prevalence of 2-methylthioadenine as a percentage of the total 




































































7.5.1 Summary of human faecal sample results 
In terms of percentage across all samples, the cobamide with 2-methyladenine as its 
lower ligand base has the highest prevalence except for patient U3’s sample. The 
second most prevalent cobamide for group U (unhappy) and H (happy) is different. In 
group U samples, it can be cobamides with either adenine (4 samples), 5-6-
dimethylbenzimidazole (2 samples), or 2-methylthioadenine (3 samples) as lower loop 
bases. For group H samples, it is mainly 2-methylthioadenine (7 samples).  
One recurring observation is that sample U3 has the largest normalised peak area 
values for several cobamides compared to rest of the samples (Table 25, highest for 
7 of the 13 detected analogues – cobinamide, p-cresole, 3,4-dimethyl phenol, 2-
amino-p-cresol, adenine, 5,6-dimethylbenzimidazole, and 2-methylthioadenine). 
Despite this, the percentage prevalence of these analogues was not the highest. 
Another interesting observation about sample U3 is that the cobamide with 2-
methyladenine as its base is not the most prevalent analogue contrary to rest of the 
patient samples (Figure 23-2). On top of this, the percentage value for U3 is much 
lower than the rest at 10% while the rest was above 30% (Figure 23-2).  
Another observation is the low frequency of detection for analogues belonging to the 
benzimidazoles. Six in total were detected: benzimidazole, 5-methylbenzimidazole, 5-
hydroxybenzimidazole, 5,6-dimethylbenzimidazole, 5-methoxy,6-
methylbenzimidazole, and 1H-naphtho[2,3-d] imidazole. Of these, only 5-6-
dimethylbenzimidazole was detected in more than 3 samples. The benzimidazole 
analogue was detected only in sample H13 which was barely present at 0.14% (Figure 
16-2). 5-methylbenzimidazole was only detected in U7 also at a percentage of 0.14% 
(Figure 19-2). 5-hydroxybenzimidazole was detected in 3 samples (U1, U5, and H13) 
but at a much higher percentage level of 8-9% (Figure 20-2). 5-methoxy,6-
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methylbenzimidazole was detected in 2 samples in group U (U3, and U7) representing 
0.3 and 1.4 % of total cobamides present in these samples respectively (Figure 24-2). 
1H-naphtho[2,3-d] imidazole was only present in 5 samples all at less than 0.90 % 
prevalence (Figure 25-2). Therefore, not only is this group of analogues occur 
remarkably infrequently, it is also present at very low levels except for 5-
hydroxybenzimidazole.  
The ‘useful’ base for humans, 5-6-dimethylbenzimidazole (cyanocobalamin) was 
detected more frequently in group U than group H. It also had higher prevalence values 
detected in group U than group H samples (excluding H11 and U2 due to low sample 
weight). The quantification of this analogue revealed no new patterns however when 
analysed with the patients’ profiles in Table 24, it can be seen that taking additional 
supplements affects the amount of this cobamide in their faeces. All the patients taking 
additional supplements had higher amounts of cyanocobalamin in their faecal samples 
(U3, U4, U5, U7, and H11 – Figures 22-5 and 22-6). Patients taking both a tablet 
containing Vitamin B12 and a boost sublingual spray is observed to have higher 
amounts of cyanocobalamin in their faeces. U3 had the highest amount and the patient 
take both multi-vitamin (with vitamin B12) and sublingual spray. Likewise, U7 and H11 
takes methylcobalamin tablets and sublingual spray and has a higher amount of 
cyanocobalamin detected than patients who took only tablet or spray. The patient U4 
who only took sublingual spray had no higher amounts of cyanocobalamin detected 
than some patients who took no additional supplements (lower than U1, U9, and H12).  
Finally, U5 only takes Vitamin B12 tablets and is shown to have higher amounts of 
cyanocobalamin detected compared to U4 and those who did not take any 
supplements except U9.  
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Other observations include the higher frequency of detection of analogue with base 
1H-naphtho [2, 3-d] imidazole in group U than H samples (4 times in group U and 1 
time in group H). 
Lastly, the percentage of the 2-methylthioadenine found in group H is generally higher 
than that found in group U. As observed in this experiment, 5 of the 9 samples from 
group H had more than 25 % of total cobamides as 2-methylthioadenine while only 1 
of 9 sample from group U was above this level. 
7.6 Animal tissue samples 
Adapting the faecal sample extraction protocol for extraction of cobamides in tissue 
samples. Three mice liver and kidney samples were sent to determine the types of 
lower ligand analogues present in these tissues. Initial testing of method was done 
with lamb liver before extraction of mice samples.   
7.6.1 Method testing with lamb liver 
Extraction procedure tested with lamb liver to determine the difference between 
presence and absence of 50 % methanol in the extraction process. Table 30 below 
shows the types of analogues detected and its normalised peak area values with and 
without methanol. It is observed that both procedures have the same variety of 
cobamides detected. However, the normalised peak area values are all higher in the 
extraction procedure without methanol. Additionally, the amount of 5,6-
dimethylbenzimidazole was quantified. The sample with methanol in the extraction 
process had 43 ng of cyanocobalamin per gram while the sample without methanol 
had 66 ng per gram. This could indicate that the presence of methanol in the extraction 
solvent reduced the amount of cobamides released or captured by the resin. Thus, the 




Table 30: The lower ligand bases detected in liver samples from extraction 
procedure with and without 50 % v/v methanol.  
 
7.6.2 Mice Liver 
Table 31-1 below shows the different analogues detected within the sample and their 
respective normalised peak area values. It is observed that the type of analogues 
detected are the same in all 3 samples and the normalised peak area values are 
similar. The prevalence of each analogue in each liver sample also shows similar 
values as the percentages are just within 2 % of each other (Table 31-2). Lastly, 5,6-
dimethylbenzimidazole is the most prevalent analogue in each sample.  
Table 31-1: The lower ligand bases detected in 3 mice liver samples and their 
normalised peak area values 
Integrated peak area/HBAH/g 
Lower ligand base Mice 1 Mice 2 Mice 3 
Adenine  0.019 0.007 0.011 
5,6-dimethylbenzimidazole 1.060 1.018 1.339 
2-methyladenine 0.066 0.044 0.067 
1H-naphtho[2,3-d] imidazole 0.034 0.037 0.047 
2-methylthioadenine 0.025 0.018 0.027 
 
Table 31-2: The lower ligand bases detected in 3 mice liver samples and the 
prevalence of each analogue as a percentage of the total cobamides detected within 
each sample 
Percentage (%) 
Lower ligand base Mice 1 Mice 2 Mice 3 
Adenine  1.56 0.65 0.74 
5,6-dimethylbenzimidazole 88.02 90.56 89.84 
2-methyladenine 5.49 3.90 4.50 
1H-naphtho[2,3-d] imidazole 2.83 3.33 3.14 
2-methylthioadenine 2.10 1.56 1.78 
Total 100 
Integrated peak area/HBAH/g (normalised peak area) 
Lower ligand base With 50 % v/v methanol Without methanol 
5-hydroxybenzimidazole 0.058 0.158 
5,6-dimethylbenzimidazole 1.809 4.189 
1H-naphtho[2,3-d] imidazole 0.065 0.101 
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7.6.3 Mice Kidney 
All kidney samples are observed to have the same type of cobamides detected as 
seen in Table 32-1. Their normalised peak area values are not as similar as they are 
in the liver samples. This is reiterated in Table 32-2, where bigger percentage 
differences between the analogues are seen in the kidney samples than the liver 
samples. 
Table 32-1: The lower ligand bases detected in 3 mice kidney samples and their 
normalised peak area values 
Integrated peak area/HBAH/g 
Lower ligand base Mice 1 Mice 2 Mice 3 
Adenine  0.013 0.014 0.008 
5,6-dimethylbenzimidazole 0.413 2.317 0.593 
2-methyladenine 0.030 0.067 0.042 
1H-naphtho[2,3-d] imidazole 0.017 0.124 0.036 
2-methylthioadenine 0.006 0.012 0.017 
 
Table 32-2: The lower ligand bases detected in 3 mice kidney samples and the 
prevalence of each analogue as a percentage of the total cobamides detected within 
each sample 
Percentage (%) 
Lower ligand base Mice 1 Mice 2 Mice 3 
Adenine  2.70 0.53 1.19 
5,6-dimethylbenzimidazole 86.14 91.45 85.28 
2-methyladenine 6.36 2.63 5.98 
1H-naphtho[2,3-d] imidazole 3.54 4.90 5.17 
2-methylthioadenine 1.26 0.49 2.38 
Total 100 
 
7.6.4 Quantifying cyanocobalamin 
Further analysis is done for the mice liver and kidney samples by quantifying the 
amount of cyanocobalamin present in each sample shown in Figure 27. This figure 
shows that the amount of cyanocobalamin present in liver are far higher than in kidney. 
Moreover, liver samples show similar amounts of the 5,6-dimethylbenzimidazole 
analogue to each other compared to the kidney samples. This value however, is just 
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indicative since it does not account for their sample weight. Thus, the difference in 
levels could differ. 
 
Figure 27: Comparison between the amounts of cyanocobalamin detected in all 
mice tissue samples 
 
7.6.5 Summary of results from animal tissue testing 
The adapted procedure for cobamide extraction enabled the detection of various lower 
ligand bases present in the tissue samples. Presence of methanol decreased the 
normalised peak area values and does not need to be part of the extraction solvent. 
Similarities are observed between the liver and kidney samples. The types of 
cobamides detected and the most prevalent analogue (5,6-dimethylbenzimidazole) for 
both mice liver and kidney tissue are identical. However, the prevalence of each 
cobamide is different. Bigger percentage differences between the analogues are seen 
in the kidney samples than the liver samples. The quantification of 5,6-
dimethylbenzimidazole showed that liver tissues have a much higher and more 
consistent amount of cyanocobalamin than kidney samples. These could have 































Amount of cyanocobalamin in mice tissue
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7.7 Animal Serum samples 
Horse and mice serum samples were sent to determine the type of analogues that are 
present in the sample. The extraction procedure adapted for the serum did not detect 
any cobamides in the horse samples. No signals for any cobamide masses searched 
for was detected. One of the three mice serum samples had detected levels of only 
the 5,6-dimethylbenzimidazole analogue. Shown in Figure 28, the intensity of the 
signal is low, the presence of a peak at the mass for this analogue indicates that the 
sample might contain traces of this analogue. The amount quantified using the 
standard curve for this peak is 0.061 ng/mL or 61 pg/mL. More sample volume or a 
more sensitive method may be needed to capture the cobamides in serum samples to 
increase the detection of other possible analogues and improve the signal intensity. 
 
Figure 28: HPLC-MS of mice serum sample. A peak is seen at the associated mass 





This project tested the cobamide extraction procedure and used it on different 
specimens. It is tested primarily on faecal samples with a view towards the microbiome. 
Faecal samples from various animals (hedgehog, rabbit, and horses) were obtained 
for testing and optimisation of the extraction protocol. Subsequently, it was used to 
investigate the effect of supplementation on the cobamide extraction profiles of 
racehorses’ microbiome.  Next, the procedure it was used to analyse human faecal 
samples with an aim to find any relationship between the treatment responses of 
Vitamin B12 deficient patients and the types of cobamides detected. Lastly, this 
procedure was adapted for use on tissue and serum samples.  
8.1 Cobamide trial extraction procedure for faecal samples 
Although a larger sample size from different rabbits and hedgehogs would be required 
to confirm observed differences between them, the method testing showed that this 
procedure worked well for faecal samples and was able to capture a variety of 
cobamides for detection. The percentage difference between 2-methyladenine and 2-
methylthioadenine in hedgehogs is way lesser than that in rabbits. This could be 
explained by their difference in gut microbiome or different dietary habits. For instance, 
hedgehogs belong to the erinaceidae family and are not well documented to practice 
coprophagy like rabbits (44). This practice could explain why hedgehogs have more 
than twice the amount of cyanocobalamin in their faecal samples (Tables 14 and 17). 
Coprophagy allows rabbits to consume cobalamin produced by their gut bacteria that 
are present in cecotropes. These results in less cobalamin being present in the faecal 
pellets (49). Moreover, the frequency of coprophagy is affected by diet and thus, 
cobamide rich pellets will less likely be consumed (32).The difference between the pet 
and wild rabbit could be due to their different dietary habits and again, would require 
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a larger sample size to confirm that the differences are true (Table 17). This could be 
an area for future studies, whereby the effect of different dietary habits on the 
cobamide levels present in faeces is investigated. This could open doors into finding 
ways in controlling the gut microbiome in those organisms.  
Due to availability of samples, horse faecal samples were used to optimise the 
extraction protocol after method testing. Two factors, mass of sample and incubation 
time with His-BtuF nickel resin was explored. It showed that faecal samples less than 
2 g will yield inconsistent results and less number of cobamides will be detected by 
the HPLC-MS (Table 18). Moreover, His-BtuF resin is stable when incubated with the 
supernatant of faecal samples and needed to be incubated more than 3 hours to allow 
more binding to occur between the cobamides and the resin (Table 20). This allows 
more consistent and reliable results to be obtained. 
8.2 Racehorse faecal samples 
Supplementation of racehorses with hydroxocobalamin does not seem to have a 
significant effect on the types of cobamides present in the racehorses’ faecal samples. 
No significant difference or pattern was noted between the supplemented and control 
group racehorses when comparing the normalised peak area and percentage 
prevalence values. There are only two observed differences noted between the 
supplemented and control group horses. 
Firstly, cobinamide, the incomplete cobamide that is missing the lower loop is seen to 
have a pattern of gradual decrease in the normalised peak area values from June to 
September in the supplemented group only (Figure 13-1). Secondly, this pattern was 
observed for the p-cresole analogue as well (Figure 10-1). This could be an indication 
towards the effect of supplementation on the physiological change that is occurring.  
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The pattern can be due to the alternation in intestinal flora due to the exposure of extra 
Vitamin B12 .P-cresole is only known to be synthesized by Veillonellaceae, and thus, a 
gradual shift in the levels of this analogue could reflect the abundance of this taxon in 
the racehorses’ gut (29, 50). Despite this observation, the percentage prevalence of 
this analogue did not show the progressive decrease from June to September as 
observed when comparing the normalised peak area values (Figure 10-4). For the 
treatment group, the normalised peak area values decreased from June to August 
(Figure 10-1), but the percentage prevalence increased from June to August (Figure 
10-4). This indicates that the amount of p-cresole synthesized within the microbiome 
did not decrease relative to the total amount of all cobamides in its gut. The percentage 
spiked in the month of August from June could be related to the shift in the microbiome 
composition.  
This experiment was done in parallel with another study by Professor Hunter 
(supplementary- S13). In this study, the effect of supplementation on the serum levels 
of vitamin B12 and performance is investigated. The injections increased the level of 
vitamin B12 in the blood but no changes to performance was noted by the trainer. This 
increase is temporary (noted in June to July 2018) and the higher levels disappeared 
in the subsequent months (August and September 2018).  
Combining the two, no obvious relationship could be noted. Further investigations 
would be needed to delve deeper into studying why there is no significant difference 
or how differences can be caused by other factors. It could be argued that this is due 
to the sufficient supply of cobalamins from the hind gut of the horses through microbial 
synthesis to sustain themselves. Thus, most of the injected cobalamin is possibly 
excreted via the urine (51). 
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8.3 Human faecal samples 
This area of the project set out to investigate the potential link between the gut 
microbiome and the types of cobamides present in the faecal samples of patients with 
pernicious anaemia. Two groups of patients were investigated for differences in the 
cobamides present in their faeces. Patients in group H are happy with their current 
vitamin B12 treatment (only needing their hydroxocobalamin injections every 3 months 
or more) while patients in group U are unhappy with their treatment (symptoms of 
pernicious anaemia appear before their next 3 monthly injection is due). With this, the 
final objective is to find potential areas of focus to improve the outcomes of patients’ 
response to Vitamin B12 deficiency treatment.  
The results of this experiment showed that 2-methyladenine is the most prevalent 
analogue in all the human faecal samples. The second most abundant analogue is 
different between the group U (unhappy) and group H (happy) patients. The second 
most abundant analogue in the happy group is 2-methylthioadenine (Figure 23-2). The 
unhappy group patients are split between adenine, 5,6-dimethylbenzimidazole, and 2-
methylthioadenine. There is a low frequency of detection for cobamides with lower 
base belonging to the benzimidazoles observed except for 5,6-dimethylbenzimidazole. 
5,6-dimethylbenzimidazole (lower loop of cyanocobalamin) is detected more 
frequently in group U than H (Figure 22-1). Lastly, the analogue 1H-naphtho [2,3-d] 
imidazole is detected more frequently in unhappy patients’ samples than the group 
happy patients’ samples.  
Comparing these observations to a previous study (supplementary-S14), 2-
methyladenine remains the most prevalent analogue detected and the second most 
abundant is 2-methylthioadenine for majority of the samples. The supplementary study 
also showed that analogues with the lower base in the benzimidazoles class had lower 
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frequencies of detection. However, the differences between the supplementary study 
and this study is that 5,6-dimethylbenzimidazole and 1H-naphtho [2,3-d] imidazole 
was not more frequently detected in group U patient samples in the supplementary 
study.  
To sum up the observations between this project and supplementary study (S14), 2-
methyladenine is the most abundant analogue in human faecal samples. The second 
most abundant is most likely 2-methylthioadenine. The analogues belonging to the 
benzimidazoles group are not prevalent and not frequently detected. No significant 
observable differences or patterns were noted between the group H and U samples.  
Further studies can be done with larger sample sizes to test to what extent are these 
observations true. Because of sample size, statistical analysis was not performed. 
Therefore, larger sample sizes will be needed to have statistically reliable observations 
and predictions.  
Taking the patient profile in Tablet 24 into consideration, differences can be seen when 
patients take additional supplements such as multi-vitamin tablets containing B12. 
Additional B12 supplements taken on top of their 3-monthly injections increased the 
amounts of 5,6-dimethylbenzimidazole (cyanocobalamin) in faecal samples (U3, U4, 
U5, U7, and H11). Patients who took both tablets and spray (U3, U7, and H11) had 
higher amounts of cyanocobalamin than those who took just spray (U4) or tablet (U5) 
in their samples. Additionally, the patient who took tablets (U5) had higher 
cyanocobalamin than the patient who only took the spray (U4). This could indicate the 
efficiency of absorbing vitamin B12 in these patients. Having more cyanocobalamin in 
their system could mean either the patients are not absorbing it into the system and 
thus being excreted into the faeces. It could also indicate an excess in cyanocobalamin 
within the body (10).  
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Studies have been done to compare the effectiveness of these treatments as a 
replacement therapy for one another but a combination of all remains to be fully 
investigated (52–54). In these studies, oral supplements and sublingual vitamin B12 
spray was deemed to be as effective as intramuscular injections in treating patients 
with cobalamin deficiency in obtaining short term responses (52–54). Future 
investigations can be conducted to study the difference in absorption between the 
patients. Patients could be put under strict cobalamin free diets and the amount of 
cobalamins with 5,6-dimethylbenzimidazole as base consumed through treatments 
can be recorded. The amount excreted can be monitored through urine and faeces to 
give an indication of how much of the vitamin is retained. The difference in retention 
can be associated to the gut bacteria within the patients.  
A supplementary study by Cultech (supplementary-S15) was done to find out if there 
are any differences between the gut microbiome between the two patients groups and 
the control group. One point of interest could be the higher abundance of Lactobacillus 
in their microbiome in unhappy group patients compared to the happy and control 
group patients. Lactobacillus is shown to compete for available cobalamins and 
produce only pseudo-cobalamin (cobamide with adenine as its lower ligand base) 
which is not useful for humans (55).  
Other significant observations from this study include lesser abundance of 
Bifidobacterium in patients (group U and H) compared to non-patients. It has been 
found in other studies that Bifidobacterium can produce several B-vitamins including 
vitamin B12 (56). Therefore, it could be suggested that increasing this genus of bacteria 
might improve the symptoms of these patients. Lastly, Klebsiella and an unidentified 
genus were found to be higher in abundance for patients than non-patients. Klebsiella 
is known to also compete for cobalamins with the host (27). This could be a potential 
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reason why some patients are unhappy with their treatments. Having bacterial 
overgrowth in the small intestine have been shown to contribute to the level of vitamin 
B12 absorption although it could be reversed with antibiotic therapy (43, 57).  
Thus, to improve absorption or treatment outcomes by reducing the competition via 
alteration of gut microbes could be a feasible strategy. Multiple studies have also 
shown the connection between vitamin B12 and the gut by proving its association with 
inflammatory bowel disease (23, 27, 43, 58). Moreover, because different bacteria also 
require specific cobamides, the gut microbiome can be shifted by changing the levels 
of specific cobamides (23)(28). This could go beyond implications in treating 
cobalamin deficiencies. It can be potentially serve as a foundation towards making 
cobalamin treatments targeting intestinal flora and gut diseases in the future  
8.4 Animal tissue and serum samples 
The adapted procedure was able to identify the types of cobamides present in tissue 
samples. However, this procedure was not sensitive enough for serum samples. Only 
one analogue (5,6-dimethylbenzimidazole) was detected in the mice sample and none 
was detected in the racehorse serum samples (Figure 28). Although the mean vitamin 
B12 level in horse serum varies, the average can be considered around 6300 pg/mL 
(59). The lowest detected cyanocobalamin level shown in the standard curve is 1360 
pg/mL. Therefore, there should be a signal if cyanocobalamin is present in normal 
amounts (samples sent were 1.5 mL to 2 mL each). This could be due to the loss of 
these molecules during the extraction process or the concentration of these analogues 
are too low for the HPLC-MS to pick any signal up. Therefore, more samples should 
be pooled together for a large volume, or a more sensitive assay or extraction 
procedure needs to be done for the serum analysis.  
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For the tissue samples, the composition of 5,6-dimethylbenzimidazole as a percentage 
of total cobamides in the sample for both liver and kidney tissue were above 85 % 
(Tables 31-2 and 32-2). This could be an indication to the importance of these organs 
in cobalamin storage (45). The quantification of cyanocobalamin in the respective 
tissues show that liver had higher amounts than kidney (Figure 27). This amount 
however did not account for the sample weight. Studies have shown that kidney is an 
important organ for vitamin B12 homeostasis and have higher amounts of vitamin B12 
accumulation in kidneys than liver (38, 45, 60). It would be interesting to create 
standards for other cobalamin analogues and compare their amounts to see if the 
amount of other analogues present in liver tissues are higher than that in kidney 
tissues. Having these comparisons can open up studies that investigate the effect of 
any treatment on the changes in accumulation of different cobamides in these crucial 
organs. 
8.5 Conclusion 
This project showed that the extraction protocol for cobamides was able to reveal a 
complex variety of cobamides in faecal and tissue samples at different compositions. 
The protocol was shown to be effective and reproducible for faecal samples with 
masses more than 2 g. This procedure was successfully adapted for usage on tissue 
samples but a different or more sensitive method will be needed to identify the 
cobamides present in serum samples.  
Testing on racehorse faecal samples revealed that supplementing the racehorses with 
hydroxocobalamin injections for one month does not significantly alter their cobamide 
composition compared to the non-supplemented horses. Furthermore, 
supplementation does not affect their observed performance or have a lasting effect 
on serum B12 levels. Future work such as prolonging the supplementation period or 
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feeding them Vitamin B12 fortified foods instead of supplementation by injection can be 
done to affirm these conclusions  
Although major correlations were not noted between the patient faecal samples’ data 
and their treatment responses, the differences in the analogues’ composition observed 
(Section 7.5) indicates why vitamin B12 deficient patients within the same ‘group’ can 
develop varied responses to treatments. Despite the lack of significant differences 
between the two groups of patients, the cobamide extraction method could potentially 
be used to trace the amount of cyanocobalamin in faeces after consumption through 
various routes (example: tablets or sprays). Likewise, this procedure could prove 
useful in establishing the types and quantities of cobamides in foods and to track its 
movement after consumption. For example, to explore how consuming probiotics can 
affect the cobamide composition or wellbeing of pernicious anaemia patients (61). 
Furthermore, we can define the patient samples into more groups such as age or 
dietary habits to investigate their influence on cobamides present. Additionally, we can 
extend the quantification comparisons to beyond cyanocobalamin alone by making 
standards for other cobalamin analogues. Such investigations could help elucidate the 
possible roles these cobalamin analogues play in pernicious anaemia and find 
potential therapeutic targets for treating the disease. 
Lastly, if larger sample quantities can be collected, statistical analysis should be 
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10. Supplementary data 
S1 Cyanocobalamin standards 
Integrated peak area (Area) of the signal of cyanocobalamin (CN-Cbl) from HPLC-
MS with increasing concentrations of CN-Cbl loaded. 
 




[CN-Cbl] (µM) # RT [min] Area Int. Type I S/N ChromatogramMax. m/z FWHM [min]
10 1 25.8 19542186 Manual 1091676 4491.1 EIC 678.2900±0.02 +All MS678.3083
1 1 25.8 2038392 Manual 124872 762.3 EIC 678.2900±0.02 +All MS678.3029
0.1 1 25.9 204461 Manual 13692 101.1 EIC 678.2900±0.02 +All MS678.2975
0.01 1 25.5 16457 Manual 1268 10.3 EIC 678.2900±0.02 +All MS541.2606
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S3 Pet Hedgehog - Integrated peak area (Area) of the detected chromatograms of 
cobamides in Pet hedgehog faecal samples from the HPLC-MS  
 
S4 Pet Rabbit - Integrated peak area (Area) of the detected chromatograms of 









# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 22.1 37314.8 Manual 3204 23.7 EIC 508.2500±0.02 +All MS 409.1789
8 23.6 29378 Manual 1968 14.7 EIC 508.2500±0.02 +All MS 541.2575
5 22.9 7987.3 Manual 560 4.8 EIC 666.2800±0.02 +All MS 679.7894
2 22.2 3544.6 Manual 780 6.7 EIC 666.7800±0.02 +All MS 791.8316
3 22.8 34899.1 Manual 2664 24.8 EIC 672.7800±0.02 +All MS 679.7891
7 23.6 96269.7 Manual 6144 42.8 EIC 678.2900±0.02 +All MS 305.0865
4 22.9 670856.4 Manual 47656 323.4 EIC 679.7800±0.02 +All MS 679.789
6 23.4 315255 Manual 22156 182.9 EIC 695.7700±0.02 +All MS 695.7737














































































































S5 Wild Rabbit - Integrated peak area (Area) of the detected chromatograms of 
cobamides in wild rabbit faecal samples from the HPLC-MS 
 
 
S6 Ziggy horse 1- Integrated peak area (Area) of the detected chromatograms of 
cobamides in horse (named Ziggy) faecal samples of varying weights (2, 4, 6, 8, 10, 




# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
4 22.8 6556.1 Manual 496 4.3 EIC 666.2800±0.02 +All MS 679.7836
1 22.2 5477.1 Manual 620 6.5 EIC 666.7800±0.02 +All MS 791.8269
2 22.7 9504.5 Manual 796 8.7 EIC 672.7800±0.02 +All MS 679.7833
6 23.5 151075.3 Manual 11328 73.5 EIC 678.2900±0.02 +All MS 541.2542
3 22.8 418800.4 Manual 32824 228 EIC 679.7800±0.02 +All MS 679.7833
7 24.5 12808.7 Manual 1124 7.4 EIC 686.2900±0.02 +All MS 511.244
5 23.3 190450.4 Manual 14072 124.3 EIC 695.7700±0.02 +All MS 695.7685
8 24.9 41681.6 Manual 3380 18 EIC 875.5000±0.02 +All MS 875.503
2g # RT [min] Area Int. Type I S/N ChromatogramMax. m/z FWHM [min]
9 26.6 4997 Manual 552 5.1 EIC 508.2500±0.02 +All MS499.2461
8 25 4381.3 Manual 448 4.2 EIC 508.2500±0.02 +All MS465.2549
6 23.5 12950.1 Manual 1168 10.9 EIC 508.2500±0.02 +All MS541.2554
1 21.9 12918.6 Manual 1176 11 EIC 508.2500±0.02 +All MS409.1782
3 22.8 21583.6 Manual 1372 13.9 EIC 672.2700±0.02 +All MS679.7849
5 23.5 43531.8 Manual 2936 21.8 EIC 678.2900±0.02 +All MS541.2563
2 22.7 291389.5 Manual 18076 147.5 EIC 679.7800±0.02 +All MS679.7847
4 23.4 7641.1 Manual 740 7 EIC 695.7700±0.02 +All MS695.768
7 24.8 10842.5 Manual 1048 9.4 EIC 875.5000±0.02 +All MS875.501
4g # RT [min] Area Int. Type I S/N ChromatogramMax. m/z FWHM [min]
1 22 94787.8 Manual 3920 29 EIC 508.2500±0.02 +All MS409.1783
6 23 5560.7 Manual 516 5.4 EIC 666.2800±0.02 +All MS679.7859
5 22.9 12196.1 Manual 504 4.7 EIC 666.7800±0.02 +All MS679.7869
4 22.8 58751.7 Manual 4072 40.9 EIC 672.2700±0.02 +All MS679.7854
2 22.8 54628.7 Manual 3844 37.1 EIC 672.7800±0.02 +All MS679.7857
9 23.6 80151.5 Manual 5552 48 EIC 678.2900±0.02 +All MS678.2881
8 23.5 24854.9 Manual 1584 12.3 EIC 679.2800±0.02 +All MS678.2884
3 22.8 637396.9 Manual 48624 364.4 EIC 679.7800±0.02 +All MS679.7856
7 23.3 9998.9 Manual 928 8.6 EIC 695.7700±0.02 +All MS497.2 87






6g # RT [min] Area Int. Type I S/N ChromatogramMax. m/z FWHM [min]
10 26.9 11922.3 Manual 788 5.8 EIC 508.2500±0.02 +All MS435.2 95
9 25.1 14264.9 Manual 1104 7.9 EIC 508.2500±0.02 +All MS361.2129
7 23.6 17573.2 Manual 1388 9.8 EIC 508.2500±0.02 +All MS541.2544
1 22.1 50865.7 Manual 3808 26.6 EIC 508.2500±0.02 +All MS409.1778
2 22.2 11336.8 Manual 1224 12.3 EIC 666.7800±0.02 +All MS791.8306
3 22.8 75952.9 Manual 5204 47.2 EIC 672.2700±0.02 +All MS679.786
6 23.6 112710 Manual 7644 56.8 EIC 678.2900±0.02 +All MS678.2897
4 22.8 899503.5 Manual 56788 417.2 EIC 679.7800±0.02 +All MS679.7859
5 23.4 18889.6 Manual 1548 16.8 EIC 695.7700±0.02 +All MS393.1823
8 24.9 7528.5 Manual 776 6.4 EIC 875.5000±0.02 +All MS451.2 95
8g # RT [min] Area Int. Type I S/N ChromatogramMax. m/z FWHM [min]
1 22.1 91946 Manual 7648 50.3 EIC 508.2500±0.02 +All MS409.1803
8 23.7 72188 Manual 5360 35.3 EIC 508.2500±0.02 +All MS678.2959
10 25.2 29245 Manual 1928 12.8 EIC 508.2500±0.02 +All MS771.3303
12 27 29837 Manual 2184 14.5 EIC 508.2500±0.02 +All MS499.2465
11 26.9 14934 Manual 1320 6 EIC 659.2800±0.02 +All MS499. 46
3 22.9 14284 Manual 1104 7.9 EIC 666.2800±0.02 +All MS679.7915
2 22.3 34171 Manual 2748 22.3 EIC 666.7800±0.02 +All MS791.8367
5 22.9 93733 Manual 6576 46.7 EIC 672.2700±0.02 +All MS679.7919
7 23.7 175469 Manual 12360 80.6 EIC 678.2900±0.02 +All MS678.2956
4 22.9 1191147 Manual 95744 771.6 EIC 679.7800±0.02 +All MS679.792
6 23.5 25123 Manual 2188 19.2 EIC 695.7700±0.02 +All MS695.773
9 25 49595 Manual 4440 24.2 EIC 875.5000±0.02 +All MS875.5112
10g # RT [min] Area Int. Type I S/N ChromatogramMax. m/z FWHM [min]
10 26.8 15120 Manual 1284 11.5 EIC 508.2500±0.02 +All MS419.2526
9 25.1 24417 Manual 2040 18.6 EIC 508.2500±0.02 +All MS361.2106
6 23.6 28612 Manual 2456 22.3 EIC 508.2500±0.02 +All MS678.2876
1 22.1 78977 Manual 5932 52.5 EIC 508.2500±0.02 +All MS409.1765
2 22.2 36518 Manual 2404 21 EIC 666.7800±0.02 +All MS791.8 56
4 22.9 87258 Manual 5304 45 EIC 672.2700±0.02 +All MS679.7831
7 23.7 156860 Manual 10172 71.2 EIC 678.2900±0.02 +All MS678.2875
3 22.9 1133841 Manual 73560 533 EIC 679.7800±0.02 +All MS679.7833
5 23.4 17429 Manual 1652 15.4 EIC 695.7700±0.02 +All MS695.7646





S7 Ziggy Horse 2 - Integrated peak area (Area) of the detected chromatograms of 
cobamides in horse (named Ziggy) faecal samples of varying incubation times with 




12g # RT [min] Area Int. Type I S/N ChromatogramMax. m/z FWHM [min]
1 22.1 91049.9 Manual 6260 35.3 EIC 508.2500±0.02 +All MS409.1815
7 23.7 64126.4 Manual 4772 26.8 EIC 508.2500±0.02 +All MS541.2616
10 25.2 24429.6 Manual 2212 11.7 EIC 508.2500±0.02 +All MS673.3377
11 26.9 30816.3 Manual 2168 12 EIC 508.2500±0.02 +All MS499.2455
12 26.9 14954 Manual 1356 6.7 EIC 659.2800±0.02 +All MS499.2457
2 22.3 37352.3 Manual 2972 27.7 EIC 666.7800±0.02 +All MS791.8369
3 22.9 113313.3 Manual 8308 49.7 EIC 672.2700±0.02 +All MS679.7917
6 23.7 154556.2 Manual 10148 65.4 EIC 678.2900±0.02 +All MS541.2614
4 22.9 1211596 Manual 83468 700.4 EIC 679.7800±0.02 +All MS679.7918
8 24.6 7174 Manual 744 5.8 EIC 686.2900±0.02 +All MS629.3153
5 23.4 21428.9 Manual 2068 18.6 EIC 695.7700±0.02 +All MS695.773
9 25 54958.6 Manual 4684 27.4 EIC 875.5000±0.02 +All MS875.514
1H # RT [min] Area Int. Type I S/N Chromatogram Max. m/z 1H
12 26.7 90702 Manual 5968 32 EIC 508.2500±0.02 +All MS 499.2489
10 25 136361 Manual 7952 43.6 EIC 508.2500±0.02 +All MS 301.1759
8 23.5 103371 Manual 7748 41.6 EIC 508.2500±0.02 +All MS 1015.496
1 21.9 217971 Manual 16160 87.7 EIC 508.2500±0.02 +All MS 508.253
13 26.7 34036 Manual 2624 9 EIC 659.2800±0.02 +All MS 499.2485
11 25 47417 Manual 3160 10.9 EIC 659.2800±0.02 +All MS 301.1764
5 22.8 13779 Manual 1096 7.7 EIC 666.2800±0.02 +All MS 679.7937
3 22.7 196185 Manual 13836 95.2 EIC 672.2700±0.02 +All MS 679.7932
2 22.7 312857 Manual 21396 184.1 EIC 672.7800±0.02 +All MS 679.793
7 23.5 136764 Manual 8768 61.2 EIC 678.2900±0.02 +All MS 1015.496
4 22.8 1920960 Manual 133812 986.9 EIC 679.7800±0.02 +All MS 679.7932
6 23.3 13734 Manual 1328 9 EIC 695.7700±0.02 +All MS 695.7751
9 24.8 301449 Manual 20676 109.6 EIC 875.5000±0.02 +All MS 875.5164
3H # RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 21.9 198215 Manual 14488 56.2 EIC 508.2500±0.02 +All MS 508.2512
8 23.5 159277 Manual 12564 48.2 EIC 508.2500±0.02 +All MS 1015.495
10 24.9 126104 Manual 8372 32.3 EIC 508.2500±0.02 +All MS 301.1734
12 26.7 115927 Manual 7524 29.3 EIC 508.2500±0.02 +All MS 499.2462
11 25 33644 Manual 2276 6.4 EIC 659.2800±0.02 +All MS 301.1733
13 26.7 39097 Manual 2848 8 EIC 659.2800±0.02 +All MS 499.2461
2 22.1 16221 Manual 1604 12.4 EIC 666.7800±0.02 +All MS 791.8363
4 22.7 183886 Manual 13548 96.5 EIC 672.2700±0.02 +All MS 679.7903
3 22.7 310425 Manual 22072 172.4 EIC 672.7800±0.02 +All MS 679.7904
7 23.5 160100 Manual 9888 67.1 EIC 678.2900±0.02 +All MS 1015.495
5 22.7 1767201 Manual 128804 1039.8 EIC 679.7800±0.02 +All MS 679.7904
6 23.2 13822 Manual 1188 10.7 EIC 695.7700±0.02 +All MS 305.0868













6H # RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 21.8 217256 Manual 16348 64.5 EIC 508.2500±0.02 +All MS 508.2478
9 23.3 189223 Manual 14648 57.4 EIC 508.2500±0.02 +All MS 1015.488
12 24.8 121892 Manual 8748 33.9 EIC 508.2500±0.02 +All MS 301.1713
13 26.6 116210 Manual 8436 32.7 EIC 508.2500±0.02 +All MS 499.2421
11 24.8 38682 Manual 2616 6.8 EIC 659.2800±0.02 +All MS 301.1712
14 26.6 46724 Manual 3236 8.3 EIC 659.2800±0.02 +All MS 499.2419
4 22.6 22230 Manual 1412 10.6 EIC 666.2800±0.02 +All MS 679.7859
2 21.9 32854 Manual 2584 19.1 EIC 666.7800±0.02 +All MS 791.8309
6 22.6 261356 Manual 17816 109.2 EIC 672.2700±0.02 +All MS 679.7856
3 22.6 349144 Manual 23372 209.8 EIC 672.7800±0.02 +All MS 679.7856
8 23.3 249235 Manual 15944 101.8 EIC 678.2900±0.02 +All MS 1015.488
5 22.6 2707120 Manual 195428 1419 EIC 679.7800±0.02 +All MS 679.7856
7 23.1 26815 Manual 2028 17.6 EIC 695.7700±0.02 +All MS 305.0873
10 24.6 307476 Manual 22612 170.9 EIC 875.5000±0.02 +All MS 875.5091
18H # RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 21.9 191748 Manual 15204 55.1 EIC 508.2500±0.02 +All MS 508.2443
9 23.4 132636 Manual 10724 38.3 EIC 508.2500±0.02 +All MS 1015.482
11 24.9 104739 Manual 7688 26.4 EIC 508.2500±0.02 +All MS 301.1689
13 26.6 103475 Manual 7648 27.9 EIC 508.2500±0.02 +All MS 499.2393
12 24.9 39598 Manual 2308 6 EIC 659.2800±0.02 +All MS 301.169
14 26.6 40377 Manual 3024 7.5 EIC 659.2800±0.02 +All MS 499.2395
6 22.7 16355 Manual 1280 10 EIC 666.2800±0.02 +All MS 679.7826
2 22.1 16761 Manual 1024 8.3 EIC 666.7800±0.02 +All MS 791.8257
5 22.7 249525 Manual 16600 126.4 EIC 672.2700±0.02 +All MS 679.7825
3 22.7 317731 Manual 20996 193.9 EIC 672.7800±0.02 +All MS 679.7825
8 23.4 209727 Manual 12980 75.8 EIC 678.2900±0.02 +All MS 1015.482
4 22.7 2556487 Manual 177652 1173.8 EIC 679.7800±0.02 +All MS 679.7824
7 23.2 25384 Manual 1776 15.9 EIC 695.7700±0.02 +All MS 305.0849
10 24.8 189158 Manual 15252 94 EIC 875.5000±0.02 +All MS 301.1684
24H # RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 21.7 242156.5 Manual 16792 66.6 EIC 508.2500±0.02 +All MS 508.2537
8 23.3 120075.4 Manual 10140 39.3 EIC 508.2500±0.02 +All MS 678.3026
12 24.9 112676.8 Manual 7184 27.7 EIC 508.2500±0.02 +All MS 301.1758
13 26.6 92914.9 Manual 6728 26.7 EIC 508.2500±0.02 +All MS 499.2485
11 24.8 37630.7 Manual 2000 6.1 EIC 659.2800±0.02 +All MS 301.1759
14 26.6 33328.8 Manual 2708 8.3 EIC 659.2800±0.02 +All MS 499.2483
6 22.6 18116.7 Manual 1060 8 EIC 666.2800±0.02 +All MS 679.7945
2 22.1 24084.6 Manual 1640 13.5 EIC 666.7800±0.02 +All MS 791.838
5 22.6 215557.4 Manual 15880 105 EIC 672.2700±0.02 +All MS 679.7944
3 22.6 282460.5 Manual 19540 166 EIC 672.7800±0.02 +All MS 679.7942
7 23.3 6863489 Manual 443868 2128.7 EIC 678.2900±0.02 +All MS 678.3025
4 22.6 2343428 Manual 165216 1299.3 EIC 679.7800±0.02 +All MS 679.7935
9 24.3 9688.3 Manual 988 7.1 EIC 686.2900±0.02 +All MS 629.316
10 24.7 209327.1 Manual 15840 124.4 EIC 875.5000±0.02 +All MS 875.5171
106 
 
S8 Racehorse - Integrated peak area (Area) of the detected chromatograms of 
cobamides in racehorse faecal samples collected in June, August, and September 
2018 




# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 23 238811.2 Manual 16288 63.5 EIC 508.2500±0.02 +All MS 508.2476
7 24.6 86677.2 Manual 4948 19.4 EIC 508.2500±0.02 +All MS 1015.484
10 26.1 24555.3 Manual 1704 6.2 EIC 508.2500±0.02 +All MS 499.2417
11 28 13320.4 Manual 1244 4.5 EIC 508.2500±0.02 +All MS 499.2432
5 23.9 13715 Manual 788 5 EIC 666.2800±0.02 +All MS 679.7859
2 23.4 7194.1 Manual 592 4.8 EIC 666.7800±0.02 +All MS 791.8326
4 23.9 153090.4 Manual 9236 61.1 EIC 672.2700±0.02 +All MS 679.7858
8 24.7 68739.5 Manual 3684 26.6 EIC 678.2900±0.02 +All MS 1015.483
3 23.9 1307852 Manual 76296 531.9 EIC 679.7800±0.02 +All MS 679.7859
6 24.4 78540 Manual 5260 49 EIC 695.7700±0.02 +All MS 695.7699
9 26 34192.6 Manual 2356 15.2 EIC 875.5000±0.02 +All MS 301.1719
ASH
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
2 23.1 24219.3 Manual 1820 7.9 EIC 508.2500±0.02 +All MS 409.1809
9 24.6 9804.6 Manual 776 3.3 EIC 508.2500±0.02 +All MS 678.794
12 27.8 13161.9 Manual 948 4.1 EIC 508.2500±0.02 +All MS 499.2474
1 21.6 5117.4 Manual 456 2.9 EIC 666.2800±0.02 +All MS 666.277
3 23.4 2690.9 Manual 276 1.7 EIC 666.2800±0.02 +All MS 791.8342
6 23.9 14776.1 Manual 1124 7.3 EIC 666.2800±0.02 +All MS 679.7895
7 23.9 66149 Manual 4260 40.4 EIC 672.2700±0.02 +All MS 679.7893
4 23.9 97226.8 Manual 5632 59 EIC 672.7800±0.02 +All MS 679.7891
10 24.7 73052.7 Manual 4856 28.3 EIC 678.2900±0.02 +All MS 678.2937
5 23.9 1236984 Manual 80044 571.6 EIC 679.7800±0.02 +All MS 679.7891
8 24.5 37471.5 Manual 2440 22.7 EIC 695.7700±0.02 +All MS 695.7737
11 26 21988.3 Manual 1808 17.4 EIC 875.5000±0.02 +All MS 301.1732
BD
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
3 22.9 31869.9 Manual 2108 8.1 EIC 508.2500±0.02 +All MS 784.8317
12 25.7 74196.9 Manual 3704 14.3 EIC 508.2500±0.02 +All MS 301.1732
14 27.5 41014.8 Manual 2624 10.1 EIC 508.2500±0.02 +All MS 499.2451
13 25.8 21530.4 Manual 1384 3.9 EIC 659.2800±0.02 +All MS 771.3302
1 21.3 20380 Manual 1324 7.1 EIC 666.2800±0.02 +All MS 666.2835
2 22.4 36131.5 Manual 2408 12.9 EIC 666.2800±0.02 +All MS 666.2838
8 23.6 25674.5 Manual 1756 9.4 EIC 666.2800±0.02 +All MS 679.7936
4 23 72987.7 Manual 2900 24.3 EIC 666.7800±0.02 +All MS 791.8396
6 23.6 65062.8 Manual 4068 26.9 EIC 672.2700±0.02 +All MS 679.7937
5 23.6 179364.2 Manual 11268 80.4 EIC 672.7800±0.02 +All MS 679.7936
10 24.4 43614.1 Manual 3508 18.7 EIC 678.2900±0.02 +All MS 678.2948
7 23.6 2296691 Manual 143884 1001.9 EIC 679.7800±0.02 +All MS 679.7935
9 24.1 121049.9 Manual 7608 58 EIC 695.7700±0.02 +All MS 695.7763






# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
3 23.8 47125 Manual 2880 11.1 EIC 508.2500±0.02 +All MS 314.0925
9 25.3 16441 Manual 1120 4.3 EIC 508.2500±0.02 +All MS 678.2925
12 26.7 38309 Manual 2440 9.4 EIC 508.2500±0.02 +All MS 301.1721
13 28.4 18223 Manual 1296 5 EIC 508.2500±0.02 +All MS 499.2435
1 22.3 18549 Manual 1160 8.1 EIC 666.2800±0.02 +All MS 666.2776
2 23.5 18519 Manual 1432 10 EIC 666.2800±0.02 +All MS 436.6981
4 24 22288 Manual 1544 11.8 EIC 666.7800±0.02 +All MS 791.8347
7 24.6 118712 Manual 8188 60.5 EIC 672.2700±0.02 +All MS 679.7871
5 24.5 149252 Manual 8988 80.7 EIC 672.7800±0.02 +All MS 679.7868
10 25.4 212371 Manual 11044 60.2 EIC 678.2900±0.02 +All MS 678.2925
6 24.6 866886 Manual 57332 479.9 EIC 679.7800±0.02 +All MS 679.7868
8 25.1 57905 Manual 3944 30.5 EIC 695.7700±0.02 +All MS 316.1077
11 26.7 21047 Manual 1220 10.2 EIC 875.5000±0.02 +All MS 301.1718
COOL
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 23.3 151836 Manual 9444 41.6 EIC 508.2500±0.02 +All MS 508.2499
8 24.9 52997.4 Manual 3460 15.3 EIC 508.2500±0.02 +All MS 678.2936
10 26.4 28037.5 Manual 1680 7.4 EIC 508.2500±0.02 +All MS 301.1735
11 26.4 8758.4 Manual 832 2.1 EIC 659.2800±0.02 +All MS 301.1716
5 24.2 12247.7 Manual 800 5 EIC 666.2800±0.02 +All MS 679.789
2 23.5 9639.7 Manual 852 7.4 EIC 666.7800±0.02 +All MS 791.8327
4 24.2 221089.2 Manual 13728 88.5 EIC 672.2700±0.02 +All MS 679.789
7 24.9 149505.7 Manual 8120 49.3 EIC 678.2900±0.02 +All MS 678.2933
3 24.2 1425616 Manual 96148 766.3 EIC 679.7800±0.02 +All MS 679.789
6 24.7 90643.1 Manual 5164 44.8 EIC 695.7700±0.02 +All MS 695.7715
9 26.3 28932.5 Manual 1988 14.7 EIC 875.5000±0.02 +All MS 301.1739
COR
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 23.1 141205 Manual 8780 34.6 EIC 508.2500±0.02 +All MS 508.2553
7 24.6 52320.7 Manual 3364 13.2 EIC 508.2500±0.02 +All MS 1015.497
10 26.1 87178.1 Manual 4696 18.4 EIC 508.2500±0.02 +All MS 605.2558
12 27.8 43245.9 Manual 2464 9.7 EIC 508.2500±0.02 +All MS 499.2494
11 26.2 21783.4 Manual 1780 4.7 EIC 659.2800±0.02 +All MS 499.2494
13 27.9 18972.3 Manual 1308 3.4 EIC 659.2800±0.02 +All MS 499.2492
5 24 8163.9 Manual 1020 7.3 EIC 666.2800±0.02 +All MS 679.7977
4 23.9 79723 Manual 5288 40.3 EIC 672.2700±0.02 +All MS 679.7961
2 23.8 211511.2 Manual 12200 98.5 EIC 672.7800±0.02 +All MS 679.796
8 24.7 23016.9 Manual 1680 10.5 EIC 678.2900±0.02 +All MS 1015.494
3 23.9 1867344 Manual 121332 920.6 EIC 679.7800±0.02 +All MS 679.7959
6 24.4 151332.5 Manual 10328 86.4 EIC 695.7700±0.02 +All MS 695.7785





# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
3 24.1 172589 Manual 10592 42.6 EIC 508.2500±0.02 +All MS 508.2466
10 25.7 53815 Manual 3320 12.8 EIC 508.2500±0.02 +All MS 1015.482
12 27.2 73656 Manual 4944 19.2 EIC 508.2500±0.02 +All MS 301.17
14 28.8 31230 Manual 2724 9.7 EIC 508.2500±0.02 +All MS 499.2402
13 27.2 24464 Manual 1568 4.7 EIC 659.2800±0.02 +All MS 605.2445
2 23.8 12940 Manual 1220 7.7 EIC 666.2800±0.02 +All MS 666.2758
6 24.9 17438 Manual 1236 7.8 EIC 666.2800±0.02 +All MS 679.7856
1 23.7 17354 Manual 976 8.5 EIC 666.7800±0.02 +All MS 508.2459
5 24.9 82481 Manual 4724 31.2 EIC 672.2700±0.02 +All MS 679.7852
4 24.9 186175 Manual 11016 85.3 EIC 672.7800±0.02 +All MS 679.7853
9 25.7 123770 Manual 6216 34 EIC 678.2900±0.02 +All MS 678.2891
7 25 2298476 Manual 141840 989.6 EIC 679.7800±0.02 +All MS 679.7852
8 25.5 120714 Manual 7844 57.2 EIC 695.7700±0.02 +All MS 695.7676
11 27.1 18320 Manual 1264 9.3 EIC 875.5000±0.02 +All MS 301.1695
DR
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
2 23 111455 Manual 6880 27.9 EIC 508.2500±0.02 +All MS 508.2527
9 24.5 36297 Manual 2492 10.1 EIC 508.2500±0.02 +All MS 1015.492
12 25.9 40532 Manual 2388 9.4 EIC 508.2500±0.02 +All MS 301.1743
14 27.7 19292 Manual 1608 6.2 EIC 508.2500±0.02 +All MS 499.2468
13 26 10915 Manual 716 2.3 EIC 659.2800±0.02 +All MS 301.1766
1 21.5 12774 Manual 1148 7.6 EIC 666.2800±0.02 +All MS 666.2806
7 23.8 13675 Manual 876 5.8 EIC 666.2800±0.02 +All MS 679.7908
3 23.2 15674 Manual 1420 13.2 EIC 666.7800±0.02 +All MS 791.8364
6 23.8 106357 Manual 6696 52.6 EIC 672.2700±0.02 +All MS 679.7908
4 23.7 202941 Manual 11112 107.5 EIC 672.7800±0.02 +All MS 679.7906
10 24.5 86245 Manual 4992 32.1 EIC 678.2900±0.02 +All MS 678.2969
5 23.8 1282349 Manual 81304 728.5 EIC 679.7800±0.02 +All MS 679.7908
8 24.3 69511 Manual 4688 34.7 EIC 695.7700±0.02 +All MS 695.7745





# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
2 23.5 48769.9 Manual 3768 16.1 EIC 508.2500±0.02 +All MS 508.2517
9 25.1 15618.2 Manual 1728 7.4 EIC 508.2500±0.02 +All MS 678.2971
11 26.5 37278.8 Manual 2148 9.2 EIC 508.2500±0.02 +All MS 301.1754
14 28.3 19253.6 Manual 1384 5.9 EIC 508.2500±0.02 +All MS 499.2472
13 26.6 12940.7 Manual 848 2.5 EIC 659.2800±0.02 +All MS 605.2536
1 22 4298.7 Manual 556 3.9 EIC 666.2800±0.02 +All MS 666.7811
7 24.4 15468.4 Manual 912 6.4 EIC 666.2800±0.02 +All MS 679.7925
3 23.7 6184.1 Manual 612 5.3 EIC 666.7800±0.02 +All MS 791.8355
5 24.3 65805.7 Manual 4124 32.4 EIC 672.2700±0.02 +All MS 679.7925
4 24.3 116667.8 Manual 7344 67.6 EIC 672.7800±0.02 +All MS 679.7922
10 25.2 161069.9 Manual 9316 56.5 EIC 678.2900±0.02 +All MS 678.297
6 24.4 1363601 Manual 80556 594.4 EIC 679.7800±0.02 +All MS 679.7922
8 24.9 129677.3 Manual 8912 79.5 EIC 695.7700±0.02 +All MS 695.7763
12 26.5 4112.2 Manual 704 6.3 EIC 875.5000±0.02 +All MS 301.1697
F2U
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 23.4 80223 Manual 5900 23.9 EIC 508.2500±0.02 +All MS 508.2552
7 25 27470 Manual 1768 7.2 EIC 508.2500±0.02 +All MS 1015.493
10 26.5 62446 Manual 3060 12.4 EIC 508.2500±0.02 +All MS 301.1755
12 28.3 28517 Manual 1856 7.2 EIC 508.2500±0.02 +All MS 499.2496
11 26.5 17147 Manual 976 2.8 EIC 659.2800±0.02 +All MS 301.1754
5 24.3 16970 Manual 964 7.1 EIC 666.2800±0.02 +All MS 679.7936
4 24.2 141126 Manual 9656 73.7 EIC 672.2700±0.02 +All MS 679.794
2 24.2 189689 Manual 10716 107.5 EIC 672.7800±0.02 +All MS 679.7939
8 25.1 77471 Manual 4288 26.2 EIC 678.2900±0.02 +All MS 585.3749
3 24.2 1234660 Manual 80408 610.3 EIC 679.7800±0.02 +All MS 679.7939
6 24.8 85449 Manual 5676 59.4 EIC 695.7700±0.02 +All MS 695.7769





# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
3 23.4 90935 Manual 6544 27.8 EIC 508.2500±0.02 +All MS 508.2546
10 25 32582.8 Manual 1928 8.3 EIC 508.2500±0.02 +All MS 678.2996
14 26.5 51405.1 Manual 3324 14 EIC 508.2500±0.02 +All MS 301.1759
12 26.4 12067.4 Manual 740 2.4 EIC 659.2800±0.02 +All MS 301.1734
1 21.9 34344.6 Manual 2332 14.3 EIC 666.2800±0.02 +All MS 666.2846
2 23 21277.5 Manual 1456 8.9 EIC 666.2800±0.02 +All MS 666.2873
8 24.3 26713.2 Manual 1600 9.8 EIC 666.2800±0.02 +All MS 679.7962
4 23.7 31182.4 Manual 2140 16.8 EIC 666.7800±0.02 +All MS 791.8407
7 24.3 185939.2 Manual 11944 111.2 EIC 672.2700±0.02 +All MS 679.7963
5 24.3 248916 Manual 13928 119.2 EIC 672.7800±0.02 +All MS 679.7961
11 25.1 169237.8 Manual 9812 64.8 EIC 678.2900±0.02 +All MS 678.2997
6 24.3 2383093 Manual 158096 1238 EIC 679.7800±0.02 +All MS 679.7961
9 24.9 117349.9 Manual 6988 53.5 EIC 695.7700±0.02 +All MS 695.7783
13 26.4 4531.5 Manual 684 6.4 EIC 875.5000±0.02 +All MS 301.1836
WR
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 23 97266 Manual 6352 23.1 EIC 508.2500±0.02 +All MS 508.2537
6 24.6 34737 Manual 2376 8.6 EIC 508.2500±0.02 +All MS 1015.497
9 26 54090 Manual 2996 10.9 EIC 508.2500±0.02 +All MS 301.1743
11 27.9 23309 Manual 1416 4.9 EIC 508.2500±0.02 +All MS 499.2486
10 26.2 15285 Manual 1060 3.1 EIC 659.2800±0.02 +All MS 499.2485
4 23.9 17724 Manual 1344 8.2 EIC 666.2800±0.02 +All MS 679.7949
3 23.9 75485 Manual 5752 42.5 EIC 672.2700±0.02 +All MS 679.7949
7 24.7 102791 Manual 5828 36.7 EIC 678.2900±0.02 +All MS 678.299
2 23.9 1782163 Manual 120164 913 EIC 679.7800±0.02 +All MS 679.7948
5 24.4 80053 Manual 4864 43.7 EIC 695.7700±0.02 +All MS 316.1096
8 26 14716 Manual 1128 10.9 EIC 875.5000±0.02 +All MS 301.1749
FT
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
2 23.7 83193 Manual 6228 24.3 EIC 508.2500±0.02 +All MS 508.2471
7 25.2 27831 Manual 1968 7.6 EIC 508.2500±0.02 +All MS 1015.483
10 26.8 72207 Manual 3632 13.7 EIC 508.2500±0.02 +All MS 771.3225
12 28.5 32170 Manual 2000 7.6 EIC 508.2500±0.02 +All MS 499.2415
11 26.8 24573 Manual 1236 3.1 EIC 659.2800±0.02 +All MS 771.321
13 28.5 12612 Manual 892 2.3 EIC 659.2800±0.02 +All MS 499.2403
1 23.3 121240 Manual 3188 16.7 EIC 666.2800±0.02 +All MS 679.7927
3 24 113286 Manual 3776 28.8 EIC 666.7800±0.02 +All MS 791.8282
5 24.6 36576 Manual 2048 16.6 EIC 672.2700±0.02 +All MS 679.7861
8 25.3 68362 Manual 3888 22.2 EIC 678.2900±0.02 +All MS 678.2888
4 24.6 1832482 Manual 116036 710.8 EIC 679.7800±0.02 +All MS 679.7858
6 25.1 102742 Manual 6208 48.8 EIC 695.7700±0.02 +All MS 695.767





# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
4 23.2 35862.7 Manual 2840 11.3 EIC 508.2500±0.02 +All MS 508.2488
12 24.8 11914.7 Manual 844 3.4 EIC 508.2500±0.02 +All MS 678.2931
13 26.1 29079.8 Manual 2004 8 EIC 508.2500±0.02 +All MS 301.1701
16 27.9 12895.1 Manual 1116 4.5 EIC 508.2500±0.02 +All MS 499.2424
15 26.2 8913.9 Manual 724 1.9 EIC 659.2800±0.02 +All MS 301.1737
1 21.8 5254.1 Manual 584 4 EIC 666.2800±0.02 +All MS 666.2771
2 22.4 2839.6 Manual 264 1.8 EIC 666.2800±0.02 +All MS 365.1535
3 22.8 7282.4 Manual 696 4.7 EIC 666.2800±0.02 +All MS 666.2833
7 24 9881.4 Manual 796 5.4 EIC 666.2800±0.02 +All MS 679.7873
5 23.4 23077.9 Manual 1512 12.7 EIC 666.7800±0.02 +All MS 791.8319
8 24.1 112281.8 Manual 6992 53.3 EIC 672.2700±0.02 +All MS 679.7871
11 24.8 405441.5 Manual 21584 115.7 EIC 678.2900±0.02 +All MS 678.2924
6 24 952815.3 Manual 57572 425 EIC 679.7800±0.02 +All MS 679.7872
10 24.8 8010.2 Manual 716 5 EIC 689.2800±0.02 +All MS 678.291
9 24.6 47971.3 Manual 2968 27.6 EIC 695.7700±0.02 +All MS 695.7735
14 26.1 12407.5 Manual 1036 7.9 EIC 875.5000±0.02 +All MS 301.1711
LH
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
2 23.2 68392 Manual 4288 20 EIC 508.2500±0.02 +All MS 508.2544
7 24.8 26400 Manual 2052 9.6 EIC 508.2500±0.02 +All MS 678.3029
10 26.1 55954 Manual 2688 12.5 EIC 508.2500±0.02 +All MS 301.1753
12 27.8 28717 Manual 1524 7.1 EIC 508.2500±0.02 +All MS 499.2494
11 26.2 16201 Manual 876 2.3 EIC 659.2800±0.02 +All MS 771.3337
13 27.8 10558 Manual 1000 2.6 EIC 659.2800±0.02 +All MS 499.248
1 22.8 33414 Manual 1704 10.2 EIC 666.2800±0.02 +All MS 666.2854
3 23.4 47809 Manual 2800 21.4 EIC 666.7800±0.02 +All MS 791.8418
5 24 38785 Manual 2432 18 EIC 672.2700±0.02 +All MS 679.7961
8 24.8 109230 Manual 6488 34.4 EIC 678.2900±0.02 +All MS 678.3017
4 24 1601906 Manual 100908 746 EIC 679.7800±0.02 +All MS 679.7958
6 24.5 109150 Manual 7408 58.2 EIC 695.7700±0.02 +All MS 695.7797
9 26 17631 Manual 1852 13.7 EIC 875.5000±0.02 +All MS 301.1762
LR
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 22.9 41479.7 Manual 2760 11.2 EIC 508.2500±0.02 +All MS 485.3546
6 24.4 15619.9 Manual 1112 4.5 EIC 508.2500±0.02 +All MS 678.2942
9 26 32377.1 Manual 1928 7.8 EIC 508.2500±0.02 +All MS 301.1717
11 27.8 16911.1 Manual 1080 4.4 EIC 508.2500±0.02 +All MS 499.2455
10 27.6 6150.1 Manual 592 1.5 EIC 659.2800±0.02 +All MS 499.245
4 23.8 10607.5 Manual 828 5.5 EIC 666.2800±0.02 +All MS 679.7907
3 23.8 94197.1 Manual 6108 38.4 EIC 672.2700±0.02 +All MS 679.7907
7 24.6 101089.6 Manual 6060 33.9 EIC 678.2900±0.02 +All MS 585.3715
2 23.8 1018954 Manual 69984 499.6 EIC 679.7800±0.02 +All MS 679.7907
5 24.3 56425.7 Manual 3524 28.5 EIC 695.7700±0.02 +All MS 695.7753





# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
3 23.7 54265 Manual 3388 14.8 EIC 508.2500±0.02 +All MS 508.2552
9 25.4 17952.6 Manual 1020 4.4 EIC 508.2500±0.02 +All MS 678.2994
12 26.7 21345.9 Manual 1332 5.8 EIC 508.2500±0.02 +All MS 301.1768
14 28.4 13059.8 Manual 1048 4.6 EIC 508.2500±0.02 +All MS 499.2515
13 26.8 6410.7 Manual 524 1.8 EIC 659.2800±0.02 +All MS 301.1788
1 22.1 8521.6 Manual 732 4.6 EIC 666.2800±0.02 +All MS 666.2743
2 23.3 6649.8 Manual 828 5.2 EIC 666.2800±0.02 +All MS 666.2766
4 23.9 20774.8 Manual 1812 15.2 EIC 666.7800±0.02 +All MS 791.8384
5 24.5 90971.1 Manual 5724 41.1 EIC 672.2700±0.02 +All MS 679.7936
8 25.4 212020.1 Manual 11088 70 EIC 678.2900±0.02 +All MS 678.2989
6 24.5 754689.9 Manual 47668 353.4 EIC 679.7800±0.02 +All MS 679.7935
10 25.4 2356.9 Manual 380 2.8 EIC 689.2800±0.02 +All MS 678.2995
7 25 49185.3 Manual 3160 27.5 EIC 695.7700±0.02 +All MS 695.7792
11 26.6 4133.5 Manual 468 3.4 EIC 875.5000±0.02 +All MS 301.1768
REC
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
8 24.4 29718 Manual 1836 7 EIC 508.2500±0.02 +All MS 678.2988
11 25.9 63708.8 Manual 3080 11.7 EIC 508.2500±0.02 +All MS 499.2465
13 27.6 33156.8 Manual 2432 9.3 EIC 508.2500±0.02 +All MS 499.2493
12 26 24029.4 Manual 1480 3.9 EIC 659.2800±0.02 +All MS 301.1739
14 27.6 12520.5 Manual 880 2.3 EIC 659.2800±0.02 +All MS 499.2501
1 21.5 20948.9 Manual 1584 10.2 EIC 666.2800±0.02 +All MS 666.2863
2 22.6 15871.3 Manual 1264 8.1 EIC 666.2800±0.02 +All MS 436.6992
6 23.8 19806.1 Manual 1332 8.6 EIC 666.2800±0.02 +All MS 679.7933
3 23.2 13050.8 Manual 864 6.4 EIC 666.7800±0.02 +All MS 791.8387
5 23.8 68274.7 Manual 4320 30.1 EIC 672.2700±0.02 +All MS 679.7934
9 24.6 166309.1 Manual 9740 56.4 EIC 678.2900±0.02 +All MS 678.2983
4 23.8 1618317 Manual 104640 751 EIC 679.7800±0.02 +All MS 679.7933
7 24.3 87136.2 Manual 5940 45.4 EIC 695.7700±0.02 +All MS 695.7775
10 25.8 5065.3 Manual 904 7.3 EIC 875.5000±0.02 +All MS 301.1793
SD
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
12 28.4 27302.6 Manual 1412 6.2 EIC 508.2500±0.02 +All MS 499.247
11 26.7 43349 Manual 2456 10.8 EIC 508.2500±0.02 +All MS 301.1717
7 25.2 27928.8 Manual 1968 8.6 EIC 508.2500±0.02 +All MS 678.2936
2 23.6 90790.2 Manual 5688 25.1 EIC 508.2500±0.02 +All MS 508.2503
1 23.3 11963.7 Manual 816 5.4 EIC 666.2800±0.02 +All MS 437.1946
3 23.9 8011.5 Manual 668 5.9 EIC 666.7800±0.02 +All MS 791.8257
5 24.5 69851.6 Manual 4076 26.2 EIC 672.2700±0.02 +All MS 679.7885
8 25.3 211050.9 Manual 10984 65.9 EIC 678.2900±0.02 +All MS 678.2936
4 24.4 1208026 Manual 82516 624.2 EIC 679.7800±0.02 +All MS 679.7885
9 25.3 2835.2 Manual 256 2 EIC 689.2800±0.02 +All MS 678.2923
6 25 48165.9 Manual 2856 24.7 EIC 695.7700±0.02 +All MS 695.772






# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
3 24.3 54525 Manual 3356 12.7 EIC 508.2500±0.02 +All MS 791.8283
7 25.7 20851 Manual 1376 5.2 EIC 508.2500±0.02 +All MS 678.2884
9 27.1 88447 Manual 4764 18 EIC 508.2500±0.02 +All MS 301.1698
12 28.9 40863 Manual 2208 8.3 EIC 508.2500±0.02 +All MS 499.24
10 27.1 23661 Manual 1396 3.7 EIC 659.2800±0.02 +All MS 301.1705
11 28.7 13621 Manual 904 2.4 EIC 659.2800±0.02 +All MS 499.2411
1 22.8 56704 Manual 2408 11.1 EIC 666.2800±0.02 +All MS 666.2773
2 23.9 49991 Manual 2724 12.6 EIC 666.2800±0.02 +All MS 436.6925
4 25 345300 Manual 19184 113.5 EIC 672.2700±0.02 +All MS 679.785
8 25.9 160717 Manual 8624 50.4 EIC 678.2900±0.02 +All MS 678.2883
5 25.1 2687457 Manual 162340 1132.7 EIC 679.7800±0.02 +All MS 679.7851






# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 22.6 700386 Manual 43620 181.8 EIC 508.2500±0.02 +All MS 508.2457
7 24.1 443918 Manual 26252 109.3 EIC 508.2500±0.02 +All MS 1015.483
10 25.7 192876 Manual 10696 44.1 EIC 508.2500±0.02 +All MS 499.2397
11 27.4 154218 Manual 8576 35.3 EIC 508.2500±0.02 +All MS 499.2409
9 25.6 59276 Manual 3580 9.4 EIC 659.2800±0.02 +All MS 499.2397
12 27.4 68345 Manual 4328 11.3 EIC 659.2800±0.02 +All MS 499.2408
5 23.4 34122 Manual 2200 13.5 EIC 666.2800±0.02 +All MS 679.7837
2 22.8 16802 Manual 1276 10.3 EIC 666.7800±0.02 +All MS 791.8247
4 23.4 835487 Manual 50124 393.7 EIC 672.2700±0.02 +All MS 679.7836
3 23.4 3151911 Manual 190032 1443.3 EIC 679.7800±0.02 +All MS 679.7836
6 24 118775 Manual 7640 53.3 EIC 695.7700±0.02 +All MS 1015.482
8 25.5 271925 Manual 16832 124.3 EIC 875.5000±0.02 +All MS 875.5017
4WS
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 23 397189 Manual 25684 105.3 EIC 508.2500±0.02 +All MS 508.2445
8 24.7 118595 Manual 5376 22.2 EIC 508.2500±0.02 +All MS 1015.48
11 26.2 55566 Manual 2644 7.3 EIC 659.2800±0.02 +All MS 499.2389
12 28 35456 Manual 2148 6 EIC 659.2800±0.02 +All MS 553.2843
6 23.9 27638 Manual 1984 12.8 EIC 666.2800±0.02 +All MS 679.784
2 23.2 21182 Manual 1208 9.8 EIC 666.7800±0.02 +All MS 791.8236
5 23.9 351569 Manual 20464 139 EIC 672.2700±0.02 +All MS 679.7834
3 23.9 550415 Manual 30444 238.4 EIC 672.7800±0.02 +All MS 679.7833
9 24.8 249488 Manual 13280 74.2 EIC 678.2900±0.02 +All MS 678.2864
4 23.9 3838775 Manual 231404 1616.5 EIC 679.7800±0.02 +All MS 679.7834
7 24.5 37298 Manual 2564 19.8 EIC 695.7700±0.02 +All MS 347.1939
10 26.1 195245 Manual 11364 69.7 EIC 875.5000±0.02 +All MS 499.2396
A&4E
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 26.7 117939 Manual 7108 33.1 EIC 508.2500±0.02 +All MS 508.2518
7 28.3 27671 Manual 1752 7.8 EIC 508.2500±0.02 +All MS 678.2961
11 29.6 150372 Manual 7932 36.4 EIC 508.2500±0.02 +All MS 499.2466
12 31 77487 Manual 4168 19.4 EIC 508.2500±0.02 +All MS 499.2477
10 29.5 44732 Manual 2376 8.9 EIC 659.2800±0.02 +All MS 499.2468
13 31 30953 Manual 2140 8 EIC 659.2800±0.02 +All MS 499.2474
4 27.5 45653 Manual 3032 18.1 EIC 666.2800±0.02 +All MS 679.7919
2 26.9 58669 Manual 1644 14.5 EIC 666.7800±0.02 +All MS 679.7922
3 27.5 598243 Manual 34332 253.8 EIC 672.7800±0.02 +All MS 679.7915
8 28.4 399801 Manual 22844 129.7 EIC 678.2900±0.02 +All MS 678.2959
5 27.6 3208070 Manual 195456 1421.4 EIC 679.7800±0.02 +All MS 679.7918
6 28.1 51791 Manual 2744 23 EIC 695.7700±0.02 +All MS 958.4334
9 29.4 168226 Manual 11372 86.6 EIC 875.5000±0.02 +All MS 875.5121
6 27.7 419508 Manual 22156 146.6 EIC 672.2700±0.02 +All MS 679.7916
ASH
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 25.3 155273 Manual 8636 41.7 EIC 508.2500±0.02 +All MS 508.2519
7 26.8 51872 Manual 2648 12.8 EIC 508.2500±0.02 +All MS 678.2977
9 28.2 84965 Manual 5336 25.9 EIC 508.2500±0.02 +All MS 875.514
12 29.9 39426 Manual 2664 12.9 EIC 508.2500±0.02 +All MS 499.2472
11 28.3 22871 Manual 1300 4.8 EIC 659.2800±0.02 +All MS 875.5156
13 29.9 13239 Manual 888 3.3 EIC 659.2800±0.02 +All MS 499.2467
2 25.5 64382 Manual 2072 17.4 EIC 666.7800±0.02 +All MS 679.7928
5 26.1 423731 Manual 25112 161.1 EIC 672.2700±0.02 +All MS 679.7926
3 26.1 470583 Manual 28744 288.8 EIC 672.7800±0.02 +All MS 679.7925
8 27 269547 Manual 14324 103 EIC 678.2900±0.02 +All MS 678.2964
4 26.1 3191297 Manual 199940 1570.1 EIC 679.7800±0.02 +All MS 679.7926
6 26.7 77519 Manual 5396 50.2 EIC 695.7700±0.02 +All MS 695.7748





# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
3 23.6 449287 Manual 23684 93.9 EIC 508.2500±0.02 +All MS 508.2415
10 25.1 139808 Manual 8484 33.3 EIC 508.2500±0.02 +All MS 1015.476
14 26.7 564694 Manual 27668 108.9 EIC 508.2500±0.02 +All MS 499.2386
15 28.4 261165 Manual 14300 55.5 EIC 508.2500±0.02 +All MS 499.2378
13 26.6 181442 Manual 8736 21.3 EIC 659.2800±0.02 +All MS 499.2388
16 28.4 106970 Manual 6108 14.9 EIC 659.2800±0.02 +All MS 499.2378
1 22.1 10603 Manual 776 4.8 EIC 666.2800±0.02 +All MS 666.2791
2 23.2 25615 Manual 1136 7 EIC 666.2800±0.02 +All MS 436.69
8 24.5 72041 Manual 4424 27.1 EIC 666.2800±0.02 +All MS 679.7822
4 23.9 11424 Manual 676 5.5 EIC 666.7800±0.02 +All MS 791.8182
7 24.5 251467 Manual 13176 77.9 EIC 672.2700±0.02 +All MS 679.782
5 24.4 1229071 Manual 69800 487.4 EIC 672.7800±0.02 +All MS 679.7819
11 25.2 95035 Manual 4592 30.4 EIC 678.2900±0.02 +All MS 1015.476
6 24.4 8207801 Manual 461568 2547.5 EIC 679.7800±0.02 +All MS 679.7821
9 25 209537 Manual 14260 108.6 EIC 695.7700±0.02 +All MS 695.7622
12 26.5 266213 Manual 15880 109.4 EIC 875.5000±0.02 +All MS 499.2384
COOL
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
15 29.6 97144 Manual 5820 22.9 EIC 508.2500±0.02 +All MS 499.2418
13 28 193674 Manual 9796 38.9 EIC 508.2500±0.02 +All MS 499.2425
10 26.6 158617 Manual 8972 35.8 EIC 508.2500±0.02 +All MS 1015.486
3 25 507319 Manual 31684 126.4 EIC 508.2500±0.02 +All MS 508.2477
14 28 56472 Manual 2984 9.6 EIC 659.2800±0.02 +All MS 499.2424
8 25.9 59695 Manual 3540 23.4 EIC 666.2800±0.02 +All MS 679.7876
2 24.7 18098 Manual 1096 7.3 EIC 666.2800±0.02 +All MS 436.6924
1 23.5 15417 Manual 1552 10.3 EIC 666.2800±0.02 +All MS 666.2772
4 25.3 108136 Manual 3328 27.9 EIC 666.7800±0.02 +All MS 679.788
7 25.9 385101 Manual 20344 121.8 EIC 672.2700±0.02 +All MS 679.7875
5 25.8 922522 Manual 55656 499.6 EIC 672.7800±0.02 +All MS 679.7876
11 26.6 172816 Manual 9044 51.7 EIC 678.2900±0.02 +All MS 1015.486
6 25.9 5103137 Manual 319964 2476.5 EIC 679.7800±0.02 +All MS 679.7876
9 26.4 81547 Manual 4580 37.1 EIC 695.7700±0.02 +All MS 1015.487
12 27.9 197688 Manual 12340 91.2 EIC 875.5000±0.02 +All MS 499.2426
DDR
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
17 29.5 162799 Manual 9144 37.2 EIC 508.2500±0.02 +All MS 499.2434
14 27.8 368447 Manual 18560 75.9 EIC 508.2500±0.02 +All MS 499.2431
11 26.4 68052 Manual 4256 17.5 EIC 508.2500±0.02 +All MS 1015.49
3 24.9 226576 Manual 12712 52.5 EIC 508.2500±0.02 +All MS 508.2496
16 29.4 56695 Manual 3200 10.1 EIC 659.2800±0.02 +All MS 499.2435
15 27.9 103812 Manual 5276 16.6 EIC 659.2800±0.02 +All MS 499.2432
6 25.6 17470 Manual 1208 3.8 EIC 659.2800±0.02 +All MS 679.7905
9 25.8 59855 Manual 3804 23.3 EIC 666.2800±0.02 +All MS 679.7903
2 24.5 22052 Manual 1212 7.4 EIC 666.2800±0.02 +All MS 436.6959
1 23.5 19085 Manual 1336 8.2 EIC 666.2800±0.02 +All MS 666.2786
4 25.2 32045 Manual 2352 17 EIC 666.7800±0.02 +All MS 791.8313
8 25.8 95632 Manual 5648 36.4 EIC 672.2700±0.02 +All MS 679.79
5 25.6 706204 Manual 44140 426.7 EIC 672.7800±0.02 +All MS 679.79
12 26.5 108197 Manual 6848 44.1 EIC 678.2900±0.02 +All MS 1015.489
7 25.8 4536757 Manual 274312 2087.8 EIC 679.7800±0.02 +All MS 679.7899
10 26.3 77567 Manual 4200 34.1 EIC 695.7700±0.02 +All MS 695.7691
13 27.8 148803 Manual 9820 60.2 EIC 875.5000±0.02 +All MS 499.2429
DR
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
11 27.3 217694 Manual 13280 53.7 EIC 508.2500±0.02 +All MS 499.241
9 25.5 436464 Manual 24864 102.5 EIC 508.2500±0.02 +All MS 605.2465
6 24 133600 Manual 9104 37 EIC 508.2500±0.02 +All MS 958.4277
1 22.4 364908 Manual 21744 89.6 EIC 508.2500±0.02 +All MS 508.246
12 27.3 90734 Manual 5224 14.1 EIC 659.2800±0.02 +All MS 499.2407
10 25.6 127635 Manual 6572 17.8 EIC 659.2800±0.02 +All MS 605.2466
4 23.3 76653 Manual 3836 23 EIC 666.2800±0.02 +All MS 679.7864
2 23.2 1878406 Manual 112264 723.6 EIC 672.7800±0.02 +All MS 679.7866
7 24.1 242328 Manual 13248 79.3 EIC 678.2900±0.02 +All MS 958.4254
3 23.2 8632524 Manual 555056 3027.9 EIC 679.7800±0.02 +All MS 679.7866
5 23.8 278816 Manual 17000 115 EIC 695.7700±0.02 +All MS 958.4276
8 25.4 517333 Manual 32384 193.8 EIC 875.5000±0.02 +All MS 605.2463




# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
13 27 135220 Manual 7640 30.5 EIC 508.2500±0.02 +All MS 499.2418
10 25.1 119418.2 Manual 6096 24.3 EIC 508.2500±0.02 +All MS 605.2466
7 23.6 156319.5 Manual 9516 37.6 EIC 508.2500±0.02 +All MS 1015.483
12 26.9 54202.7 Manual 3140 9.2 EIC 659.2800±0.02 +All MS 499.2417
11 25.1 40716 Manual 2016 5.9 EIC 659.2800±0.02 +All MS 605.2468
4 22.8 30822.7 Manual 1916 12.4 EIC 666.2800±0.02 +All MS 679.7853
1 22.3 7401.6 Manual 772 5.9 EIC 666.7800±0.02 +All MS 791.8246
3 22.8 62614.1 Manual 3628 23.4 EIC 672.2700±0.02 +All MS 679.7852
2 22.8 465753.5 Manual 27796 258.8 EIC 672.7800±0.02 +All MS 679.7852
8 23.7 25056.4 Manual 1344 8.3 EIC 678.2900±0.02 +All MS 1015.483
5 22.9 2760478 Manual 178360 1118.5 EIC 679.7800±0.02 +All MS 679.7852
6 23.4 48712.3 Manual 2956 24.3 EIC 695.7700±0.02 +All MS 1015.48
9 25 276286.9 Manual 17364 111.9 EIC 875.5000±0.02 +All MS 875.5051
GG
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
13 28.7 68733 Manual 4792 21.1 EIC 508.2500±0.02 +All MS 499.2416
11 27.1 130156 Manual 6084 26.8 EIC 508.2500±0.02 +All MS 499.2422
9 25.6 24241 Manual 1740 7.7 EIC 508.2500±0.02 +All MS 678.2899
1 23.8 59523 Manual 4116 17.7 EIC 508.2500±0.02 +All MS 508.2456
14 28.7 25292 Manual 1656 4.8 EIC 659.2800±0.02 +All MS 499.2413
12 27.1 43149 Manual 2336 6.7 EIC 659.2800±0.02 +All MS 499.2419
6 24.7 25384 Manual 1676 11.4 EIC 666.2800±0.02 +All MS 679.786
2 24.1 28734 Manual 1776 13.5 EIC 666.7800±0.02 +All MS 791.8282
5 24.7 275713 Manual 14716 89.1 EIC 672.2700±0.02 +All MS 679.7855
3 24.7 519252 Manual 28396 254.9 EIC 672.7800±0.02 +All MS 679.7856
8 25.6 306343 Manual 16156 101.4 EIC 678.2900±0.02 +All MS 678.2889
4 24.7 2446730 Manual 142136 1019.6 EIC 679.7800±0.02 +All MS 679.7857
7 25.3 43507 Manual 2964 21.6 EIC 695.7700±0.02 +All MS 695.7688
10 26.9 178117 Manual 9964 75.9 EIC 875.5000±0.02 +All MS 875.5036
LH
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
2 24.8 280914.1 Manual 17100 62.1 EIC 508.2500±0.02 +All MS 508.2493
9 26.3 84084.8 Manual 4972 17.5 EIC 508.2500±0.02 +All MS 1015.49
12 27.8 192164 Manual 9916 35.6 EIC 508.2500±0.02 +All MS 499.2446
14 29.4 83952.1 Manual 5528 19.5 EIC 508.2500±0.02 +All MS 499.246
13 27.8 46109.7 Manual 2444 7.9 EIC 659.2800±0.02 +All MS 499.245
15 29.4 31171.6 Manual 1824 5.9 EIC 659.2800±0.02 +All MS 499.2458
1 24.5 8012.2 Manual 748 5.1 EIC 666.2800±0.02 +All MS 437.1978
7 25.7 37322.3 Manual 2360 16 EIC 666.2800±0.02 +All MS 679.791
3 25.1 14092.1 Manual 1056 9.2 EIC 666.7800±0.02 +All MS 791.8334
6 25.7 93367.5 Manual 5588 34 EIC 672.2700±0.02 +All MS 679.7908
4 25.6 665286.7 Manual 41440 316.6 EIC 672.7800±0.02 +All MS 679.7909
10 26.5 54859.7 Manual 3304 23.1 EIC 678.2900±0.02 +All MS 678.293
5 25.7 3192941 Manual 196200 1409.4 EIC 679.7800±0.02 +All MS 679.7908
8 26.2 47501 Manual 3372 31.5 EIC 695.7700±0.02 +All MS 695.7716





# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
13 27.5 83444 Manual 4304 18.3 EIC 508.2500±0.02 +All MS 499.2398
11 25.6 119511 Manual 5728 24.4 EIC 508.2500±0.02 +All MS 499.24
8 24 57901 Manual 3396 14.5 EIC 508.2500±0.02 +All MS 678.288
1 22.4 100905 Manual 6032 25.7 EIC 508.2500±0.02 +All MS 508.2458
14 27.6 26298 Manual 1784 6 EIC 659.2800±0.02 +All MS 499.2398
12 25.7 40911 Manual 1920 6.4 EIC 659.2800±0.02 +All MS 499.2392
6 23.3 16764 Manual 892 8.1 EIC 666.2800±0.02 +All MS 679.7834
2 22.7 15008 Manual 1020 8.8 EIC 666.7800±0.02 +All MS 791.8244
4 23.3 185830 Manual 12276 96.5 EIC 672.2700±0.02 +All MS 679.7835
3 23.3 279503 Manual 14680 141.9 EIC 672.7800±0.02 +All MS 679.7834
9 24.1 173016 Manual 10008 64.6 EIC 678.2900±0.02 +All MS 678.2876
5 23.3 1787563 Manual 111268 696.9 EIC 679.7800±0.02 +All MS 679.7835
7 23.8 52385 Manual 4152 38.6 EIC 695.7700±0.02 +All MS 695.766
10 25.4 254779 Manual 13652 104 EIC 875.5000±0.02 +All MS 875.5019
F2U
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
12 28.2 74620 Manual 3760 14.1 EIC 508.2500±0.02 +All MS 499.2376
10 26.5 91869 Manual 4544 17 EIC 508.2500±0.02 +All MS 875.5003
1 23.5 13525 Manual 1128 4 EIC 508.2500±0.02 +All MS 784.8148
13 28.2 28305 Manual 1944 5.5 EIC 659.2800±0.02 +All MS 499.239
11 26.5 33681 Manual 1684 4.8 EIC 659.2800±0.02 +All MS 875.5004
6 24.4 36502 Manual 2264 14.6 EIC 666.2800±0.02 +All MS 679.7818
2 23.8 24566 Manual 1524 10.9 EIC 666.7800±0.02 +All MS 791.8227
5 24.4 237044 Manual 13004 78.6 EIC 672.2700±0.02 +All MS 679.7812
3 24.3 537520 Manual 28436 245.9 EIC 672.7800±0.02 +All MS 679.7812
8 25.2 40807 Manual 2636 15.1 EIC 678.2900±0.02 +All MS 541.2478
4 24.4 3531383 Manual 210700 1428.4 EIC 679.7800±0.02 +All MS 679.7813
7 24.9 57658 Manual 3728 32.3 EIC 695.7700±0.02 +All MS 695.7632
9 26.4 456476 Manual 28068 197.2 EIC 875.5000±0.02 +All MS 875.5011
FL
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 23.5 161818 Manual 8444 35.1 EIC 508.2500±0.02 +All MS 508.2475
6 25.1 65717 Manual 3884 16.1 EIC 508.2500±0.02 +All MS 958.4254
10 26.7 150390 Manual 6768 28.1 EIC 508.2500±0.02 +All MS 499.2417
11 28.3 76958 Manual 4608 19.1 EIC 508.2500±0.02 +All MS 499.2416
9 26.5 47374 Manual 2376 7.2 EIC 659.2800±0.02 +All MS 499.2416
12 28.4 28720 Manual 2236 6.8 EIC 659.2800±0.02 +All MS 499.2416
4 24.4 39443 Manual 2336 15.3 EIC 666.2800±0.02 +All MS 679.7875
2 23.8 18356 Manual 1332 10.5 EIC 666.7800±0.02 +All MS 791.8284
3 24.3 875639 Manual 49748 416.4 EIC 672.7800±0.02 +All MS 679.7874
7 25.2 174352 Manual 9504 68.3 EIC 678.2900±0.02 +All MS 678.2896
5 24.9 71690 Manual 4180 37.5 EIC 695.7700±0.02 +All MS 958.4264
8 26.5 227426 Manual 15456 97.1 EIC 875.5000±0.02 +All MS 875.5061
5 24.4 3890481 Manual 232200 1666.1 EIC 679.7800±0.02 +All MS 679.7875







# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
14 29.9 106414 Manual 7036 24.4 EIC 508.2500±0.02 +All MS 499.2473
12 28.2 287553 Manual 15032 55.5 EIC 508.2500±0.02 +All MS 499.2476
9 26.9 172658 Manual 10628 39.5 EIC 508.2500±0.02 +All MS 1015.496
1 25.2 553212 Manual 32380 120.9 EIC 508.2500±0.02 +All MS 508.2515
15 29.9 43238 Manual 2492 8.6 EIC 659.2800±0.02 +All MS 499.2473
13 28.3 89260 Manual 4356 15 EIC 659.2800±0.02 +All MS 499.2475
3 26 28911 Manual 1408 4.9 EIC 659.2800±0.02 +All MS 679.7938
7 26.1 56405 Manual 3320 19.4 EIC 666.2800±0.02 +All MS 679.7941
2 25.5 24955 Manual 1556 12.2 EIC 666.7800±0.02 +All MS 791.8351
6 26.1 502304 Manual 29608 212.6 EIC 672.2700±0.02 +All MS 679.7939
4 26.1 1209600 Manual 68928 577 EIC 672.7800±0.02 +All MS 679.7938
10 27 134969 Manual 7836 51.8 EIC 678.2900±0.02 +All MS 1015.495
5 26.1 5761933 Manual 361508 2750.5 EIC 679.7800±0.02 +All MS 679.7939
8 26.7 112920 Manual 6820 56.1 EIC 695.7700±0.02 +All MS 1015.494
11 28.1 176940 Manual 12068 67.4 EIC 875.5000±0.02 +All MS 499.2478
SD
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 23.4 203207 Manual 11004 43.9 EIC 508.2500±0.02 +All MS 508.2438
8 25 70943 Manual 3564 14.2 EIC 508.2500±0.02 +All MS 1015.48
11 26.5 243594 Manual 12832 51.2 EIC 508.2500±0.02 +All MS 499.2387
14 28.3 124948 Manual 6456 25.8 EIC 508.2500±0.02 +All MS 499.24
12 26.6 75656 Manual 3688 9.2 EIC 659.2800±0.02 +All MS 499.2389
13 28.2 45767 Manual 2616 6.5 EIC 659.2800±0.02 +All MS 499.2398
6 24.3 41946 Manual 2096 13 EIC 666.2800±0.02 +All MS 679.7843
2 23.6 75727 Manual 2452 19.9 EIC 666.7800±0.02 +All MS 679.7844
5 24.3 268398 Manual 13320 76.1 EIC 672.2700±0.02 +All MS 679.784
3 24.3 1155657 Manual 63120 416.4 EIC 672.7800±0.02 +All MS 679.7839
9 25.1 87594 Manual 4420 24.7 EIC 678.2900±0.02 +All MS 678.2879
4 24.3 3908250 Manual 229296 1513.6 EIC 679.7800±0.02 +All MS 679.784
7 24.9 49879 Manual 2824 20.3 EIC 695.7700±0.02 +All MS 679.7801
10 26.4 145212 Manual 8356 70 EIC 875.5000±0.02 +All MS 499.2386
REC
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
12 30.3 73275 Manual 3940 17.3 EIC 508.2500±0.02 +All MS 499.2459
10 28.8 143632 Manual 7248 31.9 EIC 508.2500±0.02 +All MS 936.4197
7 27.4 43645 Manual 2408 10.6 EIC 508.2500±0.02 +All MS 678.2906
1 26 131729 Manual 7940 35 EIC 508.2500±0.02 +All MS 508.2506
13 30.4 25674 Manual 1584 6.4 EIC 659.2800±0.02 +All MS 499.245
11 28.8 38679 Manual 2108 8.5 EIC 659.2800±0.02 +All MS 605.2493
6 26.8 28993 Manual 1868 13.8 EIC 666.2800±0.02 +All MS 679.7904
2 26.2 56562 Manual 2020 16.9 EIC 666.7800±0.02 +All MS 679.7907
5 26.8 266257 Manual 17048 129.7 EIC 672.2700±0.02 +All MS 679.7901
3 26.8 415357 Manual 24400 197.9 EIC 672.7800±0.02 +All MS 679.7899
8 27.6 253909 Manual 15932 108.1 EIC 678.2900±0.02 +All MS 678.2911
4 26.8 2599294 Manual 162432 1101.8 EIC 679.7800±0.02 +All MS 679.7899








# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
15 29.4 58664 Manual 3736 14.2 EIC 508.2500±0.02 +All MS 499.2444
13 27.8 124866 Manual 6528 24.8 EIC 508.2500±0.02 +All MS 499.2441
10 26.4 63634 Manual 3948 15 EIC 508.2500±0.02 +All MS 958.4301
3 24.8 217647 Manual 12424 47.1 EIC 508.2500±0.02 +All MS 508.2501
14 27.8 34228 Manual 1652 4.3 EIC 659.2800±0.02 +All MS 499.2442
8 25.7 30041 Manual 2056 5.4 EIC 659.2800±0.02 +All MS 679.7891
2 24.4 22715 Manual 892 4.9 EIC 666.2800±0.02 +All MS 436.6975
1 23.4 40095 Manual 2644 14.4 EIC 666.2800±0.02 +All MS 666.2796
4 25 104315 Manual 3068 24.1 EIC 666.7800±0.02 +All MS 679.7891
7 25.7 743267 Manual 47440 331.2 EIC 672.2700±0.02 +All MS 679.7889
5 25.7 1031076 Manual 60532 524.7 EIC 672.7800±0.02 +All MS 679.7889
11 26.5 147892 Manual 8076 52 EIC 678.2900±0.02 +All MS 678.2911
6 25.7 4166985 Manual 273464 1964.3 EIC 679.7800±0.02 +All MS 679.7889
9 26.2 54075 Manual 3248 28.2 EIC 695.7700±0.02 +All MS 958.4313
12 27.7 268399 Manual 17484 129.1 EIC 875.5000±0.02 +All MS 875.5086
4WS
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
13 30.3 107185 Manual 7236 30.3 EIC 508.2500±0.02 +All MS 499.2465
11 28.7 96024 Manual 4888 20.5 EIC 508.2500±0.02 +All MS 499.2436
8 27.3 41166 Manual 2504 10.5 EIC 508.2500±0.02 +All MS 1015.489
1 25.7 59821 Manual 3736 15.7 EIC 508.2500±0.02 +All MS 409.1783
14 30.3 34517 Manual 2028 5.5 EIC 659.2800±0.02 +All MS 499.2465
12 28.7 23979 Manual 1476 4 EIC 659.2800±0.02 +All MS 499.2442
5 26.6 38585 Manual 2776 18.8 EIC 666.2800±0.02 +All MS 679.7915
2 26 24495 Manual 1628 15.4 EIC 666.7800±0.02 +All MS 791.8324
4 26.6 223337 Manual 13000 75.1 EIC 672.2700±0.02 +All MS 679.7911
3 26.6 381875 Manual 21652 187.7 EIC 672.7800±0.02 +All MS 679.7911
9 27.4 47823 Manual 3072 19.1 EIC 678.2900±0.02 +All MS 678.2951
6 26.6 3283910 Manual 204888 1428.8 EIC 679.7800±0.02 +All MS 679.7913
7 27.1 68968 Manual 4484 36.4 EIC 695.7700±0.02 +All MS 695.7729
10 28.6 326093 Manual 18672 138 EIC 875.5000±0.02 +All MS 875.5102
A&4E
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
14 30 35583.3 Manual 1832 7.3 EIC 508.2500±0.02 +All MS 499.2445
12 28.2 72837.1 Manual 3436 13.7 EIC 508.2500±0.02 +All MS 499.2447
8 26.9 18223.7 Manual 1020 4.1 EIC 508.2500±0.02 +All MS 678.2954
1 25.3 57018.7 Manual 3980 15.9 EIC 508.2500±0.02 +All MS 508.2497
13 28.3 15333.7 Manual 1060 3.8 EIC 659.2800±0.02 +All MS 499.2447
6 26.2 21221.8 Manual 1220 8.5 EIC 666.2800±0.02 +All MS 679.7894
2 25.5 5679.6 Manual 472 4 EIC 666.7800±0.02 +All MS 791.8335
5 26.2 248867 Manual 15408 115.6 EIC 672.2700±0.02 +All MS 679.7895
3 26.2 322470.3 Manual 18276 156.8 EIC 672.7800±0.02 +All MS 679.7892
10 27 310235.2 Manual 18800 118 EIC 678.2900±0.02 +All MS 678.2936
4 26.2 1712662 Manual 109092 942.6 EIC 679.7800±0.02 +All MS 679.7894
9 26.9 11411 Manual 632 5.5 EIC 689.2800±0.02 +All MS 678.2932
7 26.8 27022.2 Manual 1808 16.2 EIC 695.7700±0.02 +All MS 958.4295






# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
13 29.6 46030 Manual 2868 10.9 EIC 508.2500±0.02 +All MS 499.2445
11 28 47681 Manual 2356 9 EIC 508.2500±0.02 +All MS 875.5091
8 26.6 40836 Manual 2312 8.8 EIC 508.2500±0.02 +All MS 678.2936
1 25.1 66725 Manual 4108 15.6 EIC 508.2500±0.02 +All MS 409.1795
12 29.6 13689 Manual 1052 2.5 EIC 659.2800±0.02 +All MS 499.2452
6 25.9 17079 Manual 944 7.2 EIC 666.2800±0.02 +All MS 679.7893
2 25.3 16999 Manual 1100 9.2 EIC 666.7800±0.02 +All MS 792.332
5 25.9 150785 Manual 9188 70 EIC 672.2700±0.02 +All MS 679.7892
3 25.9 238425 Manual 14368 120.4 EIC 672.7800±0.02 +All MS 679.789
9 26.7 134835 Manual 8436 55.8 EIC 678.2900±0.02 +All MS 678.2929
4 25.9 1586065 Manual 98060 724.1 EIC 679.7800±0.02 +All MS 679.7891
7 26.5 26657 Manual 1636 14.7 EIC 695.7700±0.02 +All MS 695.7706
10 27.9 158529 Manual 10184 89.8 EIC 875.5000±0.02 +All MS 875.5092
BD
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
14 28.9 97941 Manual 6132 23.3 EIC 508.2500±0.02 +All MS 499.2353
13 27.3 189271 Manual 10624 40.5 EIC 508.2500±0.02 +All MS 499.235
9 25.8 56091 Manual 3848 14.7 EIC 508.2500±0.02 +All MS 1015.47
2 24.3 171872 Manual 11180 42.6 EIC 508.2500±0.02 +All MS 508.2398
15 28.9 27212 Manual 2096 5.8 EIC 659.2800±0.02 +All MS 499.2351
12 27.2 54565 Manual 3924 10.8 EIC 659.2800±0.02 +All MS 499.2348
7 25.2 51195 Manual 3492 19.5 EIC 666.2800±0.02 +All MS 679.7781
1 22.8 24866 Manual 2320 12.9 EIC 666.2800±0.02 +All MS 666.2685
3 24.6 58105 Manual 3344 28 EIC 666.7800±0.02 +All MS 791.8182
6 25.2 188102 Manual 10868 70 EIC 672.2700±0.02 +All MS 679.7779
4 25.1 540004 Manual 32596 256 EIC 672.7800±0.02 +All MS 679.7778
10 25.9 173293 Manual 10332 63.3 EIC 678.2900±0.02 +All MS 678.2799
5 25.2 4232072 Manual 274892 2032.3 EIC 679.7800±0.02 +All MS 679.7779
8 25.7 121644 Manual 7592 59.6 EIC 695.7700±0.02 +All MS 695.7592
11 27.1 342742 Manual 26480 178.6 EIC 875.5000±0.02 +All MS 875.4963
COOL
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
13 29.5 144466 Manual 8140 32.4 EIC 508.2500±0.02 +All MS 499.2381
11 27.8 253767 Manual 12932 51.6 EIC 508.2500±0.02 +All MS 499.2367
8 26.3 75955 Manual 4252 17 EIC 508.2500±0.02 +All MS 1015.474
1 24.8 176981 Manual 9688 38.7 EIC 508.2500±0.02 +All MS 508.2409
14 29.5 47323 Manual 2700 7.3 EIC 659.2800±0.02 +All MS 499.2383
12 27.8 60571 Manual 3316 9 EIC 659.2800±0.02 +All MS 499.2368
6 25.8 79443 Manual 4736 25.8 EIC 666.2800±0.02 +All MS 679.7808
2 25.1 180184 Manual 6724 51.2 EIC 666.7800±0.02 +All MS 679.7809
5 25.7 335315 Manual 17904 109.8 EIC 672.2700±0.02 +All MS 679.7806
3 25.6 964737 Manual 57272 478.8 EIC 672.7800±0.02 +All MS 679.7807
9 26.5 124261 Manual 6936 42.5 EIC 678.2900±0.02 +All MS 1015.473
4 25.7 7625599 Manual 469112 3190.1 EIC 679.7800±0.02 +All MS 679.7806
7 26.2 161225 Manual 9976 83.6 EIC 695.7700±0.02 +All MS 695.7621
10 27.7 528105 Manual 35040 231.5 EIC 875.5000±0.02 +All MS 875.4988
DDR # RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
11 30.1 59502 Manual 2836 11.1 EIC 508.2500±0.02 +All MS 499.2425
9 28.4 135452 Manual 5844 23 EIC 508.2500±0.02 +All MS 499.2419
6 27 53449 Manual 3480 13.3 EIC 508.2500±0.02 +All MS 1015.483
1 25.3 173136 Manual 9392 36.9 EIC 508.2500±0.02 +All MS 508.2469
12 30.1 18271 Manual 1176 3.7 EIC 659.2800±0.02 +All MS 499.2422
10 28.4 34407 Manual 1844 5.9 EIC 659.2800±0.02 +All MS 499.2427
4 26.2 31310 Manual 1748 11 EIC 666.2800±0.02 +All MS 679.7875
2 25.6 33560 Manual 2048 17.2 EIC 666.7800±0.02 +All MS 791.8302
3 26.1 473805 Manual 25940 228.8 EIC 672.7800±0.02 +All MS 679.7872
7 27 170771 Manual 9904 69.1 EIC 678.2900±0.02 +All MS 678.2898
5 26.8 94452 Manual 5604 48.6 EIC 695.7700±0.02 +All MS 958.4257
8 28.3 306639 Manual 20584 172.5 EIC 875.5000±0.02 +All MS 875.5044
5 26.2 2796459 Manual 178352 1439.4 EIC 679.7800±0.02 +All MS 679.7874





# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
13 29.2 111792 Manual 6828 26 EIC 508.2500±0.02 +All MS 499.2358
10 27.5 169576 Manual 8768 33.9 EIC 508.2500±0.02 +All MS 499.2343
8 26.2 46130 Manual 3328 12.8 EIC 508.2500±0.02 +All MS 1015.473
1 24.6 82049 Manual 5608 21.7 EIC 508.2500±0.02 +All MS 1182.504
14 29.3 42244 Manual 2680 7.2 EIC 659.2800±0.02 +All MS 499.2358
12 27.6 50988 Manual 3016 8.2 EIC 659.2800±0.02 +All MS 499.2345
3 25.4 38594 Manual 2212 10.9 EIC 666.2800±0.02 +All MS 679.7784
2 24.9 99249 Manual 4212 35.3 EIC 666.7800±0.02 +All MS 679.7785
6 25.5 470007 Manual 27464 135.4 EIC 672.2700±0.02 +All MS 679.7781
4 25.5 572963 Manual 30712 233.9 EIC 672.7800±0.02 +All MS 679.778
9 26.3 146785 Manual 8528 51 EIC 678.2900±0.02 +All MS 678.2808
5 25.5 3933329 Manual 235104 1784.4 EIC 679.7800±0.02 +All MS 679.7781
7 26 70262 Manual 4096 34.3 EIC 695.7700±0.02 +All MS 695.7574
11 27.5 277507 Manual 17352 128.3 EIC 875.5000±0.02 +All MS 875.4955
EDE
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
2 25.2 168424 Manual 9712 35.9 EIC 508.2500±0.02 +All MS 508.2451
9 26.7 55541 Manual 3788 14 EIC 508.2500±0.02 +All MS 1015.477
12 28.1 193835 Manual 9512 35.1 EIC 508.2500±0.02 +All MS 499.2395
14 29.7 98145 Manual 5700 21.1 EIC 508.2500±0.02 +All MS 499.2389
13 28.1 51410 Manual 2480 7.8 EIC 659.2800±0.02 +All MS 499.2394
15 29.7 30938 Manual 1840 5.8 EIC 659.2800±0.02 +All MS 499.2389
1 23.8 11443 Manual 788 5.3 EIC 666.2800±0.02 +All MS 666.27
7 26.1 44606 Manual 3100 20.5 EIC 666.2800±0.02 +All MS 679.784
3 25.5 26359 Manual 1488 13.9 EIC 666.7800±0.02 +All MS 791.8241
5 26 250909 Manual 16220 118.9 EIC 672.2700±0.02 +All MS 679.7838
4 26 614267 Manual 33256 278.3 EIC 672.7800±0.02 +All MS 679.7836
10 26.8 265966 Manual 13176 92.1 EIC 678.2900±0.02 +All MS 678.2852
6 26.1 3747311 Manual 229716 1673.1 EIC 679.7800±0.02 +All MS 679.7838
8 26.6 85607 Manual 6120 53 EIC 695.7700±0.02 +All MS 695.7662
11 28.1 178056 Manual 10760 74.1 EIC 875.5000±0.02 +All MS 499.2403
WR
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 25.3 227803 Manual 12200 49.5 EIC 508.2500±0.02 +All MS 508.2477
8 26.8 63345 Manual 3444 14 EIC 508.2500±0.02 +All MS 958.4303
11 28.3 91283 Manual 4924 20 EIC 508.2500±0.02 +All MS 875.5091
13 29.9 41484 Manual 2808 10.9 EIC 508.2500±0.02 +All MS 499.2436
12 28.3 22952 Manual 1236 3.5 EIC 659.2800±0.02 +All MS 875.5087
14 29.9 19410 Manual 1140 3.2 EIC 659.2800±0.02 +All MS 499.2445
6 26.1 34828 Manual 2308 16.1 EIC 666.2800±0.02 +All MS 679.7897
2 25.6 12617 Manual 1084 9.4 EIC 666.7800±0.02 +All MS 791.8298
5 26.1 554661 Manual 32352 242.6 EIC 672.2700±0.02 +All MS 679.7896
3 26.1 718348 Manual 39744 344.3 EIC 672.7800±0.02 +All MS 679.7895
9 27 66042 Manual 4008 26.9 EIC 678.2900±0.02 +All MS 1015.487
4 26.1 3225671 Manual 199640 1433.8 EIC 679.7800±0.02 +All MS 679.7896
7 26.7 38501 Manual 1924 17.3 EIC 695.7700±0.02 +All MS 958.4303
10 28.1 262494 Manual 16584 143.7 EIC 875.5000±0.02 +All MS 875.5091
FT
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 25.6 123740 Manual 7332 29.3 EIC 508.2500±0.02 +All MS 508.2495
7 27.1 77501 Manual 5084 20.3 EIC 508.2500±0.02 +All MS 1015.487
10 28.5 207585 Manual 9312 37.2 EIC 508.2500±0.02 +All MS 499.2444
12 30.3 164171 Manual 9032 36 EIC 508.2500±0.02 +All MS 499.2448
11 28.5 49266 Manual 2004 6.1 EIC 659.2800±0.02 +All MS 771.326
13 30.3 44015 Manual 2276 6.9 EIC 659.2800±0.02 +All MS 499.2447
4 26.4 43123 Manual 2588 15.1 EIC 666.2800±0.02 +All MS 679.7897
2 25.8 91149 Manual 3856 26.2 EIC 666.7800±0.02 +All MS 679.7916
3 26.4 361875 Manual 19104 145.5 EIC 672.7800±0.02 +All MS 679.7895
8 27.2 271064 Manual 15368 101.7 EIC 678.2900±0.02 +All MS 678.2916
5 26.5 4032892 Manual 238236 1812.6 EIC 679.7800±0.02 +All MS 679.7896
6 27 124937 Manual 7172 58.6 EIC 695.7700±0.02 +All MS 695.7713
9 28.5 346360 Manual 20724 130.2 EIC 875.5000±0.02 +All MS 875.5088





# RT [min] Area Int. Type I S/N Chromatogram Max. m/z
1 25.5 28496.8 Manual 2040 8.5 EIC 508.2500±0.02 +All MS 409.1793
10 28.4 79579.1 Manual 3808 16 EIC 508.2500±0.02 +All MS 499.245
12 29.9 34026.4 Manual 1916 8 EIC 508.2500±0.02 +All MS 499.2454
11 28.4 21044.1 Manual 1060 4 EIC 659.2800±0.02 +All MS 499.2435
13 29.9 10784.4 Manual 736 2.8 EIC 659.2800±0.02 +All MS 499.2451
6 26.3 15778.2 Manual 1160 8.6 EIC 666.2800±0.02 +All MS 679.7885
2 25.7 21982.7 Manual 1768 14.3 EIC 666.7800±0.02 +All MS 791.8339
5 26.3 165509.7 Manual 10728 79.3 EIC 672.2700±0.02 +All MS 679.7883
3 26.3 209791.3 Manual 12860 115.4 EIC 672.7800±0.02 +All MS 679.7883
4 26.3 1341102 Manual 86644 603 EIC 679.7800±0.02 +All MS 679.788
8 27 7307.9 Manual 532 3.5 EIC 689.2800±0.02 +All MS 678.2935
7 26.8 19840 Manual 1876 20.1 EIC 695.7700±0.02 +All MS 695.7696
9 28.2 119212.9 Manual 7256 45 EIC 875.5000±0.02 +All MS 875.5088
9 27.1 322738.4 Manual 21312 148.6 EIC 678.2900±0.02 +All MS 678.294
LH
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z
13 29.3 94816.6 Manual 4888 19.8 EIC 508.2500±0.02 +All MS 499.2361
12 27.7 112264.2 Manual 5188 21 EIC 508.2500±0.02 +All MS 875.4957
7 26.3 39032.1 Manual 2772 11.2 EIC 508.2500±0.02 +All MS 678.2844
1 24.7 63619.3 Manual 4420 17.9 EIC 508.2500±0.02 +All MS 508.2417
14 29.3 30749.9 Manual 2352 7.1 EIC 659.2800±0.02 +All MS 499.2365
11 27.6 29774.7 Manual 2008 6.1 EIC 659.2800±0.02 +All MS 499.2354
4 25.5 31804.6 Manual 1908 12 EIC 666.2800±0.02 +All MS 679.7789
2 25 34272 Manual 2584 23.2 EIC 666.7800±0.02 +All MS 791.8192
3 25.5 468835.7 Manual 27796 211.7 EIC 672.7800±0.02 +All MS 679.7787
9 26.4 227736.4 Manual 13272 83.3 EIC 678.2900±0.02 +All MS 678.2824
5 25.6 2659938 Manual 165308 1332.4 EIC 679.7800±0.02 +All MS 679.7788
8 26.3 3493.6 Manual 324 1.7 EIC 689.2800±0.02 +All MS 678.2842
6 26.1 49722.2 Manual 3236 27.1 EIC 695.7700±0.02 +All MS 695.762
10 27.6 257724.9 Manual 15208 131.8 EIC 875.5000±0.02 +All MS 875.4959
6 25.6 131410.6 Manual 7976 46.6 EIC 672.2700±0.02 +All MS 679.7788
LR
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z
14 30.4 114294 Manual 6476 23.9 EIC 508.2500±0.02 +All MS 499.2401
12 28.9 218426 Manual 12148 44.3 EIC 508.2500±0.02 +All MS 499.24
9 27.5 71968 Manual 4364 15.6 EIC 508.2500±0.02 +All MS 1015.482
2 25.9 225773 Manual 13480 49.8 EIC 508.2500±0.02 +All MS 508.2456
15 30.4 36560 Manual 2600 7.2 EIC 659.2800±0.02 +All MS 499.2402
13 28.9 59246 Manual 2672 7.4 EIC 659.2800±0.02 +All MS 499.2397
7 26.8 51120 Manual 3100 18.6 EIC 666.2800±0.02 +All MS 679.7861
1 24.6 16421 Manual 1316 7.9 EIC 666.2800±0.02 +All MS 666.2809
3 26.2 27626 Manual 1692 14.7 EIC 666.7800±0.02 +All MS 791.8264
6 26.8 444234 Manual 24528 134.2 EIC 672.2700±0.02 +All MS 679.7858
4 26.7 825483 Manual 48952 437.8 EIC 672.7800±0.02 +All MS 679.7858
10 27.6 106068 Manual 5860 37.8 EIC 678.2900±0.02 +All MS 1015.481
5 26.8 4316203 Manual 263532 2135.3 EIC 679.7800±0.02 +All MS 679.7859
8 27.3 64722 Manual 3436 30.8 EIC 695.7700±0.02 +All MS 1015.484
11 28.7 334915 Manual 20044 132.6 EIC 875.5000±0.02 +All MS 875.503
REC 
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z
2 24.7 228343.7 Manual 12192 46.2 EIC 508.2500±0.02 +All MS 508.2409
9 26.2 96465.5 Manual 5952 22.7 EIC 508.2500±0.02 +All MS 958.4171
13 27.6 277972.9 Manual 15404 58.6 EIC 508.2500±0.02 +All MS 499.2359
15 29.2 132989.8 Manual 8204 30.5 EIC 508.2500±0.02 +All MS 499.2375
14 27.7 60756.7 Manual 3720 9.8 EIC 659.2800±0.02 +All MS 499.2363
16 29.3 44282.3 Manual 2444 6.4 EIC 659.2800±0.02 +All MS 499.2373
1 23.1 16278.5 Manual 1260 8.3 EIC 666.2800±0.02 +All MS 666.2733
7 25.5 58278 Manual 3496 23.1 EIC 666.2800±0.02 +All MS 679.7798
3 24.9 16350.7 Manual 1692 12.5 EIC 666.7800±0.02 +All MS 791.8162
6 25.5 567118.8 Manual 34508 204 EIC 672.2700±0.02 +All MS 679.7797
4 25.5 991488.2 Manual 56284 468.3 EIC 672.7800±0.02 +All MS 679.7795
10 26.3 370586.6 Manual 19528 129 EIC 678.2900±0.02 +All MS 678.2818
5 25.5 6263254 Manual 402444 2519.8 EIC 679.7800±0.02 +All MS 679.7798
11 26.4 4267.3 Manual 476 2.7 EIC 689.2800±0.02 +All MS 678.2844
8 26 116119.3 Manual 7512 60.9 EIC 695.7700±0.02 +All MS 958.4163





S9 Animal tissue  
LAMB LIVER - Integrated peak area (Area) of the detected chromatograms of 
cobamides in lamb liver samples treated with and without 50% Methanol (MetOH) 











# RT [min] Area Int. Type I S/N Chromatogram Max. m/z
2 24.8 153817 Manual 8024 34.2 EIC 508.2500±0.02 +All MS 508.2464
9 26.4 40574 Manual 2456 10.5 EIC 508.2500±0.02 +All MS 678.2903
12 27.8 198454 Manual 10056 42.8 EIC 508.2500±0.02 +All MS 499.2414
15 29.5 89406 Manual 5356 22.8 EIC 508.2500±0.02 +All MS 499.2419
13 27.8 44751 Manual 2600 6.9 EIC 659.2800±0.02 +All MS 499.2417
14 29.4 31222 Manual 2000 5.3 EIC 659.2800±0.02 +All MS 499.2419
1 23.4 11916 Manual 860 5.9 EIC 666.2800±0.02 +All MS 666.2788
7 25.7 33883 Manual 2152 14.6 EIC 666.2800±0.02 +All MS 679.7868
3 25.2 96549 Manual 4268 33.5 EIC 666.7800±0.02 +All MS 679.7873
6 25.7 207313 Manual 12272 81.2 EIC 672.2700±0.02 +All MS 679.7868
4 25.7 540857 Manual 30764 276.2 EIC 672.7800±0.02 +All MS 679.7867
10 26.5 342418 Manual 18764 116 EIC 678.2900±0.02 +All MS 678.2899
5 25.7 3261467 Manual 211432 1558.7 EIC 679.7800±0.02 +All MS 679.7868
8 26.2 73287 Manual 5480 43 EIC 695.7700±0.02 +All MS 695.7702
11 27.7 154074 Manual 10176 78.7 EIC 875.5000±0.02 +All MS 499.2418
With 50 % MetOH
# RT [min] Area Int. Type I S/N ChromatogramMax. m/z FWHM [min]
1 24.1 33155 Manual 3156 21.4 EIC 672.2700±0.02 +All MS672.2773
2 24.9 1034606 Manual 63580 312.2 EIC 678.2900±0.02 +All MS678.3009
3 24.9 37129 Manual 2140 18.6 EIC 689.2800±0.02 +All MS678.3009
4 26.2 571787 Manual 42500 281.1 EIC 875.5000±0.02 +All MS875.5171
Without 50 % MetOH
# RT [min] Area Int. Type I S/N ChromatogramMax. m/z FWHM [min]
1 24.3 60347 Manual 4372 34.3 EIC 672.2700±0.02 +All MS67 .28
3 25 1602762 Manual 95980 473.1 EIC 678.2900±0.02 +All MS678.3021
2 24.9 38547 Manual 2204 14.4 EIC 689.2800±0.02 +All MS678.3023
4 26.3 382605 Manual 28936 242.5 EIC 875.5000±0.02 +All MS875.5182
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MICE KIDNEY - Integrated peak area (Area) of the detected chromatograms of 




# RT [min] Area Int. Type I S/N Chromatogram Max. m/z
1 24.1 8258.9 Manual 980 7.5 EIC 672.7800±0.02 +All MS 679.7867
3 24.9 263171.3 Manual 19780 137.4 EIC 678.2900±0.02 +All MS 678.2963
2 24.1 19426.8 Manual 1792 13.2 EIC 679.7800±0.02 +All MS 679.783
4 25 10825.4 Manual 664 5.1 EIC 689.2800±0.02 +All MS 678.2969
5 26.2 637862.5 Manual 52084 310.7 EIC 875.5000±0.02 +All MS 875.5169
24.7 3844.2 EIC 695.7700±0.02 +All MS
Mice Kidney 2
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z
1 24.2 3267.7 Manual 572 4.5 EIC 672.7800±0.02 +All MS 679.7859
4 25 560695 Manual 33092 203.8 EIC 678.2900±0.02 +All MS 678.2998
3 24.9 30029.4 Manual 1884 14.4 EIC 689.2800±0.02 +All MS 678.2996
2 24.7 2978.7 Manual 608 5.7 EIC 695.7700±0.02 +All MS 481.2585
6 26.3 138028.9 Manual 21124 152.2 EIC 875.5000±0.02 +All MS 875.5073
5 26.2 103923.9 Manual 22272 160 EIC 875.5000±0.02 +All MS 875.5155
24.3 16114.7 EIC 679.7800±0.02 +All MS
Mice kidney 3
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z
1 23.8 5548.2 Manual 528 4.5 EIC 672.7800±0.02 +All MS 679.7881
4 24.7 396759.6 Manual 26828 156.5 EIC 678.2900±0.02 +All MS 678.297
2 24 27833.4 Manual 2448 17.6 EIC 679.7800±0.02 +All MS 679.7878
5 24.7 24078.5 Manual 1792 11.1 EIC 689.2800±0.02 +All MS 678.2974
3 24.4 11082.7 Manual 964 7.8 EIC 695.7700±0.02 +All MS 695.7706
6 25.9 669030.7 Manual 50120 323 EIC 875.5000±0.02 +All MS 875.5186
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MICE LIVER - Integrated peak area (Area) of the detected chromatograms of 












RT [min] Area Chromatogram Base
24.3 18416 EIC 672.7800±0.02 +All MS Adenine (Pseudo)
25.1 1040967 EIC 678.2900±0.02 +All MS 5,6-dimethylbenzimidazole (B12)
24.2 64917 EIC 679.7800±0.02 +All MS 2-methyladenine
25 33449 EIC 689.2800±0.02 +All MS 1H -naphtho[2,3-d] imidazole
24.8 24843 EIC 695.7700±0.02 +All MS 2-methylthioadenine
26.3 982229 EIC 875.5000±0.02 +All MS HBAH
Mice 2
RT [min] Area Chromatogram Base
24.2 7472.5 EIC 672.7800±0.02 +All MS Adenine (Pseudo)
24.9 1042803 EIC 678.2900±0.02 +All MS 5,6-dimethylbenzimidazole (B12)
24.2 44923.4 EIC 679.7800±0.02 +All MS 2-methyladenine
25 38370.2 EIC 689.2800±0.02 +All MS 1H -naphtho[2,3-d] imidazole
24.7 17977.9 EIC 695.7700±0.02 +All MS 2-methylthioadenine
26.2 1024427 EIC 875.5000±0.02 +All MS HBAH
Mice 3
RT [min] Area Chromatogram Base
24.3 8538.7 EIC 672.7800±0.02 +All MS Adenine (Pseudo)
25.1 1037186 EIC 678.2900±0.02 +All MS 5,6-dimethylbenzimidazole (B12)
24.4 51963.3 EIC 679.7800±0.02 +All MS 2-methyladenine
25.2 36225.6 EIC 689.2800±0.02 +All MS 1H -naphtho[2,3-d] imidazole
24.9 20587.5 EIC 695.7700±0.02 +All MS 2-methylthioadenine
26.4 774342.2 EIC 875.5000±0.02 +All MS HBAH
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S10 Animal serum 
MICE SERUM - Integrated peak area (Area) of the detected chromatograms of 
cobamides in mice serum samples from the HPLC-MS. Only CN-Cbl is detected and 
at very low levels.The UV chromatogram below reinforces the presence of 
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S11 Patient group H (happy) - Integrated peak area (Area) of the detected 
chromatograms of cobamides in human faecal samples belonging to the happy 
group from the HPLC-MS. Happy group means that these pernicious anaemia 
patients are satisfied with their three monthly Vitamin B12 injections. 
 
H2
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 26.2 184588 Manual 10424 77.1 EIC 666.7800±0.02 +All MS 791.8381
2 26.7 293147 Manual 20280 154.5 EIC 672.7800±0.02 +All MS 679.7962
5 27.6 10575 Manual 816 6.6 EIC 678.2900±0.02 +All MS 347.2042
3 26.8 3302931 Manual 218012 1336 EIC 679.7800±0.02 +All MS 679.7963
4 27.3 420147 Manual 29512 190.6 EIC 695.7700±0.02 +All MS 695.7778
6 28.8 226789 Manual 17184 123 EIC 875.5000±0.02 +All MS 875.5137
H5
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
7 30.4 27984 Manual 2808 15.7 EIC 659.2800±0.02 +All MS 499.2532
6 28.8 18863 Manual 1496 8.4 EIC 659.2800±0.02 +All MS 499.2527
1 26.1 35849 Manual 2728 25.4 EIC 666.7800±0.02 +All MS 791.8395
2 26.6 121772 Manual 9000 70.4 EIC 672.7800±0.02 +All MS 679.7977
3 26.7 2416840 Manual 158308 812.1 EIC 679.7800±0.02 +All MS 679.7975
4 27.2 1413403 Manual 93472 520.3 EIC 695.7700±0.02 +All MS 695.7818
5 28.6 471940 Manual 34236 234.7 EIC 875.5000±0.02 +All MS 875.5163
H7
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 26.6 145075 Manual 10408 81.8 EIC 672.7800±0.02 +All MS 679.7926
2 26.7 443229 Manual 32476 205.8 EIC 679.7800±0.02 +All MS 679.7925
3 27.2 284523 Manual 19392 135.2 EIC 695.7700±0.02 +All MS 695.7789
4 28.7 258366 Manual 19212 130.5 EIC 875.5000±0.02 +All MS 875.516
H10
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 26.7 60507 Manual 5060 37.4 EIC 679.7800±0.02 +All MS 679.7913
2 27.2 41761 Manual 3356 22.2 EIC 695.7700±0.02 +All MS 695.7781
3 28.6 102889 Manual 8284 59.6 EIC 875.5000±0.02 +All MS 875.5151
H15
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 25.4 9865.4 Manual 860 5.1 EIC 508.2500±0.02 +All MS 784.8334
8 27 11959.2 Manual 1072 6.5 EIC 508.2500±0.02 +All MS 608.1431
12 28.4 57047.5 Manual 4200 25.1 EIC 508.2500±0.02 +All MS 771.3358
14 30 80057.6 Manual 6000 35.9 EIC 508.2500±0.02 +All MS 499.2548
11 28.3 14154.8 Manual 960 5.6 EIC 659.2800±0.02 +All MS 875.5223
13 30 26441.2 Manual 2188 12.8 EIC 659.2800±0.02 +All MS 499.2549
5 26.3 29053.3 Manual 2076 16.3 EIC 666.2800±0.02 +All MS 679.8
2 25.7 48222.4 Manual 3632 33.7 EIC 666.7800±0.02 +All MS 791.8426
3 26.2 251162.2 Manual 17480 162.7 EIC 672.7800±0.02 +All MS 679.7996
9 27.1 14549.7 Manual 1068 7.1 EIC 678.2900±0.02 +All MS 541.2642
4 26.2 694929.3 Manual 152756 1163.3 EIC 679.7800±0.02 +All MS 679.7915
6 26.4 763209.9 Manual 103220 786.2 EIC 679.7800±0.02 +All MS 679.776
7 26.8 1267680 Manual 93020 646.3 EIC 695.7700±0.02 +All MS 695.7837






# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
7 28.4 37201 Manual 2276 12.7 EIC 508.2500±0.02 +All MS 875.5131
9 30 55885 Manual 3876 21.7 EIC 508.2500±0.02 +All MS 499.2494
8 30 18602 Manual 1608 7.6 EIC 659.2800±0.02 +All MS 499.2498
4 26.3 14009 Manual 1132 7.5 EIC 666.2800±0.02 +All MS 679.7937
1 25.7 31712 Manual 2628 20.6 EIC 666.7800±0.02 +All MS 791.8372
2 26.2 88872 Manual 5844 45.9 EIC 672.7800±0.02 +All MS 679.7923
3 26.3 1487142 Manual 108416 1009.3 EIC 679.7800±0.02 +All MS 679.7928
5 26.8 634244 Manual 43648 365.4 EIC 695.7700±0.02 +All MS 695.7773
6 28.3 358806 Manual 25816 175.4 EIC 875.5000±0.02 +All MS 875.5132
H11
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 25.4 17264.6 Manual 1168 8 EIC 508.2500±0.02 +All MS 679.7923
8 27 18898.9 Manual 1580 10.7 EIC 508.2500±0.02 +All MS 678.3017
12 28.3 26515.3 Manual 1900 12.9 EIC 508.2500±0.02 +All MS 438.2691
13 30 29459.4 Manual 2712 18.4 EIC 508.2500±0.02 +All MS 499.2528
4 26.2 10581.2 Manual 740 3.6 EIC 659.2800±0.02 +All MS 679.7978
14 30 10805 Manual 844 4.2 EIC 659.2800±0.02 +All MS 499.2529
6 26.2 31025.7 Manual 2252 14.9 EIC 666.2800±0.02 +All MS 679.7978
2 25.6 20460.5 Manual 1476 10.6 EIC 666.7800±0.02 +All MS 791.838
3 26.2 456567.2 Manual 29584 218.1 EIC 672.7800±0.02 +All MS 679.7974
9 27 532040.9 Manual 36828 220 EIC 678.2900±0.02 +All MS 678.3015
5 26.2 3541595 Manual 244220 1533.2 EIC 679.7800±0.02 +All MS 679.7975
10 27 6477.9 Manual 844 5.9 EIC 689.2800±0.02 +All MS 678.3035
7 26.7 493004.2 Manual 34040 244.1 EIC 695.7700±0.02 +All MS 695.7808
11 28.3 295422.4 Manual 27096 194.6 EIC 875.5000±0.02 +All MS 438.2689
H12
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
7 28.3 16062.3 Manual 1304 9.1 EIC 508.2500±0.02 +All MS 673.3458
10 30 20029.3 Manual 1688 11.8 EIC 508.2500±0.02 +All MS 499.2528
9 30 9303.9 Manual 800 4.4 EIC 659.2800±0.02 +All MS 499.2505
3 26.2 20371.8 Manual 1564 13.6 EIC 666.2800±0.02 +All MS 679.7985
1 26.1 114549.6 Manual 7420 62.2 EIC 672.7800±0.02 +All MS 679.7981
5 27.1 30008.5 Manual 2060 16.7 EIC 678.2900±0.02 +All MS 541.2677
2 26.2 1666856 Manual 142612 872.1 EIC 679.7800±0.02 +All MS 679.7974
4 26.7 216498.8 Manual 15188 119.3 EIC 695.7700±0.02 +All MS 695.7802
6 28.1 85754.1 Manual 18484 99.1 EIC 875.5000±0.02 +All MS 361.2258
8 28.3 93452.5 Manual 14364 76.8 EIC 875.5000±0.02 +All MS 499.2562
H13
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
10 28.4 155309.4 Manual 9692 64.4 EIC 508.2500±0.02 +All MS 499.2548
12 30 192056.1 Manual 12792 84.6 EIC 508.2500±0.02 +All MS 499.2549
9 28.3 30234.8 Manual 1828 10.9 EIC 659.2800±0.02 +All MS 875.5205
13 30.1 54007.8 Manual 3288 19.7 EIC 659.2800±0.02 +All MS 499.2548
14 30.9 3883.4 Manual 444 3.9 EIC 664.2700±0.02 +All MS 499.2541
5 26.4 17297.9 Manual 1076 8.9 EIC 666.2800±0.02 +All MS 679.7976
1 25.7 37717.7 Manual 2920 20.4 EIC 666.7800±0.02 +All MS 791.8415
4 26.3 210421.2 Manual 15028 105.1 EIC 672.2700±0.02 +All MS 679.7979
2 26.2 247384.3 Manual 15988 143.7 EIC 672.7800±0.02 +All MS 679.7977
7 27 28952.9 Manual 1808 12.5 EIC 678.2900±0.02 +All MS 541.2664
3 26.3 1560574 Manual 109288 654.1 EIC 679.7800±0.02 +All MS 679.7976
6 26.8 127982 Manual 9004 62.9 EIC 695.7700±0.02 +All MS 695.7812
8 28.2 62721.2 Manual 15608 99.2 EIC 875.5000±0.02 +All MS 876.5127
11 28.5 29237.3 Manual 4692 29.9 EIC 875.5000±0.02 +All MS 771.3349
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S12 Patient group U (unhappy) - Integrated peak area (Area) of the detected 
chromatograms of cobamides in human faecal samples belonging to the unhappy 
group from the HPLC-MS. Unhappy group means that these pernicious anaemia 
patients are dissatisfied with their three monthly Vitamin B12 injections. They report 




# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
9 28.4 89505 Manual 5696 34.1 EIC 508.2500±0.02 +All MS 736.9517
12 30.1 102721 Manual 7340 43.9 EIC 508.2500±0.02 +All MS 1287.298
10 28.4 18043 Manual 1500 8 EIC 659.2800±0.02 +All MS 1001.236
11 30 28596 Manual 2396 12.8 EIC 659.2800±0.02 +All MS 1287.295
4 26.3 34270 Manual 2384 15.2 EIC 666.2800±0.02 +All MS 679.8008
1 25.8 25475 Manual 2544 16 EIC 666.7800±0.02 +All MS 791.8412
3 26.3 192561 Manual 13588 106.5 EIC 672.2700±0.02 +All MS 679.8008
2 26.2 576136 Manual 42096 319.2 EIC 672.7800±0.02 +All MS 679.8006
7 27.1 74886 Manual 4712 32 EIC 678.2900±0.02 +All MS 678.3002
5 26.4 893040 Manual 121576 898.8 EIC 679.7800±0.02 +All MS 679.7761
6 26.8 385543 Manual 29036 197.3 EIC 695.7700±0.02 +All MS 695.7812
8 28.2 286009 Manual 26772 156.1 EIC 875.5000±0.02 +All MS 875.5194
U3
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 25.4 200892.8 Manual 14152 66 EIC 508.2500±0.02 +All MS 508.2594
10 26.9 213149 Manual 15312 71.2 EIC 508.2500±0.02 +All MS 678.3087
14 28.3 82535.4 Manual 5296 24.7 EIC 508.2500±0.02 +All MS 875.5227
17 29.9 111565.7 Manual 7448 34.7 EIC 508.2500±0.02 +All MS 499.2532
5 26.1 20349.4 Manual 1376 5.9 EIC 659.2800±0.02 +All MS 679.8027
15 28.3 18908.8 Manual 1184 5 EIC 659.2800±0.02 +All MS 875.5225
18 29.9 29343.3 Manual 2316 9.9 EIC 659.2800±0.02 +All MS 499.2533
6 26.1 78789.6 Manual 5884 34.4 EIC 666.2800±0.02 +All MS 679.803
2 25.6 60125.5 Manual 4444 33.9 EIC 666.7800±0.02 +All MS 791.8448
4 26.1 1058404 Manual 70680 507.6 EIC 672.7800±0.02 +All MS 679.8026
11 26.9 5186526 Manual 315912 1784.7 EIC 678.2900±0.02 +All MS 678.3087
3 26 341483 Manual 69672 436.3 EIC 679.7800±0.02 +All MS 673.2929
7 26.4 627419.9 Manual 80196 504 EIC 679.7800±0.02 +All MS 497.2398
8 26.5 30186.3 Manual 1040 7.1 EIC 686.2900±0.02 +All MS 695.7855
12 27 80593.5 Manual 4448 28.7 EIC 689.2800±0.02 +All MS 678.3086
9 26.7 1345359 Manual 93788 589.4 EIC 695.7700±0.02 +All MS 695.7847
13 28 6071.8 Manual 2144 14.9 EIC 875.5000±0.02 +All MS 361.2158





# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
8 28.2 11802 Manual 1052 6.4 EIC 508.2500±0.02 +All MS 499.2521
9 29.8 18395 Manual 1268 7.7 EIC 508.2500±0.02 +All MS 499.2516
4 26.1 13695 Manual 960 7.8 EIC 666.2800±0.02 +All MS 679.7965
1 25.5 17362 Manual 1356 12.4 EIC 666.7800±0.02 +All MS 791.841
2 26 81658 Manual 6136 53.2 EIC 672.7800±0.02 +All MS 679.7964
6 26.9 51714 Manual 3700 26.6 EIC 678.2900±0.02 +All MS 678.2992
3 26.1 1192402 Manual 89880 564.5 EIC 679.7800±0.02 +All MS 679.7965
5 26.6 896035 Manual 62520 455.5 EIC 695.7700±0.02 +All MS 695.7815
7 28.1 159706 Manual 11956 77.2 EIC 875.5000±0.02 +All MS 875.5164
U5
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
10 28.3 52626.4 Manual 3492 18.7 EIC 508.2500±0.02 +All MS 875.5167
12 29.9 75396.4 Manual 5148 27.2 EIC 508.2500±0.02 +All MS 499.2514
11 28.3 15315.1 Manual 1000 4.3 EIC 659.2800±0.02 +All MS 499.2511
13 29.9 21779.7 Manual 1788 7.7 EIC 659.2800±0.02 +All MS 499.2519
5 26.2 10308 Manual 700 5.5 EIC 666.2800±0.02 +All MS 679.7945
1 25.5 5842.1 Manual 672 6.3 EIC 666.7800±0.02 +All MS 792.3403
4 26.2 147955.8 Manual 11340 79.1 EIC 672.2700±0.02 +All MS 679.7943
2 26.1 161229.4 Manual 9820 74.1 EIC 672.7800±0.02 +All MS 679.7943
7 27 118384.9 Manual 6800 46.3 EIC 678.2900±0.02 +All MS 678.3006
3 26.2 870822.4 Manual 63356 428.9 EIC 679.7800±0.02 +All MS 679.7944
8 27 3447 Manual 440 4 EIC 689.2800±0.02 +All MS 541.266
6 26.7 137093.9 Manual 8820 72.7 EIC 695.7700±0.02 +All MS 695.7795
9 28.2 465909 Manual 36312 251.8 EIC 875.5000±0.02 +All MS 875.5172
U6
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
3 26.1 1057.6 Manual 252 2.2 EIC 666.2800±0.02 +All MS 680.2962
1 26 37284.7 Manual 2464 23.8 EIC 672.7800±0.02 +All MS 679.7931
5 26.8 12089.3 Manual 848 7 EIC 678.2900±0.02 +All MS 541.2627
2 26.1 149625.4 Manual 11312 91.7 EIC 679.7800±0.02 +All MS 679.793
4 26.6 29050.5 Manual 2428 22.2 EIC 695.7700±0.02 +All MS 695.7789
6 28 93290.8 Manual 26664 171.9 EIC 875.5000±0.02 +All MS 875.4888








# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
2 25.3 44557.3 Manual 3568 17.6 EIC 508.2500±0.02 +All MS 1182.528
7 26.8 29479.5 Manual 2104 10.4 EIC 508.2500±0.02 +All MS 678.3012
13 28.2 57554.6 Manual 3904 19.2 EIC 508.2500±0.02 +All MS 771.3343
14 29.8 64499.2 Manual 4500 22.2 EIC 508.2500±0.02 +All MS 499.2503
12 28.1 19283.4 Manual 932 4.1 EIC 659.2800±0.02 +All MS 771.3352
15 29.9 15619.1 Manual 1120 4.9 EIC 659.2800±0.02 +All MS 499.2501
3 25.5 270333.9 Manual 11508 85.1 EIC 666.7800±0.02 +All MS 792.3379
1 25.1 7194.5 Manual 504 3.8 EIC 671.2800±0.02 +All MS 1182.533
4 26 311592.1 Manual 21008 170.3 EIC 672.7800±0.02 +All MS 679.7968
8 26.9 1174159 Manual 76336 479.1 EIC 678.2900±0.02 +All MS 678.301
5 26.1 2680448 Manual 188388 1126.9 EIC 679.7800±0.02 +All MS 679.7969
10 27.7 72984.3 Manual 2584 17.3 EIC 686.2900±0.02 +All MS 790.846
9 27 25152.1 Manual 1220 9.6 EIC 689.2800±0.02 +All MS 678.3009
6 26.5 350214.8 Manual 24332 185.6 EIC 695.7700±0.02 +All MS 695.7795
11 28.1 349255.5 Manual 24272 179.4 EIC 875.5000±0.02 +All MS 790.8387
U2
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
8 30.3 8930.3 Manual 992 5.1 EIC 659.2800±0.02 +All MS 499.2529
3 26.6 21402.1 Manual 1728 11.4 EIC 666.2800±0.02 +All MS 679.7993
1 26 22526 Manual 1648 11.8 EIC 666.7800±0.02 +All MS 791.8416
2 26.6 154918 Manual 10260 84.8 EIC 672.7800±0.02 +All MS 679.7987
5 27.4 28779.2 Manual 1840 13.6 EIC 678.2900±0.02 +All MS 541.2642
4 27.1 516821.9 Manual 38572 275.3 EIC 695.7700±0.02 +All MS 695.7816
7 28.8 162203.3 Manual 19056 116.8 EIC 875.5000±0.02 +All MS 771.3372
6 28.5 35747.7 Manual 11588 70.3 EIC 875.5000±0.02 +All MS 755.352 8
4 26.7 2595355 Manual 177200 839.4 EIC 679.7800±0.02 +All MS 679.7986 11
U9
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
10 28.3 174220 Manual 11752 57.9 EIC 508.2500±0.02 +All MS 499.2502
11 29.9 243270 Manual 15480 76.3 EIC 508.2500±0.02 +All MS 499.2512
9 28.2 42180 Manual 2564 9.1 EIC 659.2800±0.02 +All MS 771.334
12 29.9 59015 Manual 3948 14 EIC 659.2800±0.02 +All MS 499.2508
1 24 15252 Manual 1448 8.4 EIC 666.2800±0.02 +All MS 666.2819
2 25.5 154329 Manual 6324 43 EIC 666.7800±0.02 +All MS 679.7986
3 26.1 433594 Manual 31080 250.8 EIC 672.7800±0.02 +All MS 679.7972
6 26.9 748776 Manual 45732 286.7 EIC 678.2900±0.02 +All MS 678.2983
4 26.1 5826950 Manual 441884 2642.5 EIC 679.7800±0.02 +All MS 679.7972
7 27 27912 Manual 2024 13 EIC 689.2800±0.02 +All MS 678.2986
5 26.6 676669 Manual 46512 288 EIC 695.7700±0.02 +All MS 695.7789
8 28.2 718063 Manual 52664 307.9 EIC 875.5000±0.02 +All MS 875.5166
U12
# RT [min] Area Int. Type I S/N Chromatogram Max. m/z FWHM [min]
1 26.3 17265 Manual 1396 12.5 EIC 672.7800±0.02 +All MS 679.7932
2 26.4 119016 Manual 9180 67.9 EIC 679.7800±0.02 +All MS 679.7931
3 27 15427 Manual 1360 10.4 EIC 695.7700±0.02 +All MS 549.4776
5 28.5 248617 Manual 37760 243.4 EIC 875.5000±0.02 +All MS 875.4876
4 28.4 134221 Manual 34020 219.3 EIC 875.5000±0.02 +All MS 875.5097
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S13 Racehorses’ sera and performance study – Overall result provided by 
Professor Hunter from a study investigating the effect of supplementation on the serum 
levels of vitamin B12  and on its observed performance by its trainer. 
STUDY OF B12 STATUS OF THOROUBRED RACEHORSES DURING THE FLAT 
SEASON June – September 2018 
This study was performed because the trainer was dissatisfied with the condition and 
performance of his horses in the early summer.  Full veterinary assessment revealed 
no reason for this and I suggested the possibility of B12 deficiency as we see in so 
many human patients with chronic fatigue. B12 determinations were performed by the 
laboratories of Rossdales veterinary practice in Newmarket. 
 Blood was collected from 20 horses in June, July August and September. 
During June-July, 10 horses received a supplementary B12 injection, (3mls 
hydroxycobalamin weekly for 4 weeks) which was stopped after the July blood 
sample. The trainer assessed his horses performance after supplementation in 
July, naming those he found to have improved, to see if this was related to B12 
status. 
 The concentration of B12 in the 20 horses ranged from 3085 pg/ml to 7177 
pg/ml, all within the normal range suggested by Addenbrooke’s (although 
normal ranges in man are still disputed and Martin may have some comments 
to make!) The yearlings at the stud ranged from 2439 to 5273 pg/ml and, rather 
to my surprise their levels were significantly lower than those of the horses in 
training (4935 +/- 905 n=20 v 3527+/- 734,n=10 t= 4.2583, p=0.0002). 
 Before supplementation there was no difference between the control group and 
the supplemented (4955+/- 937 n=10 v  4897+/- 988 n=10, t= 0.132 p=0.89). 
After supplementation (July) this changed significantly (4711+/- 895 n=10 v  
6160+/- 749 n=10, t=3.9237 p =0.001) Clearly the injections worked, and this 
was confirmed by the rise in the supplemented group alone (4955+/- 937 before 
n=10 v 6160 +/-749 after t= 3.1745, p=0.0052). 
 The changes in performance noted by The Trainer however, did not correspond 
to changes in B12 concentration. There was no difference between his ‘better 
-8 horses’ and ‘no better -12 horses ’ at the start (5267+/- 632  v  4714+/- 1014, 
t= 1.3698 p= 0.1876) nor even after supplementation! (July results (5267+/- 632  
v  5771 +/- 792, t=1.4059, p=0.1816). 
 The effects of the supplementation rapidly disappeared (July level, n=10, 
6079+/- 805  v August level n=8, 5118 +/- 1078 t= 6.0255 p = 0.0005). There 
was no evidence however, of progressive B12 depletion during the season 
(June level in unsupplemented horses,( n= 10)  4915+/-923  v September level 
n= 9,  4948+/-1015, t=0.1871 p=0.8557). 
 10 control samples were obtained from another yard.  There are no faecal 
samples corresponding to these sera.  The mean was 4377 +/- 704.53. (N=10) 
The mean of 16 values from the original trainers’s string (September values as 
closest to time of control samples) 4950 +/- 1001.29  
 By Student’s t-test T= 1.5774 P= 0.128 NS. 
In conclusion, therefore, this study suggests that these racehorses have normal 
vitamin B12 levels, which remain satisfactory throughout the season, that 
supplementary injections increase the blood concentrations very temporarily, and 
there is no correlation between B12 status and performance!
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S14 Previous human faecal samples HPLC-MS analysis results – Below are figures representing the cobamide composition in 
pernicious anaemia patients’ faecal samples. The patient samples are grouped in 4 groups.  
Group H: Happy group patients who are satisfied with their three monthly B12 injection 
Group U: Unhappy group patients whose B12 deficient symptoms surface before with their next injection is due 
Group C: Control group from the general population who report no signs of deficiency 
Group Z: Control group subjects who were serum tested to be non-deficient 
Normalised peak area of all cobamides present in each patients’ faecal samples  















































Prevalence of each analogue as a percentage of the total cobamides detected within each sample  











































Levels of individual CN-Cbl analogues by normalised peak area 






















































































































































































































































































































































































































































































































































S15 – CULTECH study 
Comparative Analysis of the Microbiota of a Population of Pernicious Anaemia 
Sufferers 
This supplementary study was done by CULTECH to find potential biological markers 
associated with Pernicious Anaemia that could uncover more ways to improve the 
outcomes of patients receiving Vitamin B12 deficiency treatments. This study tested 
faecal samples to identify microbiological representation in the gut microbiota. They 
were processed using 16s rRNA gene sequencing. Three groups of patients were 
studied. 
Group H: Happy patients who are satisfied with their 3-monthly supplementation 
Group U: Unhappy patients who are dissatisfied with their 3-monthly supplementation. 
Patients whose Vitamin B12 deficient symptoms surface before their next 3-monthly 
injection is due. 
Group C: Control, non-pernicious anaemia patients 
 
In the following page is the summary of findings provided by CULTECH. Main findings 
include: 
- Significantly lower levels of Bifidobacterium in patients than non-patients. 
- Levels of Lactobacillus was found to be enriched in the Unhappy group patients 
compared to control. 
- Levels of Klebsiella was found to be higher in patients than non-patients. 
- An unidentified genus of bacteria was found to be in higher levels in patients 
than non-patients. 
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